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     This project was undertaken to better understand the regulation and function of the 
LPA1 receptor. Two separate studies are described. In the first study, we investigated the 
role of LPA signaling in cell cycle regulation and its affects on the tumor suppressor, 
p53. In the second study we examined the internalization and trafficking of the LPA1 
receptor.  
     Through the binding and activation of at least four receptors, LPA1/Edg2, LPA2/Edg4, 
LPA3/Edg7, and PPARγ, the mitogenic receptor ligand, lysophosphatidic acid (LPA), is 
able to enhance cancer cell growth, proliferation and motility. In the first study, we show 
that LPA stimulation potently inhibits the cell cycle regulator and tumor suppressor, p53. 
Ten µM LPA reduced the cellular levels of total p53 and p53 phosphorylated at serine 15 
by approximately 50% within 1 h in A549 lung carcinoma cells and this effect was 
sustained for at least 6 h. This resulted in a corresponding decrease in p53-mediated 
transcription. Transient-transfection of the Edg-family LPA receptors, LPA1-3 in HepG2 
hepatoma cells, which do not respond to LPA, also showed this inhibitory response. The 
response was specific to LPA receptors since neither Gi-coupled M2 muscarinic 
acetylcholine receptors, nor a mutant LPA1 receptor (LPA1 R124A) which is unable to 
bind LPA, inhibited p53 activity. Either transient-transfection of the LPA-degrading lipid 
phosphate phosphatase-1 (LPP-1), or exogenous addition of phospholipase B, which 
decreases exogenous lysophosphatidate, reversed the LPA receptor-induced decrease in 
p53-mediated transcription. Although pertussis toxin did not prevent the inhibition of 
p53, a mutant LPA1 receptor (LPA1 ∆361) which lacks the C-terminal PDZ-binding 
domain, failed to inhibit p53 function. This establishes that, at least for LPA1 receptors, 
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inhibition of p53 function requires an interaction with PDZ-containing proteins. These 
data establish a novel role for LPA-mediated receptor activation in diminishing p53 
activity, which, in addition to LPA’s well-characterized effects on growth-promoting 
signaling pathways, is likely to contribute to the survival and proliferation of cancer cells. 
     Of the Edg-family LPA receptors, the LPA1 receptor is the most widely expressed. In 
the second study, we investigated the agonist-induced endocytosis of the human LPA1 
receptor, bearing an N-terminal FLAG epitope tag, in stably transfected HeLa cells. 
Treatment with LPA induced the rapid endocytosis of approximately 40% of surface 
LPA1 within 15 minutes. Internalization was both dose dependent and LPA specific since 
neither lysophosphatidylcholine nor sphingosine-1-phosphate induced LPA1 endocytosis. 
Removal of agonist following 30 minutes incubation resulted in recycling of LPA1 back 
to the cell surface. LPA1 internalization was strongly inhibited by dominant inhibitory 
mutants of both dynamin2 (K44A) and Rab5a (S34N). In addition, both dynamin2 K44A 
and Rab5 S34N mildly inhibited LPA1-dependent activation of serum response factor. 
Finally, our results also indicate that LPA1 exhibits basal, LPA-dependent internalization 
in the presence of serum-containing medium. These studies, put together, give us new 
insight on the function and cycle of the LPA1 receptor in the regulation of the cell and its 
















G protein-coupled receptors 
     Sight, smell and taste are biological sensations controlled largely by a group of 
proteins embedded in the plasma membrane called G protein-coupled receptors (GPCRs). 
Collectively, these receptors belong to a superfamily of seven-pass transmembrane 
proteins that respond to many different agonists such as odorants, photons, hormones, 
lipids, ions, amines, peptides, proteins and pheromones. Plants, yeast, insects and all 
eukaryotes have GPCRs and with over 1,000 members in the family, GPCRs are 
distinguished as the largest class of cell surface molecules in the human genome (80).     
These important receptors have a myriad of responsibilities in the cell including 
embryonic development, detecting mating pheromones, nutrient uptake, regulation of 
cellular homeostasis and the aforementioned sensory perception. 
     The serpentine-like structure of a membrane-embedded GPCR is connected by three 
extracellular loops, three intracellular loops and a disulfide link (Fig. 1). Depending on 
the receptor, conserved sequences in the second intracellular loop domain can determine 
GPCR internalization, ligand binding affinity, G protein coupling and receptor stability 
(57). Usually the critical signaling determinants of a GPCR exist within the third 
intracellular loop, but the amino acids located in the carboxyl-terminal tail are important 
in targeting and signaling as well. Peripheral ligands usually dock in an extracellular 
binding site, although this site can also be buried within the transmembrane regions.  
     Until the ligand binds to its GPCR, the receptor maintains an inactive conformation. 
1 
 
Fig. 1. A GPCR embedded in the plasma membrane. Included are the locations of 
the extracellular amino terminus and intracellular carboxyl terminus with the PDZ 
binding domain. Close by are the heterotrimeric G protein subunits α and βγ. 
However, once an agonist does bind, the GPCR undergoes a conformational change, 
which in turn activates the receptor. The receptor is closely positioned in the membrane 
next to heterotrimeric G proteins composed of α and βγ subunits and the structural 
change allows the α subunit to couple to the GPCR. After they join together, the α 
subunit can exchange its GDP for GTP, thereby activating and allowing α to dissociate 
from its βγ partner. The α subunit is then capable of associating with other molecules, 
like enzymes, protein scaffolds or ion channels causing an unleashing of signaling 
cascades throughout the cell. 
     More specifically, these cascades create fluctuations in intracellular signaling from 
second messengers and the α subunit is primarily responsible for activating these 
influential molecules. For example, the G protein α subclass, Gs, causes an increase in 
adenylyl cyclase activity and calcium channel activity, but a decrease in sodium channel 
activity which can change membrane potential. In contrast, Gi activation results in a 
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decrease in adenylyl cyclase activity and calcium, but an increase in potassium. The 
activation of other G proteins, like Gq, generates second messengers by causing 
phospholipase C (PLC) to cleave phosphatidylinositol 4,5-bisphosphate (PIP2) into the 
second messengers inositol 1,4,5-trisphosphate (IP3) and 1,2-diacylglycerol (DAG).  
     Second messengers are crucial to intracellular signaling because they allow the cell to 
rapidly amplify a signal from an activated GPCR. These molecules can also activate 
protein kinases which will further transduce the original signal. An illustration of this 
process can be seen in the previously mentioned Gq signaling pathway whereby IP3 binds 
to calcium-permeable channels on the endoplasmic reticulum membrane, which respond 
by opening and allowing calcium to flow into the cytoplasm. Additional proteins become 
activated in response to calcium, such as protein kinase C (PKC), which can 
phosphorylate the original signal-inducer GPCR to terminate signaling. Thus, ligand 
binding and GPCR activation has a variety of signaling consequences. 
     In order to help regulate GPCR-mediated signaling, several mechanisms (rapid 
receptor phosphorylation or receptor endocytosis) have been established to physically 
terminate the response (57). In this way, prolonged agonist exposure can culminate with 
either GPCR desensitization or receptor down-regulation. At a future point signal 
resensitization will again occur and the endocytosed receptors will then be recycled or 
resynthesized and sent back to the surface to receive new agonist. Through these 
mechanisms the cell is able to regulate the activity of a GPCR, thereby controlling 
cellular signaling.  
     If after extended signaling receptor desensitization is necessary, GPCR regulatory 




Fig. 2. Schematic of GPCR endocytosis and trafficking through the cell. Internalization 
begins with plasma membrane invagination and subsequent targeting to the early 
endosome by Rab5. From this endosome, the GPCR can either be sent to the late 
endosome and lysosome for degradation or it can be recycled back to the membrane.unctional desensitization. Arrestin proteins are then capable of binding specifically to 
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functional desensitization. Arrestin proteins are then capable of binding specifically to 
these phosphorylated GPCR amino acid residues on the intracellular loops of the 
receptor. Arrestin binding will also physically disrupt the interaction between the receptor 
and its G proteins, preventing further signaling. As previously mentioned, PKC is also 
capable of phosphorylating the GPCR to initiate desensitization.   
     Another option to the cell after continual ligand stimulation of the GPCR is to degrade 
it in a process called downregulation. After GPCR activation, endocytosis occurs 
whereby, in one method, the plasma membrane invaginates and the protein dynamin 
pinches off and releases the clathrin-coated vesicle from the membrane (124). Once the 
vesicle is formed, the sequestered receptor is internalized for trafficking inside the cell 
with assistance from Rab proteins, V-snares, T-snares and other proteins. The first stop 
for the newly-formed vesicle is the early or sorting endosome where its escort, Rab5, has 
taken it (Fig. 2). From there the internalized GPCR can either be sent to a recycling 
endosome which will traffic it back to the plasma membrane or the GPCR is targeted to 
the lysosome for degradation (à la downregulation). Proteins that bind to sequences in the 
carboxyl-terminal tail of a GPCR (such as the GPCR-associated sorting protein or GASP) 
are thought to be responsible for the sorting process that ultimately decides a receptor’s 
fate (220). Another factor that determines whether or not the receptor will be degraded is 
the amount of ubiquitin it has attached to it. Components called E3 ligases covalently 
attach ubiquitin molecules onto a protein. Once the protein has accumulated extensive 
ubiquitin attachments it will be targeted for degradation; however, the receptor may be 
degraded in either the proteasome or the lysosome (120, 186). In order for the cell to 
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begin receiving this response again, it must recycle internalized GPCRs and start 
resynthesizing a new pool of receptors. 
     Before publishing the study, Agonist-induced endocytosis of lysophosphatidic acid-
coupled LPA1/EDG-2 receptors via a dynamin2- and Rab5-dependent pathway in 2003, 
nothing was known about the trafficking or intracellular destinations of any LPA-coupled 
receptor. To gain further insight into how cells regulate the activity of specific LPA 
receptors, we investigated the agonist-induced trafficking of the human LPA1 receptor in 
HeLa cells. Our results indicated that LPA1 is rapidly internalized into cells via 
dynamin2- and Rab5-dependent mechanisms in an LPA-specific and LPA dose-
dependent manner and will be further presented in this thesis (Chapters 6-9).  
GPCR PDZ domains 
     The phrase “G protein-coupled receptor” insinuates the sole interaction for a GPCR is 
the G protein it couples to at the membrane. To the contrary, receptors are unfaithful to 
any single partner and some GPCRs will also couple with PDZ domain-containing 
proteins (17). PDZ domains are approximately 80 to 90 amino acid residues of a protein 
folded together that contain repeated PDZ-binding residues. These proteins recognize and 
bind motifs containing 3 to 5 amino acid consensus sequences in the carboxyl-terminal of 
either a GPCR (Fig. 1) or an ion channel. The PDZ peptide-motif that is contained in 
GPCR tails is recognized with high specificity by PDZ-containing cellular proteins (92). 
The name “PDZ” comes from the first three proteins discovered that were involved in 
these interactions: PSD-95, DLG and ZO-1. Some examples of GPCRs with PDZ-
binding domains are the β-adrenergic receptor and platelet-derived growth factor receptor 
(42, 78). These terminal PDZ motifs are important for protein binding and scaffold 
6 
 
formation; thus, the interaction provides a link between transmembrane receptors and 
assembly complexes which can mediate signal transduction.  
     The carboxyl-terminal tails of both LPA1 and LPA2 receptors contain a consensus 
PDZ docking motif (X-(S/T)-X-(V/L)). The PDZ consensus binding sequence often 
requires a terminal hydrophobic residue like Val or Leu, while the second and third PDZ 
residues indicate specificity. The terminal peptide sequence of LPA1 is: DHSVV and the 
terminal sequence for LPA2 is: DSTL. Recently it was shown that the Na+/H+ 
exchanger-regulating factor 2 (NHERF2) contains PDZ domains that interact with LPA2 
(along with the motifs DSLL, DSFL and DTRL present in other GPCRs), but not  LPA1 
or LPA3 (31, 141). In another report, the carboxyl terminal tail of LPA2 was also shown 
to bind a focal adhesion molecule, TRIP6 (225), which again was unique to that LPA 
receptor. An exclusive protein that binds to the tail of only one LPA receptor is not 
surprising considering the identity between cytoplasmic tails of LPA1 and LPA2 is 27% 
and between LPA2 and LPA3 is only 17% (225). To date there has not yet been a report 
demonstrating any PDZ-binding interaction between a specific cellular protein and the 
LPA1 receptor. 
Target: GPCRs  
     Since they are fundamental to the regulation of many diverse cellular processes, 
promising pharmacological targets have always included GPCRs. In the year 2000, 26 of 
the top 100 pharmacological drugs targeted a GPCR and 39 affected at least one part of a 
mechanism mediated by a GPCR (15). In 2003, it was reported that approximately 50% 
of all prescribed drugs were targeting a GPCR (107).  
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     Drugs that are directed at these receptors include the widely used pain relievers. 
Although its natural ligands are endorphins, the µ opioid receptor will also bind morphine 
and heroin. Having a similar molecular structure, the analgesic hydrocodone also binds to 
the µ opioid receptor and is one of the most widely prescribed drugs in the U.S. The 
desensitization of this receptor to its pain-relieving ligands is why a persistent increase in 
medicinal dosage is required for a consistent feeling of well-being or “tolerance,” in more 
general terms (60) (recall GPCR desensitization and receptor down-regulation).  
     Because of their continued successes as drug targets and the driving ambition of 
pharmaceutical companies to quickly produce a marketable drug, GPCRs will likely 
remain a top research priority for the industry. High-throughput assays are making the 
task of screening potential GPCR antagonists more effective which allows the research to 
proliferate. Name-brand drugs like Schering-Plough’s Clarinex and GlaxoSmithKline’s 
Zantac are competitive antagonists that block the histamine H1 receptor. Eli Lilly’s 
Zyprexa and Novartis’s Zelnorm both inhibit the serotonin receptor. (60) Angiotensin 
receptors have also been targets for many years because of their association with 
diabetes, hypertension, cardiac hypertrophy and other afflictions.  
 
 
Lysophosphatidic acid (LPA) receptors and LPA 
LPA receptors 
     Extracellular lysophosphatidic acid (LPA) is presented to the cell bound to serum 
albumin (201) where its diverse actions are mediated through GPCRs. To date there are 
at least five LPA receptors, including the original three endothelial differentiation gene 
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Fig. 3. GPCR signaling through Gi and Gq pathways. The leftmost signaling cascade 
begins with Gq activation of PLC, which cleaves PIP2 into DAG and IP3. This 
signaling pathway ultimately leads to an increase in calcium and activation of PKC via 
DAG. The Gi  protein is shown signaling through Akt (center) to enhance cell survival. 
In this pathway, Ras activates PI-3 kinase which causes Akt to become phosphorylated 
by kinases embedded in the membrane (not on the GPCR). Akt inhibits apoptosis-
promoting proteins like BAD. On the far right the MAPK pathway is activated by Gi 
to induce the MAPK signaling pathway components Ras, Raf, Mek and Erk which 
will cause an increase in cell proliferation and survival.  
(Edg) family GPCRs having high amino acid sequences similarities, that reportedly bind 
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(Edg) family GPCRs having high amino acid sequence similarities, that reportedly bind 
LPA: LPA1/Edg2, LPA2/Edg4, LPA3/Edg7, LPA4/GPR23 (tentatively) and the metabolic, 
nuclear hormone transcription factor receptor, PPAR-γ, expressed mainly in adipocytes to 
control energy homeostasis (4, 7, 11, 122, 138). The G alpha proteins that couple to LPA 
receptors are Gi (LPA1, LPA2) (65), Gq (LPA1, LPA3), G12/13 (LPA1, LPA2) and Gs 
(LPA4) (138, 153). i        
     Before describing each LPA receptor individually, it is important to understand their 
signaling abilities collectively since many cell types express multiple receptors. Together 
the Edg-family LPA receptors, LPA1, LPA2 and LPA3, are capable of activating Gi, Gq 
and G12/13 (65, 138, 153). As previously mentioned, LPA stimulation of Gq induces PLC 
activation which causes a rise in the second messengers IP3, DAG and calcium. The 
response after stimulation of G12/13 leads to an activation of Rho and stress fiber 
formation in the cell which is involved in cell migration. The responses to Gi include an 
inhibition of adenylyl cyclase, an activation of the phosphatidylinositol 3-kinase (PI-3K)-
Akt cell survival pathway and an activation of the MAPK pathway (Fig. 3) (44). The 
latter pathway is used by the cell to signal migration, proliferation, differentiation, 
survival, and apoptosis and not surprisingly includes proto-oncogenes, like the highly 
oncogenic member Ras. The components that activate MAPK involves the G protein Ras 
and three kinases: Raf (MAPK kinase kinase), MEK 1/2 (MAPK kinase) and ERK 1/2 
(MAPK) as the business end of the pathway which can translocate into the nucleus and 
phosphorylate over 50 substrates, including transcription factors. (102) 
     The human Edg2 protein, now referred to exclusively as LPA1, was the first LPA 
receptor cloned from a human lung cDNA library in 1997 after the tedious task of 
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screening half a million colonies to generate a few positive clones (5). Prior to its 
discovery, it was hypothesized that LPA was acting through a GPCR, but later studies 
would suggest multiple GPCRs existed to mediate LPA-induced signals. Once the 
newcomer LPA1 was cloned, a search through the 1996 Genbank database yielded a 60% 
sequence similarity to human Edg1 (now called SIP1), although at the time this was 
considered an orphan receptor since its ligand, sphingosine 1-phosphate, had not been 
positively associated with SIP1/Edg1 yet (5).  
     Multiple studies, both current and years older, point to LPA1 as the causative-signaler 
amid the LPA receptors for various affects: physiological cell migration, 
pathophysiological motility, activation by ascites in cancer, enhancement of metastatic 
potential and cell adhesion to collagen (81, 187, 232).  LPA1 is endogenously expressed 
in most cell types in the body, stimulates the closure of epithelial cells involved in wound 
healing (109) and is involved in the embryonic development of neurons (66). LPA1 has a 
disease link to pathophysiological processes like ovarian cancer, but is not the only LPA 
receptor that seems to be a contributing factor.  
     The second LPA receptor identified, LPA2, contributes to cancer metastasis because by 
itself it enhances cell proliferation and the secretion of angiogenic factors (187). 
Although LPA2 has a 72% amino acid sequence identity to LPA1 (4), the phenotypic 
differences between these two receptors are still emerging. One of the first studies on 
LPA1 and LPA2 receptors pointed out their ability to transduce calcium signaling 
differently (LPA2 uses Gi alone while LPA1 uses Gi and Gq (6)). The expression patterns 
vary markedly between the two receptors. While LPA1 is endogenously expressed in most 
cell types, with the exception of liver cells, LPA2 is the only LPA receptor represented in 
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certain breast, colorectal, ovary and lung cancer cells (81). More notably, LPA2 is 
overexpressed in between 15-30% of ovarian cancers (54). The tail of LPA2 is also 
enigmatic because the length and amino acid sequence differ between receptors from cell 
type to cell type. Nevertheless, of the LPA receptors, only the LPA2 tail has demonstrated 
protein binding (previously mentioned in the PDZ-domain section). 
     The LPA3 receptor was cloned in 1999 and has a sequence similarity to both LPA1 and 
LPA2 of approximately 50% (11). An interesting difference between LPA3 and LPA2 is 
the lack of LPA3 signaling to MAPK by LPA (11) and this receptor does not couple to 
G12/13. The expression pattern of LPA3 is not nearly as ubiquitous as LPA1 or LPA2, but it 
can abundantly appear in prostate and ovarian cancer cells (81), has been reported in 
kidney (142) and to a lesser extent in pancreatic cancer cells (232). Conspicuously, LPA3 
is overexpressed in between 44-49% of ovarian cancers (67). 
     A ‘de-orphaning project’ resulted in the 2003 discovery of LPA4, a G protein-coupled 
receptor that tentatively binds LPA. This receptor was previously referred to as 
p2y9/GPR23 and is closely related to the orphan receptor p2y5 and nucleotide receptors 
p2y1, p2y4 and p2y6 (138). A broad RT-PCR analysis demonstrated that LPA4 only 
appears in a few select cell lines, including glioblastoma and melanoma cells (81). The 
LPA research community has not yet embraced LPA4 as a bona-fide LPA receptor 
because they have not been able to independently substantiate the original claim that 
LPA4 binds LPA and transduces LPA-mediated signals, even when provided with the 
original cell-line and plasmid constructs. To date there has not been a publication from an 
independent lab verifying the original results about LPA4. Recently, LPA was referred to 
as a “putative agonist of the GPR23 [receptor]” and the authors curiously neglected to use 
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the designation LPA4 when discussing it (44). Further research demonstrating the 
efficacy of p2y9/GPR23 as a legitimate LPA-receptor is needed before future endeavors 
evaluating LPA4 are undertaken. 
     Also in early 2003, a previously recognized internal lipid receptor belonging to a 
larger group of nuclear hormone receptors was identified as capable of binding LPA 
(122). The peroxisome proliferators-activated receptor γ (PPARγ) is a nuclear 
transcription factor receptor that regulates genes which control energy metabolism (9). 
Several lipid ligands can activate PPARγ, but unlike LPA, these are all low-affinity 
ligands and prior to its relationship with LPA, it was presumed that the authentic ligand 
had not yet emerged (122). Unlike the controversy surrounding LPA4, the claims of its 
status as an LPA receptor have been duplicated and substantiated by several independent 
labs in the past year and a half. In this way, PPARγ has been shown to be both necessary 
and sufficient for the formation and accumulation of cells within arterial walls through 
mildly oxidized low density lipoprotein (LDL) (236) and will be discussed in further 
detail during the disease section of this introduction.  
LPA Abundance 
     The ligand for the aforementioned LPA receptors is LPA: a mitogenic, albumin-
bound, lipid component of serum that elicits a wide range of effects on the cell including 
proliferation, migration, morphological changes, neointima formation and cell survival 
(43, 45, 56, 66, 74, 95, 113, 158, 218, 236). It is simple and unique from other 
lysophospholipids because it lacks a head group attached to its phosphate moiety, such as 
the choline head group in lysophosphatidylcholine (193). LPA in human serum is 
produced and secreted by activated platelets in response to either coagulation or wound 
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healing and as such is a normal serum component (109, 197, 227). LPA can also be 
produced by fibroblasts, adipocytes, ovarian cancer cells and prostate cancer cells (206). 
Extracellular lipoprotein oxidation of LDL can also produce LPA (190). 
     LPA has been dubbed both an “extracellular mediator and intracellular 
messenger”(75) because a distinct source of LPA exists in the cellular cytosol which is 
produced from the phospholipid biosynthesis of phosphatidic acid (PA) (203, 230). A 
debate in the field exists surrounding whether the plasma membrane separates charged 
LPA from metabolic LPA or how and whether this lipid manages to cross the membrane 
bilayer. Fueling this quandary is a series of reports suggesting LPA binds to and activates 
intracellular receptors. Notably, the previously discussed receptor PPAR-γ is located 
exclusively inside the cell and binds LPA with high-affinity (122). Reports have 
suggested that the nuclear membrane contains functional LPA1 receptors (71, 134), but 
supportive work is needed before this is widely accepted.   
     Nevertheless, LPA can be manufactured starting with PA and vice versa, it also 
functions intracellularly as a precursor to the formation and production of PA and more-
complex lipids (129). In this intricate loop of lipid biosynthesis with PA, LPA is able to 
regulate membrane curvature and the formation of caveoli (104, 178, 206). Under normal 
conditions, the highest concentration of LPA found in rat tissue is in the brain (40) and 
this concentration increases following brain injury (200) just as the concentration will 
likewise increase on a much smaller scale during the body’s normal wound healing 
processes. 
     The amount of LPA found in the plasma of healthy volunteers is around 1 µM, while 
the amount in serum from the same group ranged from approximately 0.1-10 µM (10). A 
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different study suggested LPA is present in serum at concentrations ranging between 2-20 
µM (49). Plasma concentrations of LPA are being investigated as a potential biomarker 
for ovarian cancer with one study reporting levels elevated more than 30 units in 29 of 35 
cancer patients (53, 197). Similar studies have indicated that the amount of LPA found in 
the ascites of ovarian cancer patients can reach up to 80 µM (53, 199). 
 
A Matter of Life or Death 
     Cells depend on extracellular signaling factors to maintain homeostasis and prevent 
apoptosis. Multiple sources indicate LPA is a genuine protective factor, although the 
explanation as to how it affects survival varies widely. Several examples from reports 
illustrate a wide diversity among the cell types affected. In rat mesangial cells, 30 µM 
LPA was able to increase survival after concurrent treatment with PDGF (95). In T-cells, 
LPA concentrations at and below 1 µM decreased the apoptosis-promoting protein Bax 
(74). Renal proximal tubular cells remained viable and confluent after 10 days when 
grown in serum-free media supplemented only with 12 µM LPA (113). The intestinal 
epithelial cells of mice treated orally with 1 mM/L LPA 2 hr after radiation showed fewer 
apoptotic cells than untreated controls (43). Finally, in HEY ovarian cancer cells, LPA 
decreased the killing ability of an effective chemotherapeutic agent (63). 
     For LPA to induce cell survival, it was first suggested this effect was mediated 
through a PI-3K-independent, Gi–dependent activation of MAPK (56). In contrast, it has 
also been proposed that LPA acts through a PI3K-dependent pathway since both survival 
and proliferation were blocked by wortmannin or LY-294002, drugs which inhibits this 
15 
 
pathway (113). Another study proposed that both Gi and PI3K were fundamental to LPA-
induced Schwann cell survival (218).  
     The list continues with more explanations of how LPA increases cell survival. A study 
involving intestinal epithelial cells proposed that LPA actually inhibits the apoptotic 
mitochondrial pathway (45). Interestingly, a recent report suggested that LPA-mediated 
survival was not dependent on transactivation of either EGF, ErbB2 or PDGF receptors 
(44), implying that activated LPA receptors are directly mediating survival signals. The 
complete list for how LPA mediates survival is exhausting. It might be that LPA has 
many different pathways to influence cell survival and perhaps these events differ among 
cell lines. 
Extracellular environment of LPA  
     If the regulation of cell survival does ultimately depend on the activation of LPA 
receptors, then understanding the regulation of extracellular LPA levels is essential. 
LPA is produced externally from lysophosphatidylcholine (LPC), a component of 
lipoprotein particles found in human plasma and circulation at relatively abundant levels 
exceeding 100 µM (206). The precursor to LPC, phosphatidylcholine (PC), is also found 
at high levels of approximately 1 mM (206). Therefore, the progenitor ingredients to 
manufacture LPA are copious in the external medium.  
     The generation of extracellular LPA is catalyzed from LPC by the enzyme autotaxin 
(ATX) (Fig. 4), a transmembrane, ecto-nucleotide pyrophosphatase/phosphodiesterase, 
formerly known in relation to LPA only as lysophospholipase D (lysoPLD) (203, 205).  
ATX was identified in 1992 from melanoma cells as a tumor motility-stimulating protein 








thFig. 4. The metabolic pathway of LPA. This diagram shows a complex network
linking LPA to a variety of lipids (pink) and enzymes (blue) both intracellularly and
extracellularly. LPA is positioned at the top right of the diagram. Intracellularly, both
PLA1 and PLA2 can hydrolyze PA (at different sites) to give LPA. Alternatively,
ATX can remove the choline headgroup from LPC for LPA production extracellularly.
LPC can also be hydrolyzed to form glycerophosphocholine by the actions of PLB.ought that lysoPLD and ATX were two different, unrelated enzymes. Then in 2002 it 
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thought that lysoPLD and ATX were two different, unrelated enzymes. Then in 2002 it 
was discovered that lysoPLD, an obscure enzyme catalyzing the production of LPA, was 
actually identical to the better-known ATX (203, 205). Research since then has shown 
ATX is strikingly elevated in a number of cancer cell types, including kidney, prostate, 
ovary, lung and hepatocyte tissues (195, 196, 205, 234).  
     Many cancer cell lines are capable of releasing large amounts of LPC into the culture 
medium (237); furthermore, hepatocyte cells in particular are known for their ability to 
synthesize abundant PC (212). Using these cells as an example, the presence of both 
ATX and LPA-precursors in hepatocyte-conditioned medium would be enough to 
generate and maintain a constant, abundant pool of LPA. It is important to consider even 
serum-starved hepatocytes in culture may not have had all traces of LPA removed from 
the medium, exposing them to LPA before it is manually added to treat the cells, 
especially if the cells have had time to condition the medium over several days.  The 
presence of external LPA comes without the mammalian cell having to manufacture its 
own source of LPA internally and then maneuver it through the lipid bilayer (an idea 
which is still not clear and remains unproven). Because of this, it has been hypothesized 
that LPA acts as both an autocrine and paracrine mediator (222). Furthermore, ATX 
stimulates motility in a pertussis-toxin sensitive manner, indicating that a G protein 
signaling pathway is directly responsible (and implicating LPA and LPA receptors) for 
mediating the migratory response of ATX (110, 196).  
     Also affecting the extracellular pool of LPA molecules are lipid phosphate 
phosphohydrolases (LPPs), a class of phosphatidate phosphohydrolase homologues 
which includes the isoform LPP-1. This isoform and its relatives LPP-2 and LPP-3 are 
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six transmembrane domain proteins that can localize to the cell-surface or be retained in 
the endoplasmic reticulum. These hydrolytic ecto-enzymes expose their active sites on 
the exterior surface of the plasma membrane and are capable of increasing the 
dephosphorylation of exogenous LPA to monoacylglycerol by two-fold (Fig. 5) (51, 98, 
112).      
     Even though LPP-1 is non-selective for its lipid phosphate substrate, settling for LPA, 
PA or S1P along with others, it has been believed to negatively regulate LPA signaling 
(179, 216). One study suggested that in cancer cells, 95% of the hydrolysis of LPA 
occurs by LPPs (94). Through its hydrolysis of LPA, LPPs are preventing receptor 
activation, attenuating signal transduction, decreasing the amount of extracellular LPA 
available and thus having an indirect effect on major cell processes. The signaling 
responses diminished by overexpression of LPP-1 are MAPK, cAMP, calcium, DNA 
synthesis and cell division (148). The overexpression of LPP-1 even causes an increased 
rate of cellular apoptosis in ovarian cancer cells (98, 199) and the increase in LPA found 
in the ascites of ovarian cancer patients is thought to result at least in part from a decrease 
in mRNA activity of LPP-1 expression (199). In summary, the degradative consequence 







Fig.5. The extracellular metabolic pathway of LPA. This diagram gives a 
closer look at the cell-surface enzymatic actions that produce and degrade 
LPA along with the chemical structures of the lipids involved. Note the 
synthesis from LPC by ATX to yield LPA and LPA’s degradation by LPP-1 
to MAG at the plasma membrane.  
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Part C – Disease  
Disease 
LPA’s role in Disease 
     Recent studies have suggested that LPA might contribute to a multitude of undesirable 
health consequences like cancer, atherosclerosis and ischemia reperfusion injury (142, 
202, 206). If indeed these studies are correct, they implicate LPA as a factor in the two 
leading causes of death in the Western world: heart disease and cancer (8, 202). It will 
remain important to study the biology of LPA because of this uncertainty and for the 
hope that new treatment strategies will be developed from LPA research. 
Athclerosclerosis 
     The American Heart Association defines atherosclerosis as the process where deposits 
of cholesterol, waste, calcium and other factors build up in the inner lining of an artery, 
forming a plaque. These plaques become increasingly more dangerous as they grow and 
reduce blood flow through the artery. If they rupture, blood clots and blockage can follow 
which may lead to a stroke or heart attack, depending on the location of the ruptured 
artery. 
     Intriguingly, LPA and other platelet agonists accumulate in the lipid core of human 
atherosclerotic plaques, at elevated concentrations 13 times above normal (52, 229). The 
LPA that accumulates is probably generated by mild oxidation of LDL (190) and 
produced from the macrophages and smooth muscle cells present (193). When the lipid-
rich core of human carotid plaques was isolated, it was capable of directly activating 
platelets through aggregation and shape change; furthermore, these effects could be 
inhibited completely using an LPA receptor antagonist, implicating LPA receptor 
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specificity (167). LPA has also been shown to mediate vascular remodeling; it induces 
the accumulation of cells within the arterial walls, called neointimal lesions, and the de-
differentiation of smooth muscle cells through the LPA receptor, PPARγ (75, 236). 
     The implications here are threefold: that LPA in atherosclerotic plaques exists and has 
the potential to trigger platelet activation through LPA receptors (167). Second, treating 
patients who have a ruptured plaque with LPA receptor inhibitors might help prevent the 
formation of blood clots (167, 193). Finally, it has also been suggested that regular 
treatment with LPA receptor inhibitors might benefit people with hypertension and 
cardiovascular disease (229). 
Ovarian cancer 
     The American Cancer Society lists ovarian cancer as the fifth most common cancer in 
women and the fourth largest cause of cancer death in women. They estimate there will 
be about 25,580 new diagnosed cases of ovarian cancer in the United States in 2004 and 
approximately 16,090 women will die from the disease that same year. Unfortunately, at 
the time of initial diagnosis, two-thirds of patients already have a late-stage of the disease 
which drops their chances of survival down to 20-30% over 5 years (197).  
     A consequence of cancer forming in the peritoneal body cavity is the accumulation of 
abnormal fluid in the abdomen, called ascites. A gross amount of abnormal fluid buildup 
causes severe abdominal distention and discomfort. This uncomfortable ascetic fluid in 
ovarian cancer contains abundant tumor cells, lymphocytes and even LPA (68). The 
levels of LPA measured in the ascites of women with ovarian cancer are elevated and can 
reach up to 80 µM (53, 199), while normal levels are approximately 0.1-20 µM (10, 49). 
In gynelogical patients with stage I ovarian cancer, 80% had elevated levels of LPA with 
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a false positive rate of 5% (206, 227, 228). Similar increases are also seen in the blood of 
patient samples with cervical and endometrial cancer (173, 174, 206).  
     In approximately 15-30% of ovarian cancer cells, the LPA2 receptor and LPA2 mRNA 
are elevated (53, 54). Similarly, the LPA3 receptor is overexpressed in between 44-49% 
of ovarian cancer cells (54). Adding LPA to ovarian cancer cells in culture causes an 
activation of the proliferative signaling pathway, MAPK (226) and an increase in the 
concentration of urokinase plasminogen activator which contributes to metastasis and cell 
migration (152). Thus, LPA contributes to the growth, proliferation and metastasis of 
ovarian cancer cells through the LPA receptors. 
     Even with this new knowledge about the changes associated with LPA and ovarian 
cancer, there is still no regular, reliable screening performed in women. This is in contrast 
to prostate cancer screening where regular physical exams monitor the fluctuations in a 
man’s prostate-specific antigen (PSA) levels. Women who have yearly gynecological 
exams are usually limited to one routine screening test to monitor their reproductive 
health, a pap smear, which screens for cervical dysplasia, not ovarian cancer. The 
diagnostic test available for ovarian cancer is looking for a protein released from 
damaged cells called cancer-antigen 125 (CA-125) but it is rarely performed for 
screening. The CA-125 diagnostic test is also criticized for having a 3-7% false positive 
rate, although the National Cancer Institute claims that only 25-30% of men with elevated 
PSA levels actually have prostate cancer (1). Nevertheless, more reliable tests for ovarian 
cancer are needed.  
     Much discussion surrounding CA-125 has occurred in the past few years due to a 
widely-circulated e-mail from an anonymous source encouraging all women to demand 
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their doctors to perform a CA-125 test. In response to the increased demand for tests, a 
statement from the U.S. Preventative Services Task Force (USPSTF) recommended 
against routine screening for ovarian cancer (1). The USPSTF defended their position 
listing several reasons: first, they found no evidence that earlier diagnosis of ovarian 
cancer reduced mortality; second, there is only a 1:70 incidence of ovarian cancer in the 
overall population; finally, the USPSTF felt that false-positives would lead to harm (i.e. 
“potential distress and anxiety in otherwise healthy women”) (1). Instead they 
recommended the position previously held by the American College of Obstetricians and 
Gynecologists which is to “remain vigilant for the early signs and symptoms of ovarian 
cancer, such as abdominal or pelvic pain and unexplained weight loss (1).” 
     Unfortunately, it is not always the case that this utopian vigilance by doctors exists; 
furthermore, moderate weight loss would typically not be the kind of “symptom” a 
woman sadly reports to her doctor during their one-minute, once-a-year exchange. 
Oftentimes, the initial misdiagnosis of ovarian cancer is irritable bowl syndrome (IBS) or 
other gastrointestinal problems because the symptoms are not specific. Only later when a 
woman’s abdomen size competes with that of a woman who is pregnant does it become 
obvious the cause is not IBS. By that time, it could be too late for successful treatment. 
Cancer in the abdominal area has the unpleasant ease of metastasizing to organs in the 
peritoneal cavity which makes treatment more difficult. To reemphasize this point again, 
the high mortality associated with ovarian cancer is often from late-stage detection (197). 
This is why studying LPA and LPA receptors is so important for this disease; better 
screening and diagnostic tests for women are desperately needed and fluctuations in LPA 
could become an early disease biomarker. 
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Secretion of mediating factors 
     A discussion surrounding the involvement of LPA in cancer would not be complete 
without also mentioning the release of paracrine signaling molecules. LPA stimulation 
can cause the cell to produce TGF-beta (147), insulin-like growth factor II (72, 73), IL-6, 
IL-8 (55, 192) and vascular endothelial growth factor, VEGF (93). These effects may be 
specific to cancer cells as one report indicated that LPA stimulated the expression of IL-6 
in ovarian cancer cell lines, but not in the normal ovarian surface epithelial cells (29).  
     The anti-inflammatory cytokine IL-6 is induced by the immune system under alarming 
conditions to aid the induction of an acute phase reaction along with controlling the level 
of proinflammatory cytokines (223). Interleukin-6 is also capable of acting as an 
autocrine growth factor in malignancy; furthermore, the survival rate of ovarian cancer 
patients declines with increasing levels of IL-6 (16). Similarly, IL-8 and VEGF are both 
negatively linked to ovarian cancer and they contribute to the progression of ovarian 
cancer possibly by promoting metastases (54). IL-8 expression is also associated with a 
higher invasiveness potential of cancer cells in vitro ((64 Vignon, Lazennec 2003)Testing 
the IL-8 produced by cancer cells revealed the cytokine was identical to that normally 
produced by a monocyte (64). VEGF is an angiogenic factor that stimulates vascular 
endothelial cells to develop new blood vessels and it is often elevated in human cancers 
as tumors strive to maintain a supply of nutrients critical for their survival (93). This and 
other research suggests that LPA probably contributes to and exacerbates tumorigenesis 






Obesity, cancer and LPA  
    It is rapidly becoming common knowledge that obesity is a contributing factor in a 
variety of ailments such as high blood pressure, high cholesterol, heart disease, diabetes, 
sleep apnea, depression, asthma and even cancer of the uterus, gall bladder, breast, colon, 
and kidney (171). According to a recent survey by the National Health Policy Forum, 
obesity is becoming the fastest growing health crisis in the U.S. (171). In 1991, 
approximately 12% of the U.S. population was considered obese. Today, nearly 30% are 
obese and an additional 34% are overweight (171); thus, the majority of people in the 
U.S. have a serious weight problem. Fast food and sedentary lifestyles threaten to 
consume many lives because of the health risks being overweight has on the rest of the 
body.   
     The previous list of cancers associated with obesity did not include ovarian cancer, but 
a variety of studies suggest there may be a correlation. The American Cancer Society 
conducted an epidemiological survey of over 300,000 women in the U.S. and Puerto Rico 
and concluded that obesity resulted in an increase of 36% for the risk of ovarian cancer 
mortality in postmenopausal women (163). Japan, an Asian country often idealized for a 
healthier diet and lifestyle than the West, has seen an rise in ovarian cancer in the past 
decade and has hypothesized that the reason is a marked increase in obesity (133). 
     Obesity is linked to the etiology of many cancers because as the ratio of body mass 
index and body fat increases, so does the risk, prognosis and mortality from cancer due to 
the changes in endocrine function, hormones, receptors and growth factors (176). More 
specifically, fat cells or adipocytes secrete causative agents in hormone-related cancers: 
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estrogen, progesterone, androgens and testosterone (163, 164). Besides hormones, 
adipocytes also secrete abundant fatty acids, eicosanoids and even LPA (59, 207). In 
genetic obesity and adipocyte differentiation, fat cells are capable of up-regulating ATX 
expression which would result in even more LPA production (59). Also interesting is that 
the secretion of these paracrine factors controls adipocyte growth and recruits new fat 
cells to the tissue, increasing overall tissue mass(59). Therefore, as fat cells produce 
factors like LPA, they cause an increase in fat and unwanted cell proliferation, perhaps 
contributing to the etiology of ovarian cancer. 
The tumor suppressor p53  
     Twenty-six years ago in 1979, a new molecule named after its molecular weight of 53 
kDa, p53, was discovered. The initial description of p53 was a protein that accumulated 
in the nuclei of cancer cells (114). At the time researchers didn’t realize what they had 
stumbled upon was actually a mutant form of p53, a common denominator in 50% of all 
human cancers (13, 18, 157, 162, 169, 175, 235). Damage to the p53 gene is the most 
frequently observed alteration involved in tumorigenesis (191). Today a Pubmed 
literature search for “p53” retrieves over 33,500 articles, demonstrating the enormous 
amount of research that has occurred on this important protein since its discovery. 
     The p53 protein is critical to the cell because it is a tumor-suppressor and transcription 
factor that affects DNA repair, apoptosis and cell cycle progression. Checkpoint controls 
in the cell’s replication cycle prevent the reproduction of mutant cells. One of p53’s 
cellular-gatekeeping functions is to halt the progression of cell replication in G1 and G2 
phase if there has been damage to the DNA from drugs, UV light, etc. Normally, p53 is 
kept at relatively low concentrations in the cell because the half-life is only around 30 
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minutes (119). After DNA damage p53 accumulates in the nucleus, becomes stabilized 
and phosphorylated. The p53 protein can then upregulate genes involved in cell cycle 
arrest. One example of this is the increase in the cyclin-kinase inhibitor, p21, which 
blocks cyclin-kinase complexes necessary for cell-cycle progression. An arrest after 
DNA damage is critical to the cell because it allows time to repair the problem before 
replication proceeds (88).  
     Apoptosis is another process controlled largely by p53 under stress-induced 
conditions. If the cellular damage is well beyond the repair that would occur during cell-
cycle arrest, a buildup of p53 can induce the death pathway. A cell has two components 
influencing apoptosis: extrinsic signals from cell surface “death” receptors and intrinsic 
signaling mainly from the mitochondria (47). Remarkably, p53 is involved in both 
processes. For the extrinsic involvement, p53 is capable of increasing the expression of 
death receptors (88).  For its intrinsic involvement, p53 activation can modulate protein 
expression involved in mitochondrial membrane permeability (128).         
     Surprisingly for a transcription factor, p53 has been microscopically observed 
localized to the mitochondria. There p53 directly forms complexes with the anti-apoptotic 
protein Bcl-2 to inhibit its protection; this in turn causes an interaction with apoptotic-
promoting proteins and ultimately releases cytochrome c from the mitochondria (128). 
The release of cytochrome c initiates a death signal by activating proteins such as caspase 
3 and caspase 9 to begin apoptosis. Caspases belong to a larger family of cysteine 
proteases that are capable of cleaving proteins along nuclear lamina, for example, which 
is terminal to the life of a cell. 
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Fig. 6. The degradative pathway of p53 shows ubiquitination by Mdm2 and 
subsequent delivery to the proteasome. Phosphorylated p53 in the nucleus binds to 
DNA to upregulate genes. 
 
     The regulation of p53 is largely influenced by the protein murine double-minute 2, 
Mdm2 (also referred to by its human counterpart, Hdm2). To target a protein for 
destruction in the proteasome, at least four or more 76 amino-acid ubiquitin proteins must 
be covalently attached in tandem to the lysine residues on a protein for an adequate 
degradation signal. The Mdm2 protein is an E3 ubiquitin ligase that promotes the 
ubiquitination and degradation of p53 in an autoregulatory feedback loop.       
     Activating p53 will cause it to induce the transcription of Mdm2, which then binds 
p53 and inhibits its further activity. In other words, p53 positively regulates Mdm2 and 
Mdm2 negatively regulates p53. The negative regulation of p53 occurs threefold: first by 
Mdm2 binding to p53’s N-terminal domain to block transcriptional activation (130, 143); 
second, by conjugating ubiquitin to the Lys residues on p53 which target it to the 
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proteasome for degradation (90); finally, Mdm2 simultaneously directs the nuclear export 
of p53 and delivery to the cytosolic proteasome (21, 70).  
     Damage to the DNA is one catalyst for the disruption of Mdm2 binding and would 
then be follow with p53 phosphorylation, stabilization, activation and accumulation. 
More specifically, within minutes after DNA damage, p53 is phosphorylated at serine 15 
along its N-terminus which induces a conformational change in p53 and prevents its 
interaction with Mdm2 (188, 189). The association of p53 and Mdm2 is so critical, 
altering the integrity of Mdm2 or affecting the regulatory pathway of Mdm2 will 
functionally inactivate p53 (69, 233). 
     Because a strong link between LPA and cell survival has been established and since 
LPA is a well-known mitogen, we were curious what regulatory effects the LPA 
receptors might have on the cell cycle. The p53 tumor suppressor was of particular 
interest because it is modulated by LPA and aberrantly expressed in many cancers. 
Previously, no research has documented any connection between Edg-family LPA 
receptors and p53. The majority of findings that support a role for LPA mediating cellular 
apoptosis suggest that this occurs through the Gi signaling pathway (45, 56, 95, 113), 
making LPA-mediated signal transduction through a receptor PDZ-binding domain a 
unique find. In addition, to date there has not been a direct correlation with ecto-enzymes 
modulating the LPA signaling through these receptors. This subsequent chapters 
presented in this thesis will answer some of these questions and highlight the importance 
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     Lysophosphatidic acid (LPA) is a mitogenic lipid found in bodily fluids that elicits a 
wide range of effects on the cell including: proliferation, migration, morphological 
changes, neointima formation and survival (30, 45, 56, 66, 74, 95, 236). LPA is produced 
in blood by activated platelets in response to wound healing (109, 227) and is also 
produced by a variety of cancer cells (48, 185). The diverse actions of LPA are primarily 
mediated through one of three seven-transmembrane, G protein-coupled receptors 
(GPCRs): LPA1/Edg2, LPA2/Edg4, LPA3/Edg7, and by the metabolic receptor, PPAR-γ 
(4, 7, 11, 122, 138). Recent studies suggest that the orphan receptor GPR23 is also a high 
affinity LPA receptor (138). The LPA-binding GPCRs can collectively activate the 
following classes of G alpha proteins: Gi, Gq, and G12/13 (96, 138, 153). The resultant 
effects of LPA are mediated through the activation of downstream signaling pathways 
controlled by the balance of these G alpha proteins (208). 
     LPA potently stimulates the growth, survival and motility of a variety of cancer cells, 
which can produce and release LPA themselves (129). A variety of cancer cells have 
been shown to secrete an ecto-lysophospholipase D enzyme known as autotaxin (ATX), 
which can use extracellular lysophosphatidylcholine as a substrate to produce LPA (196, 
203, 205). ATX stimulates motility in an LPA-dependent and pertussis-toxin sensitive 
manner (110, 196). LPA signaling leads to the activation of both cell-proliferative 
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signaling pathways, such as the Ras/MAP kinase pathway, and cell survival pathways, 
such as the phosphatidylinositol-3 kinase (PI-3K)/Akt pathway (218). These effectors are 
primarily activated via pertussis toxin-sensitive, Gi signaling. 
     Although much is known about the effects of LPA signaling on cancer cell growth and 
motility, relatively little is known about LPA’s effects on cell cycle regulators, such as 
the p53 tumor suppressor. p53 is a transcription factor that controls the expression of 
genes encoding proteins that effect apoptosis and cell cycle progression (161, 184, 198). 
DNA damage causes phosphorylation-induced stabilization of p53 which then up-
regulates cyclin kinase inhibitors to block cyclin-kinase complexes that are necessary for 
cell-cycle progression (50, 170, 224). If the damage is irreparable, then p53 up-regulates 
the expression of genes that promote apoptosis, such as Bax (181, 182). Although human 
cancers differ in a multitude of factors, a common denominator that is consistently seen 
throughout numerous types of cancer is inactivation of p53 function in about 50% of all 
cancers (77). 
     Given the strong mitogenic effects of LPA and the commonly observed loss of p53 
function in cancer cells, we investigated whether LPA signaling affected the function of 
the p53 tumor suppressor. We found that signaling initiated by all three Edg-family LPA 
receptors (LPA1, LPA2, and LPA3) potently inhibited p53-mediated transcription and 
promoted the loss of p53 protein in both A549 lung cancer cells and HepG2 hepatoma 
cells. In the case of LPA1, we found that inhibition of p53 is likely mediated through a 
novel mechanism: interaction with PDZ domain containing proteins via its PDZ-binding 





MATERIALS AND METHODS 
 
Cell culture 
HepG2 cells were obtained from Dr. Athanassios Sambanis (Georgia Institute of 
Technology, Atlanta) and maintained as described previously (137). A549 cells were 
purchased from the American Type Culture Collection (Manassas, VA) and grown at 
37°C and 5% CO2 in F12K Kaighn’s modification medium (Mediatech, Herndon, VA) 
supplemented with 10% fetal bovine serum, 100 I.U./ml penicillin, 100 µg/ml 
streptomycin (HyClone, Logan, UT) and 1.5 g/liter sodium bicarbonate (Biosource 
International, Camarillo, CA). The HeLa cells were maintained in Dulbecco’s modified 
Eagle’s medium (DMEM) supplemented with 10% FBS, 100 I.U./ml penicillin, and 100 
mg/ml streptomycin (complete medium) at 37°C with 5% CO2. 
 
Reagents 
Lysophosphatidic acid (18:1 LPA; 1-oleoyl-2-hydroxy-sn-glycero-3-phosphate) (Avanti 
Polar Lipids, Alabaster, AL) was stored in chloroform at -20°C and dried down 
immediately before use under a stream of nitrogen. LPA was then reconstituted in 1% 
fatty-acid free, charcoal-stripped BSA as previously described (111, 152). Mouse anti-
p53 antibody (DO-1), which detects total p53, and mouse anti-β-actin antibody, which 
was used to monitor loading accuracy, were obtained from Santa Cruz Biotechnology Inc 
(Santa Cruz, CA). Phosphorylated p53 at serine 15 (Pp53[S15]) was detected with 
affinity-purified rabbit anti-Phospho-p53[S15] antibodies from Cellular Signaling 
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Technology (Beverly, MA) and Santa Cruz Biotechnology. The FLAG epitope tag was 
visualized using primary mouse anti-FLAG antibodies obtained from Sigma (St. Louis, 
MO) followed by fluorescent secondary antibodies. Carbamoylcholine chloride 
(carbachol) and actinomycin D were also purchased from Sigma. Pifithrin-alpha (PFT-α) 
was obtained from EMD Biosciences, Inc. (San Diego, CA). Pertussis toxin was obtained 
from BIOMOL (Plymouth, MA). All other reagents were from Sigma Chemical Co. 
 
Plasmids  
The original plasmid encoding the human FLAG-LPA1 receptor was a kind gift from 
Junken Aoki (University of Tokyo, Japan) and the modified construction of the FLAG-
LPA1 plasmid has been reported (154). To enhance the cell-surface expression of LPA2 
and LPA3, PCR was used to attach a signal leader sequence from the influenza 
hemaglutinin protein onto the amino terminus of the plasmid preceding the FLAG 
epitope tag. The FLAG-LPA2 vector was constructed using the primers 5’-
ATGCGGATCCATGGACTACAAAGACGAT –3’ and 5’ –GATCTCAGTCCTGTTGG 
TTGGG-3’. The FLAG-LPA3 vector was constructed by isolating total RNA from 
OVCAR-3 cultured cells with a GenElute Direct mRNA Miniprep kit (Sigma). Following 
isolation, RT-PCR was performed using the following oligonucleotides: 5’-
GATCATGAAGACCATCATCGCCCTGAGCTACATCTTCTGCCTGGTGTTCGCCG
ACTACAAGGACGATGATGACAAGATGAATGAGTGTCAC-3’ and 5’-CGATTTAG 
GAAGTGCTTTTA-3’. The RT-PCR reaction included 10 ng RNA, 10 µM sense and 
anti-sense primers, deoxynucleotides, reaction buffer, and 0.5 U of Taq DNA polymerase 
(Invitrogen, Carlsbad, CA) in a final volume of 50 µl. The mixes were first incubated at 
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50°C for 30 min to allow mRNA to be copied into cDNA, followed by a 2 min hold at 
94°C and 40 cycles of 94°C for 15 s, 55°C for 30 s and 72°C for 2 min. After the PCR 
reaction, a single 1062 bp band was observed, which was purified and subcloned into 
pcDNA3.1 V5/His mammalian expression vector (Invitrogen). LPA1-∆361 was 
constructed using wild-type LPA1 plasmid as the template and modifications were made 
as follows: 5’- GATCATGAAGACCATCATCGCCCTGAGCTACATCTTCTGCCTG 
GTGTTCGCCGACTACAAAGACGATGACGATAAA-3’ and 5’-AGCTAGCTCGAG 
CTAGTGGTCATTGCTGTGAAC-3’. The PCR cycle began with a 2 min hold at 94°C, 
followed by 25 cycles of 1.5 min 94°C, 1.5 min 55°C and 3 min 72°C before a 72°C hold 
for 10 min. The PCR products were purified and inserted into pcDNA3.1/V5-His using a 
TOPO TA Cloning Kit (Invitrogen). All of the DNA sequences were confirmed by DNA 
sequencing (Georgia Tech DNA Sequencing Facility, Atlanta). The LPA1-R124A 




For indirect immunofluorescence studies in HepG2 cells, Exgen 500 reagent (Fermentas, 
Hanover, MD) was used for transient transfection in complete media and the control 
comparison was made using the plasmid, pEGFP-N2 (BD Biosciences Clontech, Palo 
Alto, CA). For all other studies, HepG2 and A549 cells were transfected using 





Preparation of whole-cell lysates  
A549 cells were grown in 150 mm dishes for 24 h before washing with serum-free 
medium (SFM) and starved in SFM for 12-16 h prior to the treatments indicated above 
and in figure legends. Cells were rinsed with ice-cold PBS supplemented with 
phosphatase inhibitors (Active Motif, Carlsbad, CA), detached by scraping and collected 
by centrifugation. Pellets were then solubilized on ice for 30 min with intermittent 
agitation in lysis buffer (10 mM Tris pH 7.4, 100 mM NaCl, 1 mM EDTA, 1 mM EGTA, 
1 mM NaF, 20 mM Na4P2O7, 2 mM Na3VO4, 1% Triton X-100, 10% glycerol, 0.1% SDS 
and 0.5% deoxycholate, (Biosource International) supplemented with 1 mM PMSF from 
a 0.3 M stock and protease inhibitor cocktail (1:10 dilution; Sigma). Protein 
concentration was quantified using a BCA protein assay (Pierce, Rockford, IL). 
 
Indirect Immunofluorescence and Quantitation  
Immunofluorescence staining was performed as previously described (36). Briefly, cells 
were grown on glass coverslips and fixed in 2% formaldehyde in PBS before rinsing in 
PBS supplemented with 10% fetal calf serum (PBSserum) and incubation with primary 
antibodies. Coverslips were subsequently rinsed three times with PBS-serum and 
incubated with fluorescently-labeled secondary antibodies. During the last wash, Hoechst 
33342 dye (Molecular Probes, Eugene, OR) was added to label the DNA. Samples were 
mounted onto glass slides and observed with an Olympus BX40 epifluorescence 
microscope equipped with a 60X plan-apochromat lens and digital photomicrographs 
were obtained with a MagnaFire SP digital camera. All photographs were obtained using 




     For quantitation of fluorescence intensity, photomicrographs of 25 cells per time point 
or experimental treatment were obtained from each experiment that was repeated at least 
three independent times. The fluorescence intensity of the nuclear-localized p53 was 
measured in each cell using Metamorph Imaging Software (Universal Imaging 
Corporation, Downington, PA). The fluorescence intensity produced by p53 was 
normalized by first subtracting the background and then dividing that value by the 
fluorescence intensity of DNA labeled with Hoechst dye for each cell. Normalized data 
averages of each photomicrograph from all experiments were combined to obtain a grand 
average throughout. The data are presented as the mean ± S.E.M. 
 
ELISA for p53 
Whole cell lysates were collected and processed as described in the methods above. 
Twenty-five micrograms of whole cell protein was used to determine total p53 and 
Pp53[S15] levels at each experimental point. Analysis for these determinations was 
performed using p53-specific ELISA kits (Biosource) following the Manufacturer’s 
protocol. The final protein concentrations obtained were calculated by comparing the 
absorbance of triplicate samples to a standard curve from control p53 samples provided 
in the kit. Graphs of standard curves must have met the following criteria: R2 values 
>0.98 and readings equivalent to Manufacturer’s OD listed values for experiments to be 
considered acceptable. The amount of protein from the experimental samples was 
controlled so that the measured absorbance fell within the limits of the standard curve and 
no values were extrapolated. The data shown are presented as percent of control 
(untreated sample) combined from three independent experiments of triplicate samples 




Luciferase reporter gene assay  
Both firefly luciferase and Renilla (pRL-TK) luciferase activities were measured 36 h 
post-transfection using a dual luciferase assay kit (Promega, Madison, WI) as previously 
described (35,36). The construct pSRE-luc (BD Biosciences Clontech) expresses firefly 
luciferase and is stimulated by serum response factor (SRF) activation. The pp53-TA-luc 
vector contains a p53-response element, where p53 binds, that is upstream of the 
luciferase reporter (BD Biosciences Clontech). The plasmid, pRL-TK, which 
constitutively expresses Renilla luciferase (Promega), was used to normalize for 
differences in transfection efficiency. The normalized value is defined as the ratio of the 
(SRE, or p53-induced) firefly luciferase activity to Renilla luciferase. The data are 
presented as percent of control and were compared to untreated controls. They are shown 
as the mean ± S.E.M. of triplicate measurements from a representative experiment that 
was repeated at least three times. 
 
Statistical analysis  
The data was analyzed using either a single-factor or two-factor ANOVA followed by a 







     We were interested in determining whether the mitogenic lipid, LPA, affected the 
function of cell cycle regulators in cancer cells. Of particular interest was the tumor 
suppressor p53 since it can arrest damaged cells in G1 (184) and cause apoptosis once 
nuclear threshold levels are reached (116, 168). To address this question, we investigated 
the effects of LPA stimulation on the level of p53 protein present in A549 human lung 
carcinoma cells since these cells rapidly proliferate, express wild-type p53, and 
endogenously express LPA receptors (81, 117). In addition, we also used human 
epithelial liver hepatocellular carcinoma HepG2 cells as a comparative model because 
they are unresponsive to LPA and also express wild-type p53 (61, 91, 137). 
     First, we compared the relative expression of p53 protein in HepG2 cells, A549 cells 
and OVCAR-3 cells, which express high levels of mutant p53 (159, 231). The results 
indicate that A549 cells express approximately twice as much p53 when compared to 
HepG2 cells (Fig. 7A), which express very low amounts of endogenous p53. OVCAR-3 
cells express much higher levels of non-functional, endogenous p53 compared to either 
A549 cells, or HepG2 cells.  
     To determine whether LPA had any effect on p53 levels, A549 cells were treated with 
a physiological concentration of 10 µM LPA for 1-24 h and whole cell extracts were 
prepared and analyzed by ELISA (Fig. 7B). Treatment of A549 cells with 10 µM LPA 
for 1 h led to a 50% reduction in the levels of both total and active, serine15-
phosphorylated p53 (Pp53[S15]), which remained at this level for up to 6 h. The levels of 
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Fig. 7. LPA treatment reduces the level of p53 tumor suppressor protein in A549 
lung carcinoma cells. (A) HepG2, A549 and OVCAR-3 cells were grown in 10 cm 
dishes in complete media for 48 h prior to preparation of whole-cell lysates and 
immunoblotting with mouse anti-p53 (DO-1) antibody. (B) After growing A549 cells 
in 150 mm dishes, cells were rinsed and serum-starved overnight before treatment 
with 10 µM LPA for the times indicated. Whole cell extracts were analyzed for total 
p53 (white boxes) and phosphorylated Pp53[S15] (black triangles) by ELISA. The 
level of p53 (total or phosphorylated) protein in LPA-treated samples was normalized 
to that observed in untreated cells. The data represent the mean ± S.E.M. of three 
independent experiments performed in triplicate. 
both total and phosphorylated p53 began to increase after 6 h of LPA treatment and both 
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total and phosphorylated p53 began to increase after 6 h of LPA treatment and returned to 
control levels after 8 h. Independent quantitation using indirect immunofluorescence 
microscopy yielded identical results (data not shown). 
     We also examined the effects of LPA stimulation on the intracellular distribution of 
endogenous p53 protein (Fig. 8). In control cells, p53 was localized primarily to the 
nucleus and was also present in punctate spots that were dispersed throughout the 
cytoplasm (Fig. 8A). These cytoplasmic p53 spots co-localized with anti-ubiquitin 
antibodies suggesting that the p53 in these spots was ubiquitylated. Treatment with 1 µM 
LPA for 1 h led to a significant reduction in labeling of nuclear p53 and labeling of the 
cytoplasmic structures was also greatly diminished (Fig. 8B, 1 µM LPA). For 
comparison, we examined the effects of a known p53 inhibitor, pifithrin-α, which blocks 
p53-dependent transcriptional activation and apoptosis (103).  
 






Fig. 8. Sustained LPA treatment decreases nuclear localization of p53. (A) A549 
cells were plated onto glass coverslips prior incubation for 8 h in SFM. The cells were 
fixed and incubated with mouse anti-p53 antibody (DO-1) and rabbit anti-ubiquitin 
antibody followed by fluorescently-labeled secondary antibodies. (B) Approximately 
2 x 105 A549 cells were plated. After 16 h of serum-starvation, cells were then either 
left untreated (Untreated), treated with 1 µM LPA for 1 h (1 µM LPA), treated with 20 
µM pifithrin-α for 16 h (20 µM Pif-α), or with both 20 µM pifithrin-α and 1 µM LPA 
for 16 h (LPA+Pif-α). (C) A549 cells grown on glass coverslips were serum-starved 
for 16 h prior to treatment with the indicated concentrations of LPA for 6 h. Total p53 
was localized by indirect immunofluorescence microscopy using mouse anti-p53 
(DO-1) primary antibody followed by anti-mouse Cy3 secondary antibody. The 
fluorescence intensity of nuclear p53 staining was normalized to DNA labeled 
Hoechst dye and was quantified by image analysis as described in METHODS. The 
data represent the mean ± S.E.M. of the fluorescence intensity of nuclear p53 in LPA-
treated cells relative to that observed in untreated cells and are from a representative 




Treatment of A549 cells with 20 µM pifithrin-α for 16 h strongly reduced both nuclear 
and cytoplasmic labeling of p53 and was similar to the effects of LPA (Fig. 8B, 20 µM 
Pif-α). Interestingly, concurrent treatment of cells with both LPA and pifithrin-α, for 16 
h, resulted in a synergistic reduction in p53 staining (Fig. 8B, LPA + Pif-α). A549 cells 
were also incubated with various concentrations of LPA for 6 h and the LPA dose-
dependent loss of nuclear p53 staining was quantified using Metamorph image analysis 
software (Fig. 8C). We observed a progressive reduction in nuclear p53 labeling as the 
concentration of LPA was increased through the physiological range. Reduction in 
nuclear p53 staining was first apparent at 0.01 µM and was the greatest at 10 µM LPA (~ 
50% of control). In conclusion, the loss of nuclear p53 labeling paralleled the reduction in 
cellular p53 protein levels observed by ELISA (Fig. 7B). 
     Next, we determined the effects of LPA stimulation on p53-mediated transcription by 
using a p53-stimulated luciferase reporter gene assay. For these experiments we 
examined both A549 cells, which express endogenous LPA receptors, and HepG2 cells 
(LPA unresponsive cells) after expression of individual LPA receptors. A549 and HepG2 
cells were transiently co-transfected with a plasmid encoding a firefly luciferase reporter 
gene, whose expression is driven by a basal promoter and an upstream p53 response 
element, and with the plasmid pRL-TK, which constitutively expresses Renilla luciferase 
and serves to control for variations in transfection efficiency. The results in Fig. 9A show 
that LPA stimulation of native A549 cells led to a 60% reduction in p53-mediated 
transcription of the luciferase reporter gene (Control, black bar). In contrast, LPA 
stimulation of native HepG2 did not affect p53-mediated transcription, which is 
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consistent with previous reports showing that HepG2 cells are unresponsive to LPA (61, 
Fig. 9. Overexpression of the Edg-family LPA receptors inhibits the transcriptional 
activation of p53. A549 cells (A) or HepG2 cells (B) seeded in 24-well dishes were transiently 
transfected with the indicated plasmids along with p53 luciferase reporter and pRL-TK (Renilla 
luciferase) construct. Transient expression levels of FLAG-LPA receptors were kept within 10% 
of each other. Twenty-four h post-transfection, cells were incubated overnight with 10 µM LPA 
before measuring both firefly and Renilla luciferase. The data are presented here as percent of 
control (mean ± S.E.M. of triplicate samples) and the graphs are from a representative 
experiment, which was repeated at least three times with similar results. **P<0.01, comparison 
of cells treated with or without LPA to untreated, control cells. (C) HepG2 cells were transiently 
transfected with pEGFP (control) or FLAG-tagged LPA receptors before processing for indirect 
immunofluorescence. Primary antibody staining to determine the localization of LPA receptors 
was performed using mouse anti-FLAG antibodies and Ser15 phosphorylated p53 using rabbit 
a t -Pp53[S15] antib dies in the presence of 10% sa onin.  
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91, 137). Over-expression of any of the three Edg-family encoded LPA receptors, LPA1, 
LPA2, or LPA3, strongly reduced p53-mediated transcription in both A549 and HepG2 
cells to approximately 10- 35% of that observed in the corresponding control, 
untransfected cells. Additionally, indirect immunofluorescence studies showed that over-
expression of LPA1, LPA2, or LPA3 strongly reduced the nuclear localization of active 
p53[S15] in HepG2 cells (Fig. 9C) even in the absence of added LPA. 
     Neither the inhibition of p53-mediated transcription, nor the loss of nuclear p53 
localization by over-expression of LPA receptors required the addition of exogenous 
LPA. We hypothesized that these cells produced LPA themselves, which in turn would 
activate the transfected receptors. To test this, we examined the effects of a mutant LPA1 
receptor, LPA1 R124A, which cannot bind and be activated by LPA (172, 217). The data 
in Fig. 10A indicate that, unlike wild type LPA1 receptors, over-expression of the LPA1 
R124A receptor in HepG2 cells does not inhibit p53-mediated transcription supporting 
the hypothesis that the transfected LPA receptor must be capable of binding LPA in order 
to inhibit p53 function. We also speculated that if these cells produced LPA to activate 
the transfected receptors, then over-expression of lysophospatidate phosphatase 1 (LPP1), 
an enzyme that degrades LPA (98, 148), should prevent the inhibition of p53. We 
observed that transient transfection of LPP1 alone significantly elevated the 
transcriptional activity of endogenous p53 in A549 cells (Fig. 10B) and that co-
expression of LPP1 with wild type LPA1 receptors prevented the inhibition of p53-
mediated transcription, which was readily observed in cells transfected with LPA1 
receptor plasmids alone. Similar results were also observed in HepG2 cells (data not 
shown). As our first alternative approach, we determined the effects, on p53-mediated 
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transcription, of exogenously adding phospholipase B (PLB) to A549 cells transfected 
with LPA1-encoding plasmids (Fig. 10C). Addition of PLB to adipocytes inhibits LPA 
signaling by degrading either extracellular lysophosphatidylcholine (LPC), which is a 
substrate for LPA production via phospholipase D, or LPA itself (207). Addition of 
exogenous PLB prevented the inhibition of p53-mediated transcription by overexpressed 
LPA1 receptors in A549 cells. For another alternative approach, we determined the 
effects, on p53-mediated transcription, of adding a commercially-available inhibitor of 
LPP-1 activity to HepG2 cells transfected with either LPA1 or LPA1 and LPP-1 together. 
The LPP-1 inhibitor decreased p53-mediated transcription, likely because it affects the 
exogenous pool of LPP-1 and increases available LPA in the medium. Taken together, 
these results indicate that the inhibition of p53-mediated transcription observed in cells 
transiently transfected with LPA receptors requires receptor activation and that the 






Fig. 10. The inhibition of p53-mediated transcription requires LPA receptor 
activation and is prevented by LPP1. (A) Transient transfection of HepG2 cells or (B) 
A549 cells were performed using plasmids indicated in the figures along with p53 
luciferase and pRL-TK plasmids. Twenty-four h posttransfection, the cells were treated 
overnight with 10 µM LPA, followed with quantitation of luciferase activities. The data 
are presented here as a percent of control and are from a representative experiment that 
was repeated at least three times with similar results. **P<0.01, comparing p53 luciferase 
activity in LPA receptor-transfected cells compared to control, untransfected (control) 
cells. (C) A549 cells were transiently transfected prior to treatment overnight with 3 U/mL 
phospholipase B.  (D) HepG2 cells were transfected as indicated and treated for 16 h with 
1 µM of an LPP-1 inhibitor. *P<0.05, comparing transfected pairs either  untreated or 
treated with the inhibitor. 
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     Transcriptional inhibitors such as actinomycin D (ActD) greatly enhance the stability 
and nuclear accumulation of p53, which ultimately leads to the induction of apoptosis 
(28, 100, 101). To determine whether LPA would still inhibit p53 in the presence of 
ActD, we compared the effects of these two compounds, administered alone or in 
combination, on both the nuclear accumulation of p53 and on p53-mediated transcription 
in A549 cells (Fig. 11). Whereas LPA treatment (10 µM, 1 h) reduced the nuclear 
accumulation of both total p53 and Pp53[S15], ActD treatment (2 µg/ml for 2 h) 
increased both total and phosphorylated p53 levels in the nucleus (Fig. 11A and B). In 
contrast, treatment of A549 cells with both LPA and ActD prevented the decrease in 
nuclear p53 levels observed in cells treated with LPA alone. This established that the 
ActD-induced p53 stabilization is dominant to the LPA-induced decrease in p53. In 
addition, we also found that ActD reversed the inhibition of p53-mediated transcription in 





Fig. 11. Inhibitors of transcription prevent the LPA-mediated decrease of nuclear 
p53. (A and B) Serum-starved A549 cells were treated with either 10 µM LPA for 1 h, 
2 µg/ml actinomycin D for 2 h, or with 2 µg/ml actinomycin D (2 h) followed by 10 
µM LPA for an additional 1 h. Total p53 (A) was localized using mouse anti-p53 
(DO-1) antibody and phosphorylated p53[S15] (B) was localized using rabbit anti-p53 
and fluorescently labeled secondary Cy antibodies. The fluorescence intensity of 
nuclear p53 staining was normalized to DNA labeled with Hoechst dye and was 
quantified as described in METHODS. The data represent the mean ± S.E.M. of the 
fluorescence intensity of nuclear p53 in LPA-treated cells relative to that observed in 
untreated cells and are from a representative experiment that was repeated at least 
three times with similar results. (C) HepG2 cells were transiently transfected in SFM 
with the indicated plasmids along with p53 luciferase reporter and pRL-TK (Renilla 
luciferase) construct. Twenty-four hours posttransfection, cells were incubated 
overnight with 2 µg/ml actinomycin D before measuring luciferase. The data are 
presented as a percent of control, untreated cells (mean ± S.E.M. of triplicate samples) 
from a representative experiment that was repeated three times with similar results. 
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     The Edg-family of LPA receptors are coupled to multiple classes of G proteins 
including: Gi, Gq, and G12/13 (96) and the LPA-induced stimulation of cell survival is 
mediated in many cases through the stimulation of Gi and βγ signaling pathways (45, 56, 
74). To investigate whether overexpression of other GPCRs which couple specifically to 
Gi might also inhibit p53 function, we examined the effects of over-expression of the 
muscarinic acetylcholine type 2 receptor (M2 mAChR) on p53-mediated transcription in 
HepG2 cells (Fig. 12A). In contrast to LPA1 receptor transfected cells, over-expression of 
the Gi-coupled M2 mAChR and stimulation with its agonist, carbachol (1 mM), did not 
reduce p53-mediated transcriptional activation of the p53 luciferase reporter gene. 






Fig. 12. LPA-mediated p53 suppression is not dependent on Gi signaling. (A) 
HepG2 cells were transiently transfected with either pBluescript plasmid, plasmid 
encoding LPA1 or plasmid encoding M2 muscarinic acetylcholine receptor (M2 
mAChR) in addition to the p53 luciferase and pRL-TK plasmids as described in 
METHODS. The control and FLAG-LPA1 transfected cells were treated overnight 
with 10 µM LPA and the M2 mAChR cells were treated overnight with 1 mM 
carbachol. Luciferase activities were measured as described in METHODS and then 
normalized to untreated, control cells. **P<0.01 comparing p53 luciferase activity in 
either LPA1- or M2 mAChR-transfected cells to control, untreated cells. (B) HepG2 
cells, transfected with pBluescript or LPA1 plasmids, were treated overnight with 
either 10 µM LPA, 25 ng/ml pertussis toxin or both before measuring firefly and 
Renilla luciferase as described in METHODS. 
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     We also tested the Gi signaling inhibitor, pertussis toxin, and found that it had no 
1 and LPA2 receptors, but not LPA3 receptors, contain 
effect on the LPA1-induced inhibition of p53 (Fig. 12B) suggesting that the mechanism of 
LPA-mediated inhibition of p53 was not mediated through Gi-dependent signaling 
pathways. Further experiments that tested the effects of constitutively-active and 
dominant-negative mutants for Gi, Gq, and G12/13 proteins neither mimicked nor inhibited, 
respectively, the LPA receptor-induced inhibition of p53 (data not shown). Taken 
together, these data suggested that the inhibition of p53 function by LPA receptors was 
not mediated by traditional G-protein-dependent signaling pathways and so we 
investigated another possibility. 
     We noted that both the LPA
consensus PDZ-binding domains (S/T-X-V/L) in their cytoplasmic tails (Fig 13A), which 
would permit them to associate with PDZ domain-containing proteins. To test whether 
interaction of an LPA receptor with a putative PDZ domain-containing protein might be 
important for the inhibition of p53 function, we generated a truncation mutant of the 
LPA1 receptor (LPA1 ∆361) where the final three cytoplasmic amino acids (SVV) that 
comprise the PDZ-binding domain were deleted. Indirect immunofluorescence studies 
indicated that this receptor localized to the plasma membrane and underwent agonist-
induced internalization into punctate endosomal structures like wild type LPA1 receptors 
(Fig. 13B). To assess signaling, we determined the ability of this mutant receptor to 
stimulate the G12/13- and Rho GTPase-dependent activation of the serum response factor 
transcription factor in HepG2 cells. The data in Fig. 13C indicated that LPA1 ∆361 
receptor promoted the LPA-induced activation of an SRE-luciferase reporter gene 
plasmid similar to wild type LPA1 receptors. In contrast to SRF stimulation, LPA1 ∆361 
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receptors failed to inhibit p53-mediated transcription (Fig. 13D). These data suggested 
that, at least for LPA1 receptors, the inhibition of p53 function depends upon the 




Fig. 13. The PDZ-binding domain of the LPA1 receptor is required for inhibition 
p53- mediated transcription. (A) Schematic representation of the C-terminus of wild 
type LPA1, LPA2 and the site of truncation of the LPA1-∆361 mutant. (B) HeLa cells 
were transfected and after 36 hours, the cells were incubated in the absence 
(Untreated) or presence of 10 µM LPA for 30 min before processing for indirect 
immunofluorescence localization of LPA1. (C and D) HepG2 cells were transfected 
with plasmids encoding either SRE-luciferase (C) or p53- luciferase (D) along with 
pRL-TK and either pBluescript (control), wild-type FLAG -LPA1 or FLAG-LPA1-
∆361 in SFM. After 24 h posttransfection, cells were incubated in the absence or 
presence of 10 µM LPA for 16 h prior to determination of luciferase activity. The data 
(mean ± S.E.M.) are shown as a percent of  control and are from a representative 








      LPA signaling inhibited p53-mediated transcription and promoted a rapid decrease in 
the levels of p53 protein present in A549 lung carcinoma cells and LPA receptor-
transfected HepG2 hepatoma cells. In the case of LPA1 receptors, the inhibition of p53-
mediated transcription depended upon the presence of an intact C-terminal PDZ-binding 
domain. Overexpression of LPA receptors strongly inhibited p53 function even in the 
absence of exogenously added LPA. This inhibition was prevented upon co-expression of 
the lipid phosphate phosphatase, LPP1, which can degrade exogenous LPA, or lipid 
phosphates that are produced downstream of LPA receptor activation (22). Furthermore, 
addition of exogenous phospholipase B, which decreases the accumulation of exogenous 
LPA, also blocked the inhibition of p53 function. This suggests that production of 
extracellular LPA may activate the transfected receptors. Consistent with this hypothesis, 
transfection of cells with mutant LPA1 R124A receptors, which cannot bind LPA, failed 
to inhibit p53 activity indicating that the observed inhibition of p53 requires LPA 
receptor activation.  
     LPA stimulation of A549 lung carcinoma cells led to a rapid loss of p53 protein from 
the nucleus of these cells (Fig. 8) and a concurrent decrease in the cellular levels of total 
p53 and Pp53[S15] (Fig. 7). The p53 protein contains several nuclear import signals 
(NLS) as well as multiple nuclear export signals (NES) (127, 139, 239). In non-
tumorigenic cells, association of p53 with the E3 ubiquitin ligase, MDM2, promotes 
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ubiquitylation and nuclear export of p53 with subsequent degradation of the protein by 
cytoplasmic proteasomes (83, 106, 221). Previous studies have also shown that serine 15 
lies within an N-terminal NES and that phosphorylation of this residue prevents nuclear 
export of p53 (239). Our data demonstrate that stimulation of endogenous LPA receptors 
in A549 cells (Fig. 8) and transient transfection of any of the three Edg-family LPA 
receptors into either A549 cells, or HepG2 cells decreased Pp53[S15] in the nucleus (Fig. 
9C). These results are consistent with a model where LPA signaling lowers the 
abundance of cellular protein of Ser15-phosphorylated p53, which in turn promotes the 
nuclear export of p53. Our immunofluorescence studies also showed that p53 localized to 
numerous punctate structures in the cytoplasm, which co-localized with anti-ubiquitin 
antibodies (Fig. 8A). The decrease in Ser15-phosphorylated p53 could result from either 
LPA-mediated inhibition of kinases that phosphorylate p53 at this site (e.g., ATM or 
ERK) (12, 183), or by enhancement of serine/threonine phosphatases that 
dephosphorylate p53 at this site (e.g., PP5) (240). 
     Consistent with the loss of nuclear p53 protein, we observed a decrease in p53-
mediated transcription in LPA stimulated cells (Fig. 9). It was intriguing that over-
expression of LPA receptors alone was sufficient to promote the inhibition of p53-
mediated transcription. However, several lines of evidence support the specificity of this 
response. First and most important, stimulation of native, untransfected A549 cells with 
LPA inhibited p53-mediated transcription (Fig. 9A, control cells). Second, transfection of 
HepG2 cells with the LPA1 R124A receptor mutant did not inhibit p53-mediated 
transcription (Fig.10A). Arginine 124 is located in the extracellular domain of the LPA1 
receptor and is critical for binding to LPA; mutation of this residue to alanine inhibits 
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LPA binding and activation of the receptor (172, 217). Third, coexpression of LPA1 and 
the lipid phosphate phosphatase, LPP-1, prevented the inhibition of p53- mediated 
transfection (Fig. 10B). Over-expression of LPP-1 attenuates the stimulation of MAP 
kinases, phospholipase D, and cell division by exogenously added LPA (98, 148). 
Finally, we also observed that LPA inhibition of p53-mediated transcription is prevented 
by treatment of A549 cells with exogenous phospholipase B, which degrades 
lysophosphatidylcholine and LPA and inhibits LPA signaling (207) (Fig. 10B). These 
data indicate that LPA produced by the A549 and HepG2 cells is sufficient to activate the 
transfected LPA receptors. To further support the specificity of LPA-induced inhibition 
of p53, we observed that over-expression of the M2 mAChR, another Gi-coupled receptor 
did not inhibit p53-mediated transcription (Fig. 12A), but rather it increased p53-
mediated transcription. Together with the finding that pertussis toxin did not rescue the 
LPA-induced inhibition of p53 activity; our data suggests that the inhibition of p53 is 
independent of LPA receptor stimulation of Gi-mediated signaling pathways. 
     How do LPA receptors inhibit p53 activity? At least in the case of the LPA1 receptor, 
the mechanism of p53 inhibition is likely to involve association with a PDZ-containing 
protein. This hypothesis is based on the finding that a mutant LPA1 receptor, which lacks 
the C-terminal PDZbinding domain (LPA1 ∆361), is unable to inhibit p53-mediated 
transcription (Fig. 13). However, this mutant LPA receptor is functional in LPA-mediated 
signaling since it was able to undergo agonist-induced internalization. The mutant also 
stimulated SRF-mediated transcription which is Rho- and G12/13 dependent (Fig. 13B and 
C). This suggests that the lack of inhibition of p53-mediated transcription by LPA1 ∆361 
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is specific to this signaling event and not due to a global defect in LPA signaling by this 
receptor. 
     Many GPCRs, such as β-adrenergic receptors contain C-terminal PDZ-binding 
domains and associate with a variety of PDZ-containing proteins such as PSD-95 (92) 
and the Na/H exchanger regulatory factor (NHERF) 1 and 2 (78, 79). Although several 
proteins that interact with the C-terminal tail of the LPA2 receptor have recently been 
reported (141, 225), thus far no LPA1 interacting proteins have been reported. Of 
particular interest is the recent finding that NHERF2 binds to the PDZ-binding domain of 
the LPA2 receptor to promote phospholipase C β3 activation (141). We are currently 
investigating whether the LPA2-induced inhibition of p53 activity requires its PDZ-
binding domain. It is intriguing that over-expression of LPA3 also inhibits p53-mediated 
transcription and yet this receptor does not contain a consensus PDZ-binding domain 
raising the possibility that LPA3 may inhibit p53 activity through a distinct mechanism 
from LPA1.  
     LPA is a potent mitogen for a variety of normal and tumorigenic cells and is known to 
promote both cell proliferative and anti-apoptotic signaling pathways (129). Studies on 
the cellular mechanisms involved in mediating the pro-growth effects of LPA have 
focused on the activation of Ras/MAP kinase and Rho GTPase signaling pathways as 
well as stimulation of the serine/threonine kinase, Akt. However, relatively little is 
known about the effects of LPA signaling on cell cycle regulators such as the p53 tumor 
suppressor. Our studies highlight a previously unappreciated effect of LPA signaling, 
namely that it potently inhibits transcriptional activation of p53 and enhances p53 
degradation. In normal cells, activated p53 promotes G1 cell cycle arrest and/or apoptosis 
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in response to DNA damage (88). p53 is either mutated or inactivated in 50% of all 
cancers, which enhances the ability of cancer cells to evade cell cycle arrest and 
apoptosis. In tumor cells that contain wild type p53 protein key down-stream effectors 
such as the cyclin kinase inhibitor, p21CIP1, are often mutationally inactivated. We 
propose that LPA receptor-mediated inhibition of p53 activity in cells that express wild 
type p53, such as A549 cells, may enhance cancer cell survival by preventing the 
activation of apoptosis. The combined effects of LPA on cancer cells to promote cell 
proliferative signaling, while inhibiting p53-mediated transcription are likely to 
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     LPA is a major serum phospholipid that exhibits growth factor-like properties towards 
a variety of cells (131). Some of the pleiotropic cellular effects exerted by LPA include 
the stimulation of cell migration (135), tumor cell invasion (194) and neurite retraction 
(97), as well as growth stimulation of a variety of normal and tumorigenic cells (209). 
Most of these effects are mediated by the binding of LPA to cell-surface serpentine 
receptors that couple to and activate heterotrimeric G proteins of the Gi, Gq and G12/13 
families (218). LPA stimulation of cells via these G-protein pathways has been shown to 
inhibit adenylyl cyclase, induce intracellular calcium release, activate rho GTPases, 
stimulate transcription of serum responsive genes, and activate the ERK1/2 mitogen-
activated protein kinases (86, 96, 132, 209).  
     Molecular cloning studies have identified three mammalian receptors that belong to 
the endothelial differentiation gene (EDG) family of G-protein-coupled receptors 
(GPCRs) that are activated by LPA: LPA1/EDG-2, LPA2/EDG-4 and LPA3/EDG-7 (30). 
These receptors were initially termed EDG receptors since they share sequence homology 
with the sphingosine-1-phosphate (S1P)-specific S1P1/EDG-1 receptor (87). 
Heterologous expression studies have shown that all three receptors can activate Gi- and 
Gq-coupled signaling pathways (96). LPA1 and LPA2, but not LPA3, can additionally 
stimulate G12/13-coupled pathways. Recent studies have also indicated that LPA is a 
potent mitogen for ovarian cancer epithelial cells and that increased LPA concentrations 
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in the serum and ascites might serve as a useful biomarker for ovarian cancer (53, 131, 
227). 
     These studies also suggest that expression of LPA2 or LPA3, which are not expressed 
in normal ovarian epithelial cells, is upregulated in ovarian cancer epithelial cells (53). 
Interestingly, LPA1 has been shown to be a negative regulator of ovarian cancer cell 
growth (67). Of the three known LPA receptors, LPA1 shows the widest tissue 
distribution. Human LPA1 is expressed in adult organs such as brain, heart, ovary, testes, 
colon, prostate and spleen, but is not detectably expressed in liver, thymus or lung (35, 
84). 
     Agonist binding and activation of most GPCRs usually results in the rapid 
phosphorylation and endocytosis of the receptor (57). GPCR endocytosis serves as an 
entry point for targeting activated GPCRs into a variety of intracellular compartments 
including endosomes and lysosomes. Dephosphorylation of receptors in endosomes and 
subsequent recycling back to the cell surface constitutes GPCR resensitization, whereas 
targeting receptors to lysosomes for degradation is used for GPCR downregulation. Thus 
far, nothing is known about the trafficking or intracellular destinations of any LPA-
coupled receptor. 
     To gain further insight into how cells regulate the activity of specific LPA receptors, 
we investigated the agonist-induced trafficking of the human LPA1 receptor in HeLa 
cells. Our results indicate that LPA1 is rapidly internalized into cells via dynamin2- and 
Rab5-dependent mechanisms in an LPA specific and LPA dose-dependent manner. 
Interestingly, we find that LPA1 is internalized and recycled at a low basal level when 
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cells are cultured in medium that contained 10% FBS, which suggested that LPA levels 






MATERIALS AND METHODS 
 
Cells, reagents and antibodies 
HeLa cells were maintained in Dulbecco’s modified Eagle’s medium (DMEM) 
supplemented with 10% FBS, 100 I.U./ml penicillin, and 100 mg/ml streptomycin 
(complete medium) at 37°C with 5% CO2. Mouse monoclonal antibodies against the 
FLAG epitope tag were purchased from Sigma, mouse antibodies against the early 
endosomal marker EEA1 were obtained from Transduction Laboratories (Lexington, 
KY), mouse antibodies to the human transferrin receptor B3/25 were from Roche 
Molecular Biochemicals (Indianapolis, IN), and mouse anti-LAMP-2 IgG (H4B4), 
developed by J. T. August and J. E. K. Hildreth, was obtained from the Developmental 
Hybridoma Bank developed under the auspices of the NICHD and maintained by the 
University of Iowa, Department of Biological Sciences (Iowa City, IA). Alexa594- and 
Alexa488-conjugated goat anti-mouse and goat anti-rabbit IgG was purchased from 
Molecular Probes (Eugene, OR). Lysophosphatidic acid (1-Oleoyl-2-hydroxy-sn-
glycerol-3-phosphate; LPA) and D-erythro sphingosine-1-phosphate (S1P) were 
purchased from BIOMOL Research Laboratories (Plymouth Meeting, PA). L-alpha-
lysophosphatidylcholine (LPC), fatty acid-free BSA, and all other chemicals were 
purchased from Sigma. Stock solutions of LPA and LPC were prepared by dissolving in 
dH2O and sonication, whereas S1P was prepared by dissolving in methanol, followed by 
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evaporation under a stream of nitrogen gas. The dried S1P was then dissolved in 4 mg/ml 
fatty acid-free BSA (Sigma) in dH2O. For lipid stimulation, cells were grown on glass 
coverslips for 16-24 hours at 37°C in complete medium and then incubated in serum-free 
DMEM (SF-DMEM) for an additional 16 hours at 37°C prior to incubation with the 
appropriate lipid in SF-DMEM.  
 
DNA manipulations and transfections 
An expression plasmid encoding the human LPA1 receptor containing an amino terminal 
FLAG epitope tag (11) was the kind gift of Junken Aoki (University of Tokyo, Japan). 
The FLAG epitope tag in this receptor is exposed to the extracellular environment when 
LPA1 is at the cell surface. To enhance cell-surface expression of LPA1, PCR was used to 
attach a signal leader sequence from the influenza hemaglutinin protein onto the amino 
terminus of FLAGtagged LPA1 cDNA using the following primers: 5’-
ATCATGAAGACCATCATCGCCCTGAGCTACATCTTCTGCCTGGTGTTCGCCGA
CTACAAAGACGATGACGATAAA-3’ and 5’-GATCTCAAACCACAGAGTGATC-3’. 
Following PCR amplification, the cDNA product was subcloned into the eukaryotic 
expression vector pcDNA 3.1/V5-His using a TOPO TA Cloning Kit (Invitrogen, 
Carlsbad, CA) All DNA sequences were confirmed by DNA sequencing (Emory 
DNA Sequencing Core Facility, Atlanta, GA).  
 
To generate stable HeLa cell transfectants, wild-type (WT) LPA1 was transfected into 
HeLa cells using the calcium phosphate coprecipitation method (Radhakrishna and 
Donaldson, 1997). At 36 hours after transfection, cells were detached and re-plated at a 
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1:25 dilution into complete medium containing 600 µg/ml G418 (Life Technologies, 
Gaithersburg, MD). Approximately two weeks later, G418-resistant clones were 
amplified and tested for LPA1 expression by indirect immunofluorescence microscopy. 
For immunolocalization studies, HeLa cells were grown on glass coverslips to 
approximately 50% confluency and transfected in six-well dishes using the calcium 
phosphate method. The cells were transiently co-transfected with either WT and mutant 
plasmids encoding green fluorescent protein (GFP)-Rab5 along with plasmids for FLAG-
tagged LPA1 into six-well dishes using 5 µg of Rab5 DNA or WT and mutant dynamin 
plasmids (10 µg of dynamin plasmid per well) with FLAG-tagged LPA1.  
 
Indirect immunofluorescence  
At 22 hours after transfection, the cells were rinsed with SF-DMEM and incubated in the 
same medium for 16-24 hours before further treatments. Cells were treated as described 
in the figure legends, fixed in 2% formaldehyde in PBS for 10 minutes, and rinsed with 
10% FBS and 0.02% azide in PBS (PBS-serum). The cells were permeabilized by 
treating with ice-cold methanol for 30 seconds at –20°C, rinsing with ice-cold PBS twice 
and incubating in PBS-serum for 5 minutes. Fixed cells were incubated with primary 
antibodies diluted in PBSserum containing 0.2% saponin for 45 minutes, and then 
washed (three times, 5 minutes each) with PBS-serum. The cells were then incubated in 
secondary antibodies diluted in PBS-serum plus 0.2% saponin for 45 minutes, washed 
with PBS-serum (three times, 5 minutes each) and once with PBS, and mounted on glass 
slides. Samples were observed using an Olympus BX40 epifluorescence microscope 
equipped with a 60X Plan pro lens and photomicrographs were prepared using a Spot RT 
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monochrome ‘C’ digital camera (Diagnostic Instruments, Sterling Hts, MI). The 
fluorescence images were photographed using the same exposure time and processed 
identically using Adobe Photoshop 5.0.  
 
Quantitation of LPA1 internalization  
HeLa cells expressing FLAG-tagged LPA1 were treated as described in the figure legends 
and fixed as described above. The fixed cells were labeled with 10 µg/ml concentration 
of Alexa488-labeled conconavalin A (ConA), which was obtained from Molecular 
Probes in the absence of detergent permeabilization to label the plasma membrane 
uniformly. The cells were then washed with PBS/serum and labeled with mouse anti-
FLAG antibodies (M1) and Alexa594- labeled goat anti-mouse antibodies in the presence 
of 0.2% saponin as described above. Photomicrographs of 24 cells per time point or 
experimental treatment were obtained from a total of three independent experiments 
using a Zeiss (Heidelberg, Germany) LSM 510 laser scanning confocal microscope 
equipped with a 63XPlan-Apochromat oil immersion lens. The percentage of cell-surface 
receptors was determined by measuring the extent of LPA1 colocalization with the cell-
surface marker Alexa594-labeled ConA. Quantitation of co-localization was performed 
as described previously using Metamorph Imaging System Software (Universal Imaging 
Corporation, West Chester, PA) (215). Briefly, background was substracted from 
unprocessed images and the percentage of LPA1 pixels (red) overlapping ConA pixels 
(green) was measured. The data was normalized to untreated cells (time=0) and the 
percentage of internalized receptors was calculated by subtracting the percentage of cell-
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surface receptors from 100%. The data is presented as mean (± s.e.m.) and statistical 
analysis was performed using ANOVA followed by a Dunnett’s post-hoc test.  
 
Immunoblotting 
At 30-36 hours after plating, cells were detached from a T-75 flask with trypsin/EDTA or 
scraped from culture dishes after the indicated treatment, washed twice with ice-cold 
PBS, and pelleted by centrifugation at 300 g for 5 minutes at 4°C. The pellets were 
resuspended in 100-200 µl of cell lysis buffer (1% NP-40, 1% sodium deoxycholate, 
0.1% SDS, 0.15 M NaCl, 0.01 M sodium phosphate pH 7.2, 2 mM EDTA, 50 mM NaF, 
0.2 M sodium orthovanadate, 0.02% azide, 100 µg/ml leupeptin and 0.1 mM PMSF) and 
incubated on ice for 15 minutes. Detergent-insoluble material was removed by 
centrifugation at 13,000 g for 10 minutes at 4°C. The samples (30 µg of protein per lane) 
were then separated by SDS-PAGE on 10% gels and transferred to nitrocellulose paper. 
MAP kinase activation was detected using the PhosphoPlus p44/42 MAP Kinase 
antibody kit (Cell Signaling, Beverly, MA) and LPA1 was detected using an affinity-
purified rabbit anti-FLAG antibody (Sigma). The binding of primary antibodies was 
detected by enhanced chemifluorescence detection (Amersham Biosciences, Piscataway, 
NJ). 
 
Measurement of serum response factor (SRF) activity  
A transcriptional reporter gene assay (Clontech) was used to monitor the activity of SRF. 
For these studies, we used the HepG2 human hepatoma cell line since this cell does not 
contain functional LPA receptors (61). Approximately 7x104 HepG2 cells were plated in 
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96-well dishes and transfected with 0.2 µg plasmid encoding FLAG- LPA1, 0.2 µg pSRE-
luc, 0.05 µg pRL-TK and either 0.2 µg of pBluescript KS+ or 0.2 µg of the GTPase 
(dynamin or Rab5) construct. Cells were transfected in SF-DMEM using lipofectamine 
(Invitrogen) at 1 µl lipofectamine per 0.4 µg DNA. pSRE-luc encodes firefly luciferase 
and contains three tandem copies of the serum response element upstream of a basal 
promoter; luciferase expression is strongly stimulated by SRF. The pRL-TK construct 
constitutively encodes Renilla reniformis luciferase whose expression is controlled by a 
thymidine kinase promoter; Renilla luciferase expression serves to monitor transfection 
efficiency. After incubation with the DNA complexes for 24 hours, the cells were rinsed 
with SF-DMEM and incubated in the same medium with either no additions or 1 µM 
LPA for an additional 16 hours. Both firefly luciferase and Renilla luciferase activity was 
measured using the Dual Luciferase Reporter Assay System (Promega, Madison, WI) and 
data were collected with a TD-20/20 luminometer (Turner Designs, Sunnyvale, CA). 
Normalized luciferase activity was calculated by dividing the firefly luciferase activity by 
the Renilla luciferase activity. Statistical analysis was performed using a single-factor 










Expression and functional analysis of epitope-tagged LPA1 receptors in HeLa cells 
To investigate the consequences of agonist stimulation on the intracellular trafficking of 
human LPA1, we established a stably transfected HeLa cell line expressing human LPA1 
containing an amino-terminal FLAG epitope tag. Western blotting showed that FLAG-
tagged LPA1 was expressed as a protein of approximately 43 kDa in cell extracts 
prepared from stably transfected HeLa cells (Fig. 14A, E2), but was not detected in 
extracts from untransfected HeLa cells (Fig. 14A, H). This is consistent with a molecular 
mass of approximately 41 kDa that was previously reported for human LPA1 (65). 
     Since HeLa cells are known to express endogenous LPA1 and LPA2 receptors, we 
wanted to determine the time course of LPA-induced activation of signaling for later 
comparison with the time course of agonist-induced LPA1 endocytosis. Stimulation of 
many cell types with LPA induces a rapid, but transient, activation of the mitogen-
activated protein kinase (MAPK) pathway (van Corven et al., 1992). Thus, we examined 
the time course of LPA-induced activation of the endogenous MAP kinases ERK1/2 (Fig. 
14B) both in stably transfected HeLa cells expressing FLAG-tagged LPA1 and in 
untransfected HeLa cells. ERK1/2 activation was assessed using commercially available 
antibodies that recognize the dually phosphorylated, active form of ERK1/2. In cells 
stably expressing FLAG- LPA1, the levels of activated ERK1/2 increased rapidly from 1 
to 5 minutes following treatment with 10 µM LPA, with peak activation occurring 
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between 5 and 10 minutes, and then steadily decreased such that very little activated 
ERK1/2 could be detected after 30 minutes of LPA treatment. In the absence of LPA 
treatment, ERK phosphorylation was not detected. Untransfected HeLa cells also 
exhibited a rapid increase in activated ERK1/2; however, we consistently observed that 
the peak ERK activation occurred between 10 and 30 minutes. This response was slightly 
slower than that observed in cells over-expressing FLAG- LPA1 and was most probably 
due to enhanced ERK activation through the elevated levels of LPA1 present in the 
FLAG- LPA1-expressing cells. Taken together, these results indicated that LPA 
















Fig. 14. Stable expression of human LPA1 in HeLa cells and LPA stimulation of
ERK1/2 activity. (A) Cell extracts were prepared from either untransfected HeLa
cells (H) or from stably transfected HeLa cells expressing LPA1 (E2). Various
amounts of extracts were separated by 10% SDS-PAGE, transferred to nitrocellulose
and probed with rabbit anti-FLAG antibodies and processed for chemiluminescence
detection. A single band of approximately 43 kDa was detected by anti-FLAG
antibodies in extracts prepared from stably transfected LPA1-expressing cells, but not
from untransfected HeLa cells. (B) Stable LPA1-expressing HeLa cells or
untransfected HeLa cells were stimulated with 10 µM LPA for the indicated times and
washed at 4°C prior to detergent solubilization. Equal amounts of cell extracts (30 µg)
were separated by SDS-PAGE and probed with rabbit antibodies against dually
phosphorylated ERK1/2 or total ERK1/2 as described in the Materials and Methods.
LPA-stimulated ERK activity is maximal between 5 and 10 minutes and then declines
by 30 minutes in the FLAG-LPA1 stable transfectants.  
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Agonist-dependent internalization and recycling of LPA1  
We next determined the effects of LPA stimulation on the cellular distribution of LPA1 
(Fig. 15) using indirect immunofluorescence. Treatment with 10 µM LPA resulted in a 
time-dependent redistribution of LPA1 from a predominantly plasma membrane (PM) 
localization, observed in unstimulated cells (Fig. 15, 0 min), to small punctate 
intracellular structures. These structures are likely to be intracellular endosomal 
compartments since they were not observed if immunofluorescence labeling was 
performed without detergent permeabilization (data not shown). In the absence of 
permeabilization, anti-FLAG antibodies only labeled the LPA1 receptors at the cell 
surface by binding to the externally oriented FLAG epitope. Furthermore, the anti-FLAG 
antibodies did not label untransfected HeLa cells (data not shown). Endosomal staining 
was first observed within 10 minutes after LPA treatment and increased in fluorescence 
intensity such that, after 30 minutes of stimulation, LPA1 localized predominantly to 
these vesicular structures. There was also a noticeable decrease in plasma membrane 
labeling after 30 minutes of LPA treatment (Fig. 15, 30 min). This pattern of localization 
was the same after 60 minutes of LPA treatment (Fig. 15, 60 min).  
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Fig. 15. LPA induces the time-dependent internalization of 
LPA1 in HeLa cells. Stably transfected HeLa cells expressing 
LPA1 were incubated for various times with 10 µM LPA, fixed 
and processed for indirect immunofluorescence localization of 
LPA1 using mouse anti-FLAG antibodies and Alexa594-labeled 
goat anti-mouse secondary antibodies. LPA1+ endosomal 
structures are first observed after 10 minutes of LPA treatment. 




     To quantify LPA1 internalization, we used a quantitative immunocytochemical 
approach that was recently used to analyze muscarinic acetylcholine receptor 
internalization in PC12 cells (215). This approach takes advantage of the observation that 
unstimulated receptors show greater co-localization with a plasma membrane marker than 
internalized receptors. Internalization is quantified by measuring the extent of 
fluorescence overlap between the receptor and plasma membrane marker using 
fluorescence imaging software (see Materials and Methods). In the case of the M4 
muscarinic acetylcholine receptor, data obtained from the fluorescence quantitation of 
receptor endocytosis was indistinguishable from data obtained through radioactive ligand 
binding experiments (215). We measured the effects of LPA treatment on the extent of 
fluorescent pixel overlap and LPA1, which was stained with mouse anti-FLAG antibodies 
and Alexa594-labeled secondary antibodies. Fig. 16A shows a representative panel of 
images, obtained by confocal microscopy, which compares the distribution of LPA1 and 
Alexa488-ConA in stably transfected HeLa cells either before or after treatment with 10 
µM LPA. Both Alexa488- ConA and LPA1 are extensively co-localized at the PM in 
untreated cells. Following LPA treatment, there is a significant reduction in the extent of 
co-localization between LPA1 and Alexa488-ConA. Quantification of the overlap in 
fluorescence showed that approximately 40% of surface LPA1 receptors are internalized 
within 15 minutes after LPA treatment and that there is no further increase in 
internalization (Fig. 16B). This is comparable with the extent of internalization of β2-
adrenergic receptors (β2ARs) (140, 180).  
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Fig. 16. Quantitation of LPA1 internalization. LPA1-
transfected cells were incubated with 10 µM LPA for various 
times and then fixed and processed for quantitation of receptor 
internalization by laser scanning confocal microscopy as 
described in the Materials and Methods. (A) A representative 
confocal image is shown of untreated and LPA-treated cells 
stained with ConA to label the PM, and anti-FLAG antibodies to 
label FLAG-tagged LPA1. Note that LPA1 extensively co-
localizes with ConA in untreated cells, but localizes to punctate 
fluorescent structures after LPA treatment. Bar, 10 µm. (B) 
Quantitation of internalization showed that approximately 40% of 
LPA1 is internalized within 15 minutes after LPA treatment. The 
data is presented as the mean ± s.e.m. at each time point (n=24 




     We next sought to determine the identity of the LPA1+ endosomal structures. We co-
localized the internalized LPA1 with different endocytic organelle markers using double-
label immunofluorescence staining (Fig. 17). The internalized LPA1 showed extensive 
overlap with both transferrin receptor (TfR) and the early endosomal marker EEA1. 
Interestingly, LPA1 appeared to coincide more with TfR+ compartments than with 
EEA1+ compartments. Since TfR labeling includes small transport vesicles, sorting 
endosomes, as well as juxtanuclear recycling endosomes, these observations are 
consistent with the possibility that internalized LPA1 traverses the same endocytic 
pathway as the TfR. By contrast, LPA1 did not colocalize with the lysosomal marker 
LAMP-2, indicating that following short-term exposure to LPA, these receptors are not 
transported to lysosomes. This raised the possibility that internalized LPA1 might recycle  
back to the cell surface. Internalization of other GPCRs, such as the β2AR, is thought to 
be required for receptor resensitization and subsequent recycling (140). Internalized 
β2ARs have been shown to be dephosphorylated in an early endosomal compartment 
prior to recycling back to the cell surface (150, 180).  
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Fig. 17. Internalized LPA1 co-localizes with the clathrin-dependent endosomal 
markers, EEA-1 and transferrin receptor (TfR). Stably transfected HeLa cells 
expressing LPA1 were treated with 10 µM LPA for 30 minutes, fixed, processed for 
double-label indirect immunofluorescence and analyzed by confocal microscopy. The 
endosomal markers EEA-1 and TfR, and the lysosomal marker LAMP-2, were 
localized with mouse monoclonal antibodies followed by Alexa488-labeled goat anti-
mouse secondary antibodies. LPA1 was localized using rabbit anti-FLAG antibodies 
followed by Alexa594-labeled goat anti-rabbit secondary antibodies. The arrows in the 
upper panels indicate endosomal structures that contain both LPA1 and TfR. The 
arrow in the bottom panel indicates a structure that is LAMP2+, but does not contain 




     We investigated whether internalized LPA1 could recycle back to the PM upon 
removal of LPA (Fig. 18). Cells were first treated with 10 µM LPA for 30 minutes to 
induce internalization of LPA1 into LPA and then incubated at 37°C for various times 
prior to fixation and immunofluorescence localization of LPA1. In the absence of LPA 
treatment, LPA1 was predominantly localized to the PM (Fig. 18A, Untreated). After 30 
minutes treatment with 10 µM LPA, LPA1 localized to numerous endosomal structures 
(Fig. 18A, +LPA). Upon removal of agonist (Fig. 18B), LPA1 first localized to large 
juxtanuclear endosomes after 5 minutes and then began to appear at the PM after 15 
minutes with a corresponding decrease in endosomal labeling. Within 30 to 60 minutes 
after removal of agonist to prevent further stimulation and internalization, LPA1 was 
predominantly localized to the PM. These observations indicated that the portion of LPA1 
receptors which previously had internalized upon LPA treatment, then rapidly recycled 










Fig. 18. Agonist removal stimulates the 
recycling of internalized LPA1 back to 
the PM. (A) Stably transfected HeLa cells 
expressing LPA1 were incubated in the 
absence (Untreated) or presence (+LPA) of 
10 µM LPA for 30 minutes. (B) The cells 
were then rinsed, incubated in serum-free 
medium for the indicated times and 
processed for indirect immunofluorescence 
localization of LPA1. Bar, 10 µm.  
LPA1 internalization is both dose dependent and LPA specific 
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LPA1 internalization is both dose dependent and LPA specific 
To determine whether LPA-induced internalization of LPA1 occurred at physiologically 
relevant concentrations of LPA, we determined the dose dependence of LPA treatment on 
LPA1 internalization (Fig. 19). Concentrations of LPA in the range of 1-10 µM have been 
reported to be required for growth stimulation of fibroblasts (210). Following 30 minutes 
incubation with different concentrations of LPA, we observed that LPA1 internalization 
was dose dependent and that labeling of small punctate endosomal structures was first 
observed after treatment with 10 nM LPA. We observed a steady increase in the number 
and fluorescence intensity of these endosomal structures as the concentration of LPA was 
increased up to 100 µM.  
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Fig. 19. Concentration dependence of 
LPA-induced LPA1 internalization. 
Stably transfected HeLa cells 
expressing LPA1 were incubated for 30 
minutes with different concentrations 
of LPA, fixed and processed for 
indirect immunofluorescence 
localization of LPA1. Endosomal 
labeling of LPA1 can be observed even 





     To determine whether internalization of LPA1 was specific for LPA, we examined the 
effects of two related bioactive lipids, S1P and LPC. S1P (100 nM) has been shown to 
potently and specifically activate the closely related S1P1/EDG-1, S1P3/EDG-3, 
S1P2/EDG-5, S1P4/EDG-6 and S1P5/EDG-8 receptors (87). Treatment of LPA1-
expressing HeLa cells with either S1P (0.1 µM or 10 µM) or LPC (1 µM) did not induce 
the internalization of LPA1. Rather, LPA1 remained at the cell surface, suggesting that 
neither of these related lipids stimulated LPA1 internalization (Fig. 20). Although cells 
treated with S1P appeared to have larger puncta, these were not internal structures since 
immunofluorescence labeling in the absence of detergent permeabilization was the same 
as that observed in permeabilized cells (data not shown). At higher concentrations of 
LPC, the cells became rounded and detached from the substratum (not shown). Taken 
together, these results indicated that LPA1 internalization was dependent upon LPA 
concentration and was specifically stimulated by LPA and not by other related lipids. 
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Fig. 20. Lipid specificity of LPA1 internalization. LPA1-
expressing HeLa cells were incubated in serum-free medium for 
16 hours prior to a 30 minutes incubation with no lipid 
(Control), 10 µM LPA, 1 µM LPC, or 10 µM S1P. Note: 
compare 1 µM LPC-treated cells with 1 µM LPA-treated cells 
in Fig. 6. The cells were then fixed and processed for indirect 




Agonist-induced internalization of LPA1 is dependent upon functional dynamin2 
and Rab5 proteins 
Since internalized LPA1 co-localized with endosomal markers of the clathrin-mediated 
endocytic pathway, we investigated whether LPA1 was perhaps internalized by clathrin-
dependent mechanisms. To address this question, we examined the effects of either WT 
or dominant-inhibitory mutants of dynamin2 and Rab5, which are known regulators of 
clathrin-dependent endocytosis (24, 26, 39). Stably transfected HeLa cells expressing 
LPA1 were transiently transfected with GFP-tagged mutants of dynamin2, K44A (Dyn2-
GFP K44A) (Fig. 21), or Rab5a, S34N (GFPRab5a S34N) (Fig. 22), as well as GFP-
tagged WT forms of these GTPases, and assessed for agonist-induced endocytosis. The 
100 kDa GTPase dynamin2 is ubiquitously expressed and is involved in the severing of 
deeply invaginated clathrincoated pits to form clathrin-coated vesicles (39). In cells 
expressing Dyn2-GFP K44A, agonist stimulated internalization of LPA1 was completely 
inhibited and LPA1 remained at the cell surface (Fig. 21B). In contrast to Dyn2-GFP 
K44A, cells transfected with WT Dyn2-GFP displayed agonist-induced internalization of 
LPA1 that was indistinguishable from cells expressing LPA1 alone. Both WT and mutant 
Dyn2 localized in a diffuse cytoplasmic pattern in the transfected cells. This suggested 
that LPA1 internalization followed a dynamin-dependent pathway. 
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Fig. 21. Dominant-inhibitory dynamin2 K44A inhibits LPA1 
internalization. (A) LPA1-expressing HeLa cells were incubated for 
30 minutes in the absence (Untreated) or presence of 10 µM LPA prior 
to indirect immunofluorescence localization of LPA1. (B) Stable LPA1 
transfectants were transiently transfected with plasmids encoding either 
WT Dyn2-GFP or dominant-inhibitory Dyn2-GFP K44A. The cells 
were then incubated with 10 µM LPA for 30 minutes, fixed and 
processed for indirect immunofluorescence localization of LPA1 using 
mouse anti-FLAG antibodies followed by Alexa594-labeled goat anti-
mouse IgG. Dynamin localization was determined by direct 





The Ras-related Rab5 GTPase is another regulator of early endocytic traffic between the 
PM and early endosomes (24). Rab5 is known to stimulate homotypic endosomal fusion 
following endocytosis. A recent study by Seachrist et al. (180) has shown the dominant-
inhibitory GFPtagged Rab5a S34N mutant potently inhibits agonist-induced 
internalization of β2-adrenergic receptors. Similarly, expression of GFP-Rab5a S34N in 
LPA1-expressing HeLa cells strongly inhibited agonist-induced internalization (Fig. 
22B). In these cells, Rab5a S34N showed a diffuse cytosolic distribution throughout the 
cell. In these same cells, LPA1 was localized at the cell surface and showed no vesicular 
labeling as observed in cells that were not transfected with GFP-Rab5a S34N. 
Transfection with WT GFP-Rab5a did not alter agonist-induced internalization of LPA1, 
which localized to punctate internal structures as observed in cells expressing LPA1 
alone. To quantify the phenotypic effects of Dyn2-GFP K44A and GFP-Rab5a S34N on 
LPA1 internalization, we scored the percentage of cells expressing these mutants for the 
presence of LPA1+ endocytic structures (Fig. 22C). In the absence of these mutant 
proteins, 71 ± 4% of the cells contained LPA1+ endocytic structures following treatment 
with 10 µM LPA for 30 minutes. However, the results from three independent 
experiments indicated that expression of either Dyn2-GFP K44A (7 ± 4%) or GFP-Rab5a 
S34N (2 ± 1%) almost completely inhibited the appearance of LPA1+ endocytic 
structures following LPA treatment. Taken together, these results indicated that LPA 























Fig. 22. Dominant-inhibitory GFP-Rab5a S34N inhibits LPA1
internalization. (A) LPA1-expressing HeLa cells were incubated for 30
minutes in the absence (Untreated) or presence of 10 µM LPA prior to
indirect immunofluorescence localization of LPA1. (B) Stable LPA1
transfectants were transiently transfected with plasmids encoding either WT
GFP-Rab5a or dominant-inhibitory GFP-Rab5a S34N. The cells were then
incubated with 10 µM LPA for 30 minutes, fixed and processed for indirect
immunofluorescence localization of LPA1 using mouse anti-FLAG
antibodies. Bar, 10 µm. (C) Quantitation of inhibitory phenotype of
dominant-negative dynamin2 and Rab5 mutants on LPA1 internalization.
Stable LPA1 transfectants that were transiently transfected with no plasmid,
Dyn2-GFP K44A, or GFP-Rab5a S34N were then incubated with 10 µM
LPA for 30 minutes. The cells were fixed and processed for indirect
immunofluorescence localization of LPA1. Two hundred cells per sample
were scored for the presence of endocytic vesicles that contained LPA1 in an
experiment. The data from three independent experiments were expressed as
the mean ± s.d. of the percentage of cells that contained LPA1+ endosomal
structures under each transfection condition (n=3). 89 
 
 
To test if either Rab5 S34N or Dyn2 K44A affected LPA1-mediated signaling, we 
examined the effects of these mutants on LPA1-mediated stimulation of transcription via 
SRF activation (3). These experiments were performed in HepG2 human hepatoma cells 
since these cells are nonresponsive to LPA (Fig. 23A) and do not express any known 
LPA receptors (61). SRF activity was monitored using a firefly luciferase reporter gene 
plasmid that contains three tandem copies of the serum response element upstream of a 
basal promoter (see Materials and Methods). HepG2 cells were transiently transfected in 
serum-free medium with plasmids encoding the firefly luciferase reporter plasmid, the 
Renilla luciferase reference plasmid (to normalize for transfection efficiency), and the 
FLAG-tagged LPA1 expression plasmid. In addition, the cells were also transfected with 
either WT or mutant Rab5 or Dyn2 expression plasmids. At 24 hours following 
transfection, the cells were incubated either in the presence or absence of 1 µM LPA for 
16 hours prior to determination of luciferase activity. In cells expressing the SRE-
luciferase plasmid alone, LPA treatment did not induce luciferase expression, which is 
consistent with the absence of LPA receptors in these cells (Fig. 23A, SRE-Luc Alone). 
By contrast, cells that co-expressed LPA1 and the SRE-luciferase construct exhibited a 
1.5- to 2-fold increase in firefly luciferase activity when treated with 1 µM LPA (Fig. 
23A, SRE-Luc + LPA1). The data in Fig. 23B and 23C show that neither expression of 
WT Rab5 nor WT Dyn2 significantly affected the LPA1-mediated induction of firefly 
luciferase activity in response to agonist treatment. Induction of SRF activity was mildly 
inhibited in cells expressing dominant-inhibitory Rab5 S34N. Co-expression of 
dominant-inhibitory Dyn2 K44A greatly elevated SRF activity in both untreated and 
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LPA-treated cells; however, this increase was observed in cells expressing Dyn2 K44A 
alone and thus was independent of LPA1 expression (data not shown). Analysis of the 
LPA-dependent increase in SRF activity (Fig. 23C) showed that both Rab5 S34N (28% 
inhibition) and Dyn2 K44A (26% inhibition) slightly diminished LPA1-dependent SRF 
activation (P<0.05). The fold increase in LPA-stimulated SRF activity was 72% (cells co-
expressing LPA1 and Rab5 S34N) and 74% (cells co-expressing LPA1 and Dyn2 K44A) 
of that observed in cells expressing LPA1 alone. These data indicate that Rab5 and Dyn2 
are critical for the agonist-induced internalization of LPA1 and can also influence LPA1-






Fig. 23. Effects of WT and mutant Rab5 and dynamin2 on LPA1 stimulation of SRF-
mediated transcription. (A) HepG2 cells were transiently transfected with plasmids encoding 
SRE-luciferase, pRL-TK alone or with an expression vector for FLAG-tagged LPA1. Cells 
were incubated in the absence or presence of 1 µM LPA for 16 hours prior to determination of 
luciferase. The data are expressed as the mean ± s.e.m. from independent experiments that 
were performed in triplicate. (B) HepG2 cells were transiently transfected with the indicated 
plasmids along with SRE-luciferase and pRL-TK. (C) The data shown in B above was re-
analyzed to determine the fold induction of luciferase activity by LPA. Fold induction was 
calculated by  dividing the normalized luciferase from each LPA-treated sample by the 
luciferase data of the corresponding untreated samples and then averaging these ratios. The 
data shown is the average fold induction ratios ± s.e.m. *P<0.05 compared with LPA1. 92 
 
 
Basal internalization and recycling of LPA1 in serum containing medium 
Given that cells in culture are constantly bathed in serum containing medium, we 
examined whether the LPA present in medium containing 10% FBS was sufficient to 
trigger LPA1 internalization. It has been estimated that normal serum levels of LPA range 
from 0.1 to 10 µM (227). Immunofluorescence localization of LPA1 in cells grown in 
10% serum showed that it was primarily localized to the PM with little vesicular labeling 
(Fig. 24A, No treatment). To investigate whether LPA1 was internalized at a low level, 
we determined the localization of LPA1 in the presence of 10% serum in the presence of 
the proton ionophore monensin. Monensin has been shown to disrupt the low pH 
environment of endosomal compartments and, as a consequence, disrupt receptor 
recycling to the PM (14). Incubation of the LPA1 stable HeLa transfectants with 25 µM 
monensin resulted in a time dependent accumulation of LPA1 in endosomal structures 
(Fig. 24A, +25 µM monensin, 15 min and 30 min). Labeling of these structures was first 
observed after 5 minutes of treatment and then steadily increased such that, after 30 
minutes of treatment, the pattern of LPA1 labeling was similar to that of cells treated with 
10 µM LPA in serum-free medium for 30 minutes (Fig. 15, 30 min). Monensin treatment 
itself did not induce LPA1 internalization since monensin treatment in serum-free 
medium did not stimulate LPA1 internalization; internalization in serumfree medium 
required the addition of LPA (Fig. 24B). Furthermore, monensin treatment inhibited 
LPA1 recycling in serum-free medium upon removal of LPA (data not shown). These 
results suggest that LPA1 undergoes a low basal internalization and most probably 





Fig. 24. LPA1 is constitutively internalized and recycled in 
serum-containing medium in the absence of added LPA. (A) 
Stable LPA1-transfected HeLa cells were incubated in serum-
containing medium with 10 µM LPA for 30 minutes prior to 
fixation and indirect immunofluorescence. Alternatively, cells were 
incubated in medium containing 10% FBS alone (No Treatment) or 
incubated in this same medium with 25 µM monensin for the 
indicated times prior to fixation and indirect immunofluorescence 
localization of LPA1. Bar, 10 µm. (B) LPA1-expressing cells were 
incubated in serum-free medium for 16 hours and then incubated 
with either 25 µM monensin alone or 25 µM monensin and 10 µM 
LPA for 15 minutes prior to fixation and indirect 
immunofluorescence. Note that there was no vesicular labeling by 







     In this study, we investigated the agonist-induced trafficking of HeLa cells expressing 
FLAG-tagged human LPA1. LPA1 was rapidly internalized from the PM in response to 
LPA stimulation in both a time-dependent and dose-dependent manner (Figs 15, 16 and 
19). LPA1 internalization was specific for LPA, since neither S1P nor LPC, which are 
structurally similar to LPA, stimulated internalization (Fig. 20). Removal of agonist 
stimulates recycling of LPA1 back to the PM (Fig. 18). Internalized LPA1 co-localized 
with the endosomal markers EEA1 and TfR (Fig. 17), which label early endosomal 
compartments of the clathrin-dependent endocytic pathway. Dominant-inhibitory mutants 
of dynamin2 and Rab5a potently inhibited LPA1 internalization and also slightly 
diminished LPA1-dependent stimulation of SRF (Figs 21-23). These results are consistent 
with the agonist-induced internalization of LPA1 following a clathrin- or caveolae- 
dependent process. Finally, our results indicate that LPA1 cycles between the PM and 
endosomes at a low basal level in cells that are cultured in serum-containing medium. 
 
LPA1 internalization is a consequence of receptor activation 
Several lines of evidence indicate that LPA1 internalization is a consequence of agonist-
induced receptor activation. First, LPA1 internalization was dependent upon LPA 
concentration. We observed that concentrations as low as 10 nM LPA could induce 
modest LPA1 internalization (Fig. 19). Internalization continued to increase as the LPA 
95 
 
concentration was increased up to 100 µM LPA. This is consistent with published reports 
that have shown LPA concentrations in this range (i.e. 0.1-20 µM) potently induce 
intracellular signaling pathways such as stress fiber formation, inhibition of forskolin-
stimulated adenylate cyclase activity and growth stimulation (65, 96, 210).  
     Second, comparison of the time course of LPA1 internalization with that of LPA-
induced MAPK activation showed that LPA1 internalization coincides with signal 
desensitization. Analysis of the time course of LPA stimulation of MAPK activity (Fig. 
14B) showed that maximal MAPK activation occurred after approximately 5 minutes of 
LPA treatment and MAPK activity then decreased between 10 to 30 minutes of LPA 
treatment. By contrast, LPA1 was primarily localized to the PM after 5 minutes of LPA 
treatment (Fig. 15). LPA1 was first observed in endosomal structures after 10 minutes of 
LPA stimulation and this endosomal labeling steadily increased thereafter. This is 
consistent with the internalization of LPA1 occurring after signal desensitization. Finally, 
LPA1 internalization was specific for LPA treatment. Neither S1P (10 µM) nor LPC (0.1 
µM) stimulated the internalization of LPA1. Thus, these observations suggest that LPA1 
internalization is a consequence of receptor activation, similar to other GPCRs that 
undergo agonist-induced internalization.  
 
LPA1 is likely to be internalized via clathrin-dependent endocytosis  
Several observations from this study are consistent with LPA1 internalization occurring 
via clathrin-dependent endocytosis. First, we observed that internalized LPA1 showed 
extensive colocalization with the clathrin-dependent endosomal markers EEA1 and TfR 
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(Fig. 17). TfRs are internalized via clathrin dependent endocytosis and EEA1 is a Rab5 
effector that is recruited to early endosomal membranes by activated Rab5 (24). 
     Second, our findings that LPA1 internalization is dependent upon the function of 
dynamin2 and Rab5a suggest that LPA1 might be internalized via clathrin-dependent 
endocytosis. Both dynamin2 and Rab5 GTPases are known regulators of clathrin-
dependent endocytosis (24, 39). Dynamin2 is ubiquitously expressed and has been shown 
to be required for the severing of deeply invaginated clathrin-coated pits to form coated 
vesicles and also for the severing of invaginated caveolae (39, 85). Following coated 
vesicle formation, the clathrin coats rapidly dissociate from coated vesicles in an ATP-
dependent fashion. The Rab5a GTPase then stimulates the homotypic fusion of these 
uncoated vesicles by regulating the formation of the proper v-SNARE/t-SNARE 
associations and by recruiting the components of the vesicle fusion machinery (126).  
     Dominant-inhibitory mutants of both dynamin2 (Dyn2 K44A) and Rab5a (Rab5 
S34N) both strongly inhibited the LPA-induced internalization of LPA1 (Figs 21 and 22). 
In cells expressing these GTPase mutants, LPA1 was confined to the cell surface. Given 
that Rab5a and dynamin2 are known regulators of clathrin-dependent endocytosis, these 
results suggest that LPA1 is likely to be internalized via clathrin-dependent endocytosis. 
However, since Dyn2 K44A inhibits both clathrin-coated vesicle formation as well as 
formation of caveolae-dependent transport structures; it remains possible that LPA1 is 
internalized by either clathrin- or caveolae-dependent mechanisms.  
     Interestingly, we observed that LPA1 was confined to the cell surface in cells 
expressing GFP-Rab5a S34N. The best described role for Rab5 is in mediating the 
homotypic fusion of early endosomes (126). However, several recent studies have also 
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shown a role for Rab5 in the sequestration of receptor–ligand complexes into clathrin 
coated pits (123, 180). A complex of Rab5 and Rab guanine nucleotide dissociation 
inhibitor (Rab-GDI) has been shown to be a necessary cytosolic component for the 
sequestration of TfRs into coated pits (123). Thus, failure to internalize LPA1 in cells 
expressing GFP-Rab5a S34N may be a consequence of a defect in receptor localization to 
coated pits.  
     Liu et al. (115), have previously shown that the S1P-coupled receptor, S1P1/EDG-1, 
also undergoes agonist stimulated internalization and extensively co-localizes with 
internalized transferrin and also partially co-localizes with lysosomal markers suggesting 
that S1P1/EDG-1 is internalized via clathrin-dependent endocytosis. Together with our 
results on LPA1 trafficking, these observations suggest that perhaps other 
lysophospholipid receptors may also undergo agonist induced internalization. Whether or 
not internalization of these other family members occurs via clathrin-mediated 
mechanisms or perhaps non-clathrin-dependent pathways remains to be determined.  
 
Role of endocytosis in regulation of LPA1 function  
GPCR endocytosis in many instances occurs subsequently to ligand-induced G-protein 
activation and involves receptor phosphorylation and the binding of arrestin proteins (57). 
Internalization is thought to contribute to either signal desensitization and/or 
resensitization once the internalized GPCR is dephosphorylated in an endosomal 
compartment. Thus, one role for LPA1 internalization might be to facilitate its 
dephosphorylation and subsequent resensitization.  
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     In addition to receptor resensitization, several observations suggest a broader role for 
GPCR endocytosis in receptor mediated signaling events. Several recent studies suggest 
that activated GPCRs can assemble multi-protein signaling complexes to initiate 
secondary signaling events from endosomal compartments within cells. Studies of the 
thrombin receptor, PAR1, the neurokinin-1 receptor, and the angiotensin 1a receptor have 
shown that following agonist treatment, these internalized GPCRs form complexes, via 
β-arrestin, with downstream components of the MAPK signaling pathway including 
Raf1, MEK1 and ERK2 (41, 118). Interestingly, these MAPK components colocalize 
with the internalized GPCRs on endosomal structures. It has been suggested that this may 
provide a G-protein independent mechanism to target activated ERKs to specific 
intracellular compartments to phosphorylate cytoplasmic targets selectively. 
     The data in Fig. 23 indicate that inhibition of LPA1 internalization slightly decreased 
LPA-dependent induction of SRF-mediated transcription; dominant-inhibitory Rab5a 
S34N and Dyn2 K44A reduced LPA1-dependent activation of SRF by 28% and 26%, 
respectively. However, these mutants strongly inhibited LPA1 internalization (Fig. 22), 
suggesting that the primary effect of these mutants was to impede LPA1 endocytosis. 
LPA-dependent activation of SRF is mediated through the stimulation of Ras- and Rho-
dependent signaling (86, 210) through Gβγ and G12/13 signaling pathways. Others have 
shown that dynamin mutants can inhibit LPA-induced ERK activation via the Ras 
pathway (38, 105). Thus, one possible explanation for the slight reduction in LPA1- 
dependent SRF activation is that dyn2 K44A and Rab5a S34N might inhibit the 
Ras/ERK-dependent component of SRF activation.  
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     It is also possible that LPA1 internalization may be important for other LPA-
dependent signaling processes. The data in Fig. 24 suggests that LPA1 is internalized and 
most probably recycled at a low basal level in cells cultured in serum containing medium. 
Given that serum contains LPA, this basal internalization is likely to represent agonist-
induced uptake. If so, then this raises the question of what the long-term signaling 
consequence of such basal uptake is on cells. Further studies of the role of LPA1 
localization in the regulation of LPA-stimulated signaling, as well as other LPA-coupled 
receptors, is likely to provide important information about the role of endocytosis in 
regulating LPA-induced cellular responses.  
     Finally, an important implication of our finding that LPA1 is internalized in serum-
containing medium is that LPA1 internalization may be a useful diagnostic measure of the 
relative levels of LPA present in clinical serum samples. Recent observations indicate 
that serum LPA levels are increased in patients with ovarian cancer even at early stages 
(227). Measurement of LPA1 internalization could be adapted into a simple bioassay for 





PERSPECTIVE AND FUTURE DIRECTIONS 
 
Discussion of LPA results 
     Evidence is presented in the first study of this thesis that suggests LPA signaling 
inhibits p53-mediated transcription and promotes a decrease in total and phosphorylated 
p53 [S15] protein levels (Fig. 7, 9). In addition, both LPA receptor activation and the 
presence of the C-terminal PDZ domain appear necessary for mediating the inhibition 
since LPP-1, PLB, LPA1-R124A and LPA1-361 have stabilizing affects on p53 
transcription (Fig. 10, 13). Using chemical inhibitors and dominant-negative plasmids 
expressing G proteins, we were unable to link the LPA affects on p53 to any of the Gi, Gq 
or G12/13 pathways directly (Fig. 12 and data not shown), suggesting that a multi-protein 
assemblage may be responsible which includes the PDZ binding domain. 
     In the second study of this thesis, analysis of the LPA-stimulated time course of 
MAPK activity in HeLa cells stably expressing LPA1 showed that maximal MAPK 
activation occurred after approximately 5 minutes of LPA treatment (Fig. 14B top). The 
response time was twice as fast as that in HeLa cells which were not stably transfected 
(Fig. 14B bottom), indicating that LPA-activation of the LPA1 receptor can induce the 
MAPK pathway rapidly, leading to an increase in cell proliferation and survival. Since 
the time of MAPK phosphorylation occurs within 5 minutes and the time needed for 
internalization is at least 15 – 30 minutes (Fig. 15, 16), it is possible that ERK is recruited 
to the receptor.   
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     GPCR internalization is thought to contribute to either signal desensitization and/or 
resensitization once the internalized GPCR is dephosphorylated in an endosomal 
compartment. Thus, one role for LPA1 internalization might be to facilitate its subsequent 
resensitization. We analyzed the time needed for LPA1 receptor recycling (Fig. 18) and 
found that within 60 minutes after internalization, the receptor is back at the cell surface 
ready to receive new agonist. Also, the data in Fig. 24 suggests that LPA1 is internalized 
and recycled at a low basal level in cells cultured in serum-containing medium. Our data 
also show that within 1 hour of LPA addition to the cells, total and activated p53 is 
diminished by 50% (Fig. 7) and this response was sustainable through 6 hours.  
     The two stories presented in this thesis converge with the consequences of LPA 
receptor-mediated signaling. Putting together both sets of data, LPA receptor trafficking 
and p53 signaling, a picture of the time course of LPA receptor-mediated signaling 
effects begins to emerge. Future directions could include research to further integrate 
these two separate, but interesting accounts of LPA’s affects.  
     Since normal human serum contains LPA, basal receptor internalization probably 
represents agonist-induced uptake and that raises the question of what the long-term 
signaling consequence of LPA is on cells, especially damaged and cancer cells. In vivo it 
is likely that LPA receptors are constantly cycling and a fresh pool of LPA is being 
manufactured, allowing prolonged cell proliferation (via MAPK) and survival (via p53). 







     Two lingering questions exist: first, the LPA signaling pathway initiating the 
inhibition and second, the mechanism of p53 inhibition by LPA receptors. To address the 
former question, recent studies suggest that activated GPCRs can assemble multi-protein 
signaling complexes to initiate secondary signaling events from endosomal compartments 
within cells. Several GPCRs like the thrombin receptor, PAR1, the neurokinin-1 receptor, 
and the angiotensin 1a are capable of forming complexes with components of the MAPK 
signaling pathway following agonist treatment and internalization (41, 118). 
Interestingly, these MAPK components, Raf1, MEK1 and ERK2, colocalize with the 
internalized GPCRs on endosomal structures. It has been suggested this may provide a G-
protein independent mechanism to target activated ERKs to intracellular compartments to 
selectively phosphorylate cytoplasmic targets. Perhaps the LPA receptors are capable of 
forming complexes and through these associations they are able to regulate p53.  
     Future research on the signaling aspect should include screening LPA1 receptor tails 
for protein interactions to determine the nature of the signaling pathway affecting p53. 
This is especially important because no one has yet been able to discover any interactions 
with the PDZ-binding domain of LPA1, although the LPA2 receptor appears to have 
several interactions. In this thesis, much emphasis has been placed on the PDZ-binding 
domain of the LPA receptor tails as the causative factor; however, it could also be the 
phosphorylation sites within these terminal residues which are responsible for mediating 
the inhibition on p53. This would better explain the quandary that LPA3 can also mediate 
the inhibition, yet it lacks a PDZ-binding domain. To investigate whether these terminal 
phosphorylation sites are responsible, LPA3 receptor point mutations can be designed. 
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     Although constitutively-active G proteins did not inhibit p53, a comprehensive 
analysis of the pathway affecting p53 should also use drug inhibitors to pinpoint and 
confirm the pathway required for inhibition. For example, we feel confident from the 
studies using pertussis toxin (Fig. 12) that inhibiting Gi signaling does not alter the 
inhibitory affects; however drugs to inhibit Gq should be employed to exhaust the G 
protein signaling. In addition, chemical inhibitors for each component in the MAP kinase 
pathway are commercially available and could also be used.  
     Uncovering the location and mechanism of p53 degradation is also needed to fully 
understand how the inhibition occurs. This might become a massive project as there are 
so many features and components involved in the regulation of p53, yet it is one of the 
fundamental questions with this project and will need to be addressed in the future years. 
From our studies (Fig. 7), we see a large reduction of p53 within 1 h after LPA treatment, 
but because p53 has such a rapid turn-over rate (30 min), it is possible that the diminution 
could be a product of reduced p53 transcription. Otherwise, the protein is being degraded 
in either the nuclear or cytoplasmic proteasomes of the cell. 
     If the mechanism of inhibition is proteasomic degradation, further questions will need 
to be addressed. Importantly, what is the affect on the p53-regulator, Mdm2, and is the 
LPA-mediated inhibition affecting Mdm2 to then increase p53 degradation? In other 
words, is the decrease in p53 the result of an LPA-mediated stabilizing effect of Mdm2? 
Mdm2 ubiquitinates p53 and the amount of ubiquitin attached to p53 can determine when 
it is degraded (either immediately or much later) and where it is degraded (after 
polyubiquitination degradation occurs in the nucleus while after monoubiquitination 
degradation occurs primarily in the cytoplasm).   
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     Finally, another important question to answer surrounding the LPA-mediated 
inhibition is: what exactly are the quantitative consequences of diminished p53 to the cell 
and which processes, if any, are affected: proliferation, motility, growth, etc.? In other 
words, what might be some broad beneficial or detrimental outcomes of this effect? To 
speculate on one possibility, in a developing embryo when you need cells to divide, 
having LPA and the LPA1 receptor available is helpful to stimulate growth and 
proliferation. To aid these processes, limiting the amount of p53 and other proteins which 
can counteract the cell cycle would also be advantageous to continue unfettered cell 
division. The inhibition of p53 by LPA is probably just another small part of a larger goal 
by LPA and its receptors to stimulate the cell to proliferate and divide without regulations 
in specific situations. 
     The other project presented in this thesis, the characterization of LPA1 trafficking, also 
has several interesting future directions. First, whether LPA1 requires clathrin-mediated 
endocytosis, utilizes lipid rafts or is internalized via caveolae is still uncertain. Studies 
show that dependence on dynamin2 and Rab5 (Fig. 21, 22) for internalization and 
subsequent sorting to the early endosome does not rule out the aforementioned 
possibilities of endocytosis requirements.  
     Similarly, the long-term LPA1 receptor recycling and receptor down-regulation would 
be exciting to follow-up because it affects other signaling properties of LPA1. It is also 
interesting to speculate the rationale behind receptor cycling. Perhaps the LPA receptors 
are cycling because they are continually sampling their extracellular environment for the 
growth factor, LPA. Alternatively, the LPA receptors could be cycling for reasons similar 
to receptors involved in nutrient uptake if you consider LPA as a precursor for 
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manufacturing other phospholipids necessary to the cell. More research into the function 
of the LPA receptors will elucidate the reasons for the trafficking pathway and vice versa. 
     Putting these two stories together, future research could investigate the LPA-mediated 
inhibition on p53 and LPA receptor trafficking simultaneously. For example, using the 
mutants dynamin2 K44A and Rab5 S34N, it would be interesting to see whether transient 
transfection of these plasmids affected p53 inhibition. Also, it is unclear from our 
observations where the LPA receptors are localized when the LPA-mediated effects on 
p53 occur. Since the inhibition happens between 1 to 6 hours after LPA addition, perhaps 
long-term trafficking studies with the LPA receptor would be beneficial to understanding 
this process. 
 
Broad implications of the research 
     LPA and the LPA receptors are critical to the body for important processes like 
embryonic development and wound healing. For these and other processes, LPA is 
capable of signaling through its receptors: cell growth, cell proliferation, motility, 
protection from apoptosis and cell survival. All of these processes mandate a high-level 
of regulation to maintain homeostasis. More than 100 distinct types of cancer exist and 
the majority of these have radical transformations in common: self-sufficient cell growth, 
unlimited cell proliferation, metastasis, sustained angiogenesis, protection from apoptosis 
and cell survival (82). Looking back over that list, the similarities between LPA-
stimulated LPA receptor signaling and the hallmarks of cancer cells are striking.  The 
lipid, LPA, is almost a perfect component to propagate tumorigenesis.  
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     With every new study on LPA, the implications between LPA receptor signaling and 
negative consequences in cancer and other malefactions continue. Some recent examples 
of studies include that LPA upregulates FasL which provides immune defense because 
constitutive FasL expression in normal cells causes apoptosis, yet in malignant cells it 
allows a retaliation on natural killer cells and cytotoxic T lymphocytes (125). Other 
recent research has shown that tumor cells stimulate activated platelets to begin 
producing LPA, overexpression of LPA1 induces tumor growth and metastasis (20) and 
that LPA is a survival factor in cell lines, but not normal cells (99). 
     Although there are beneficial effects that arise from normal functioning of LPA 
receptors, it would be helpful to have one antagonist that bound to all the LPA receptors 
for treatment of certain cancers, atherosclerosis and patients with ruptured plaques. 
Targeting the pool of LPA would also be another method for remediation; however, due 
to dimerization and transactivation of the LPA receptors from other GPCRs, this 
approach might be less practical. In this respect, directly targeting the source of the 
problem would probably be more useful. A small company in Utah, Echelon Biosciences 
Incorporated, has had success creating antagonists for LPA3, but there has been limited 
success with LPA1 and even less with LPA2. More research on LPA signaling pathways 
and in vivo consequences of blocking LPA receptors is needed before LPA antagonists 
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Upon agonist stimulation, many G protein-coupled receptors such as 2-adrenergic 
receptors are internalized via -arrestin- and clathrin-dependent mechanisms, whereas 
others, like M2 muscarinic acetylcholine receptors (mAChRs), are internalized by 
clathrin- and arrestin-independent mechanisms. To gain further insight into the 
mechanisms that regulate M2 mAChR endocytosis, we investigated the post-endocytic 
trafficking of M2 mAChRs in HeLa cells and the role of the ADP-ribosylation factor 
6 (Arf6) GTPase in regulating M2 mAChR internalization. Here, we report that M2 
mAChRs are rapidly internalized by a clathrin-independent pathway that is inhibited up to 
50% by expression of either GTPase-defective Arf6 Q67L or an upstream Arf6 activator, 
G q Q209L. In contrast, M2 mAChR internalization was not affected by expression of 
dominant-negative dynamin 2 K44A, which is a known inhibitor of clathrin-dependent 
endocytosis. Nevertheless, M2 mAChRs, which are initially internalized in structures that 
lack clathrin-dependent endosomal markers, quickly localize to endosomes that contain 
the clathrin-dependent, early endosomal markers early endosome autoantigen-1, 
transferrin receptor, and GTPase-defective Rab5 Q79L, which is known to swell early 
endosomal compartments. These results suggest that M2 mAChRs initially internalize via 
an Arf6-associated, clathrin-independent pathway but then quickly merge with the 









     Endocytosis is an important mechanism that is used to regulate the activity of a variety 
of cell surface receptors, including G protein-coupled receptors (GPCRs) (33, 57). 
Defining the cellular mechanisms by which GPCR endocytosis is regulated is important 
for understanding how cells attenuate GPCR signaling as well as understanding the role 
of receptor endocytosis in cell signaling. Over the past several years, it has become clear 
that different GPCRs utilize multiple, distinct pathways of internalization that display 
differential sensitivities to either pharmacological inhibitors or dominant-inhibitory 
mutants that are pathway-selective. The mechanisms that regulate the internalization of 
some receptors, such as 2-adrenergic receptors ( 2ARs), have been well characterized. 
However, the mechanisms that regulate both internalization and sorting of other 
receptors, such as the M2 muscarinic acetylcholine receptor (mAChR), are not as well 
understood (211).   
     The sequence of events leading to GPCR endocytosis is shared by many receptors. 
Upon agonist binding, these heptahelical GPCRs activate heterotrimeric G protein 
signaling pathways, which in turn regulate a variety of intracellular processes (17). Many 
GPCRs then become rapidly phosphorylated either by second messenger kinases such as 
protein kinase A or by specific G protein receptor kinases on serine/threonine residues 
present in cytoplasmically exposed domains (149). In the case of 2ARs, the critical 
serine/threonine residues reside in the cytoplasmic tail, whereas in mAChRs, the relevant 
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residues reside in the third intracellular loop (145). Phosphorylation facilitates the binding 
of a -arrestin family member, which inhibits further receptor-G protein coupling and thus 
attenuates receptor signaling. In many instances, the binding of -arrestin targets the 
GPCR to clathrin-coated pits for rapid endocytosis (58, 76, 108). Dominant-inhibitory 
mutants of either -arrestins, the 100-kDa GTPase dynamin, or clathrin heavy chain (Hub 
mutants) inhibit the internalization of GPCRs such as 2ARs, which use clathrin-
dependent mechanisms (57, 213).  
     In contrast to the 2AR, several observations indicate that the Gi-linked, M2 mAChR is 
internalized via a poorly characterized clathrin-independent endocytic pathway (25, 144, 
165, 177, 204, 211, 214). First, although -arrestin binding to this receptor is essential for 
signal attenuation, it is not required for M2 mAChR endocytosis in HEK 293 cells (144, 
214). Second, dominant-negative clathrin Hub mutants do not inhibit the agonist-induced 
M2 mAChR internalization (214). Finally, M2 mAChR internalization shows a differential 
sensitivity to mutants of dynamin, which is required for clathrin- and caveolae-mediated 
internalization (39, 85, 219). Mutant dynamin K44A potently inhibits the clathrin-
dependent internalization of GPCRs but has little effect on M2 mAChR internalization. 
However, recent studies have shown that M2 mAChR internalization is strongly inhibited 
by mutants of dynamin that lack the N-terminal GTP-binding domain ( 1-272 dynamin) 
or the K535M dynamin mutant, which cannot be stimulated by phosphatidylinositol 4,5-
bisphosphate (219). This suggests that although M2 mAChR internalization is clathrin- 
and -arrestin-independent, dynamin is still required. These findings raise the question: 
what is the endocytic pathway by which M2 mAChRs are internalized? One possible 
regulator of M2 mAChR trafficking might be the ADP-ribosylation factor 6 (Arf6) 
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GTPase, which has been shown to influence both clathrin-independent and clathrin-
dependent endocytic trafficking.  
     The Arf family of Ras-related GTPases is known to regulate intracellular trafficking 
processes in both the endocytic and secretory pathways (46, 160). The Arf6 GTPase, 
which is located at the plasma membrane (PM) and on endosomal structures, has been 
shown to influence the actin cytoskeleton (19, 62, 156) as well as clathrin-independent 
and clathrin-dependent endocytic processes (155). Activation of Arf6 can initiate cortical 
actin rearrangements to form either protrusive structures or lamellar structures in cells(19, 
156). It has recently been shown that the effects of Arf6 on membrane traffic and actin 
rearrangements in cells involves the localized elevation of cellular phosphatidylinositol 
4,5-bisphosphate levels through the stimulation of phosphatidylinositol 4-phosphate 5-
kinase  (23, 89).  
     Arf6 is also involved in the regulation of membrane trafficking in the endocytic 
pathway and has been shown to influence endosomal membrane recycling via clathrin-
independent mechanisms (155), clathrin-dependent trafficking of transferrin receptors 
(36), Fc  receptor-mediated phagocytosis in macrophages (238), apical endocytosis of 
polymeric IgA receptors in Madin-Darby canine kidney cells (2), and exocytosis of 
chromaffin granules (27). More recently, Arf6 has been implicated in the -arrestin- and 
clathrin-dependent endocytic trafficking of 2ARs (32, 151). It was shown that agonist-
bound 2ARs stimulated the -arrestin-mediated activation of Arf6, which was required 
for the efficient internalization of these receptors (32). In addition, it has been shown that 
overexpression of the ARF6 exchange factor ARNO stimulates the release of -arrestin 
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from membrane-docking sites, which then binds to the luteinizing 
hormone/choriogonadotropin receptor to mediate desensitization (136).  
     In this study, we investigated the intracellular trafficking of the M2 mAChR in HeLa 
cells. Our studies suggest that M2 mAChRs are rapidly internalized by a clathrin-
independent pathway, which is sensitive to mutants of Arf6. After internalization, M2 
mAChRs, which are initially observed in structures that lack clathrin-dependent 
endosomal markers, localize to early endosomes of the clathrin pathway that contain the 
early endosome autoantigen 1 (EEA-1) and internalized transferrin receptors. Thus, the 
M2 mAChR appears to utilize a novel endosomal trafficking pathway whereby it is 
transferred from a clathrin-independent endocytic pathway to endosomal compartments 







MATERIALS AND METHODS 
 
Reagents and Antibodies 
Rat monoclonal antibodies against human M2 mAChRs were purchased from Chemicon 
International (Temecula, CA), and mouse antibodies against the early endosomal marker, 
EEA-1, were obtained from Transduction Laboratories (Burlingame, CA). Mouse 
antibodies against the human transferrin receptor (clone B3/25) were purchased from 
Roche Biochemicals. Alexa 594- and Alexa 488-conjugated goat anti-mouse, goat anti-
rat, and goat anti-rabbit IgG and Alexa 594-labeled transferrin were purchased from 
Molecular Probes, Inc. (Eugene, OR). 3H-Labeled N-methylscopolamine ([3H]NMS) was 
purchased from PerkinElmer Life Sciences. All other reagents were obtained from Sigma.  
 
Cell Culture and DNA Transfections 
HeLa cells were maintained in Dulbecco's modified Eagle's medium supplemented with 
10% fetal bovine serum, 100 IU/ml penicillin, and 100 µg/ml streptomycin (complete 
medium) at 37 °C with 5% CO2. The HeLa cells were either grown on glass coverslips 
(for immunolocalization) and transfected in 6-well dishes or grown in 12-well dishes (for 
[3H]NMS binding) using FuGENE 6 (Roche Biochemicals) according to the 
manufacturer's directions. Plasmids encoding M2 mAChRs were transiently transfected 
into HeLa cells at 1 µg/well (6-well dish). Wild type and mutant Arf6 plasmids were 
transiently transfected at 0.5 µg of plasmid DNA/well (6-well dish), whereas G q 
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plasmids and GFP-Rab5 plasmids were transiently transfected into 6-well dishes using 
2.5 µg of DNA; wild type and mutant dynamin plasmids were transfected using 10 µg of 
plasmid/well.  
To generate stable HeLa cell transfectants, wild type M2 mAChR plasmid was transfected 
into HeLa cells using the calcium phosphate co-precipitation method (155). Thirty-six 
hours after transfection, the cells were detached and replated at a 1:25 dilution into 
complete medium containing 600 µg/ml G418 (Invitrogen). Approximately 2 weeks later, 
G418-resistant clones were amplified and tested for M2 mAChR expression by indirect 
immunofluorescence microscopy. The positive clones were expanded, and one of these 
(clone 17) was found to express moderate levels of M2 mAChRs, as judged by relative 
fluorescence intensity, and was chosen for further studies.  
Indirect Immunofluorescence 
The cells were treated as described in the figure legends at 30-36 h following 
transfection, fixed in 2% formaldehyde in phosphate-buffered saline (PBS) for 10 min, 
and rinsed with 10% fetal bovine serum and 0.02% azide in PBS (PBS-serum). Fixed 
cells were incubated with primary antibodies diluted in PBS- serum containing 0.2% 
saponin for 45 min and then washed (three times, 5 min each) with PBS-serum. The cells 
were then incubated in fluorescently labeled secondary antibodies diluted in PBS-serum 
plus 0.2% saponin for 45 min, washed with PBS-serum (three times, 5 min each) and 
once with PBS, and mounted on glass slides.  
For Alexa 594-transferrin internalization, transfected cells expressing M2 mAChRs were 
briefly rinsed three times with 0.5% bovine serum albumin in Dulbecco's modified 
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Eagle's medium and incubated in the same medium for 30 min at 37 °C. The cells were 
then incubated with both 1 mM carbamoylcholine chloride (carbachol) and Alexa 594-
transferrin (50 µg/ml) for various times, briefly rinsed with an acid wash (0.5% acetic 
acid, 0.5 M NaCl, pH 3.0) and complete medium, and then fixed and processed for 
immunofluorescence localization of M2 mAChRs. The samples were observed using an 
Olympus BX40 epifluorescence microscope equipped with a 60× Plan pro lens, and 
photomicrographs were prepared using a Spot RT monochrome C digital camera 
(Diagnostic Instruments, Inc., Sterling Heights, MI) or were observed and photographed 
with a Zeiss LSM 510 laser scanning confocal microscope.  
Loss of Cell Surface Receptor Assay 
1.5 × 105 transfected HeLa cells were grown in 4- or 12-well dishes for 24 h in complete 
Dulbecco's modified Eagle's medium and treated with or without 1 mM carbachol as 
described in the figure legends and then rinsed three times with ice-cold PBS, pH 7.4, on 
ice. Surface M2 mAChRs were detected as described  (166, 214) by incubating cells with 
the cell-impermeant muscarinic ligand, [3H]NMS (2 nM), for 2 h at 4 °C. The cells were 
washed three times (5 min each) with ice-cold PBS and solubilized with 1% Triton X-100 
in PBS for 10 min. The cell extracts were transferred to microcentrifuge tubes, and the 
insoluble material was pelleted by microcentrifugation at 14,000 rpm for 15 min at 4 °C. 
The supernatant was collected, and the protein concentration was determined from an 
aliquot using a micro-BCA protein assay (Pierce). The radioactivity present in the 
remaining sample was determined by scintillation counting. Nonspecific binding of 
[3H]NMS to untransfected HeLa cells was subtracted from the transfected samples. The 
mass of [3H]NMS bound to cells (in fmol) was calculated using the bound radioactive 
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counts/min and the specific activity of the [3H]NMS (70 Ci/mmol); this was normalized 
to the protein content of the samples. Receptor internalization is defined as the percentage 
of surface M2 receptors not accessible to [3H]NMS at each time relative to non-
carbachol-treated cells.  
 
Statistical Analysis 
The data are expressed as the means ± S.E. from the indicated number of independent 
experiments performed in either triplicate or quadruplicate. Statistical analysis was 







Agonist-induced Internalization and Recycling of M2 mAChRs in HeLa Cells 
To investigate the intracellular trafficking of the M2 mAChR, HeLa cells were transiently 
transfected with a plasmid encoding the wild type human M2 mAChR. Using a rat 
monoclonal antibody against M2 mAChRs and confocal microscopy, we examined the 
effects of agonist stimulation on the cellular distribution of M2 mAChRs (Fig. 25a). In 
untreated cells, M2 mAChRs were distributed in a diffuse pattern along the PM. The 
addition of 1 mM carbachol induced a rapid redistribution of surface M2 mAChRs into 
numerous punctate endosomal structures within 15 min at 37 °C. These endosomal 
structures were initially dispersed near the cell periphery but became clustered in the 
juxtanuclear region of cells within 20-30 min. This distribution did not noticeably change 
even up to 60 min of incubation with carbachol. 
     Next, we quantified the kinetics of M2 mAChR internalization in stably transfected 
HeLa cells for comparison with the behavior of M2 mAChRs in stably transfected HEK 
293 cells (166). M2 mAChRs exhibit rapid internalization kinetics in response to agonist 
stimulation but slow and incomplete recycling behavior in HEK 293 cells. Stably 
transfected HeLa cells expressing M2 mAChRs were incubated with 1 mM carbachol for 
various times at 37 °C and then chilled to 4 °C, and the loss of surface receptor-binding 
sites for the cell-impermeant mAChR ligand [3H]NMS was determined (Fig. 25b). 
Within 10 min after the addition of carbachol, ~80% of the initial surface [3H]NMS-




Fig. 25.  Agonist-induced internalization and recycling of M2 mAChRs in HeLa cells. 
a, HeLa cells were transiently transfected with a plasmid that encodes wild type human 
M2 mAChR and then treated with 1 mM carbachol for various times and processed for 
confocal microscopy using a monoclonal rat anti-M2 mAChR antibody. Bar, 10 µm. b, 
Stably transfected HeLa cells expressing M2 mAChRs were incubated for various times 
with 1 mM carbachol prior to determination of surface M2 mAChRs using [3H]NMS 
binding. M2 mAChR internalization is expressed as the percentage of surface M2 receptors 
that became inaccessible to [3H]NMS at each time, relative to non-carbachol-treated cells 
(mean ± S.E.; n = 3 independent experiments, in triplicate). c, Time course of recycling. 
Stable M2 mAChR transfectants were incubated with 1 mM carbachol for 60 min, washed, 
and incubated for various times in carbachol-free medium prior to the determination of 
surface M2 mAChRs. The data are expressed as the percentages of surface M2 receptors 
present at each time, after agonist removal, relative to non-carbachol-treated cells 
(mean ± S.E.; n = 5 independent experiments, in triplicate).  119 
 
punctate endosomal structures (Fig. 25a). The kinetics of M2 internalization was also 
determined in transiently transfected cells (see Fig. 29, diamonds), where we observed 
that ~50% of surface M2 mAChRs were internalized after 15 min of agonist treatment. 
This is consistent with the immunofluorescence observations in Fig. 25a showing both 
PM and endosomal staining in transiently transfected cells after 15 min of agonist 
treatment. Thus, M2 mAChRs are rapidly internalized in HeLa cells, which is similar to 
what has been reported for M2 mAChR internalization in HEK 293 cells (166). 
     Next, we examined whether internalized M2 mAChRs recycled back to the cell surface 
upon agonist removal (Fig. 25c). Stably transfected cells were treated with 1 mM 
carbachol for 60 min at 37 °C, washed, and warmed for various times in growth medium 
that did not contain carbachol, prior to quantifying the reappearance of surface [3H]NMS-
binding sites. After 2 h of agonist removal, we observed a recovery of surface M2 
mAChRs to ~50% of the level observed in unstimulated cells. This was not due to new 
synthesis of M2 mAChRs, because the observed increase in [3H]NMS-binding sites after 
2 h of agonist removal was the same when measured in the presence or absence of 
20 µg/ml cycloheximide (data not shown). These results indicated that M2 mAChRs were 
rapidly internalized in HeLa cells in response to agonist stimulation, whereas M2 mAChR 
recycling was a relatively slow and incomplete process. The kinetics of internalization 
and recycling were similar to those described for M2 mAChRs expressed in HEK 
293 cells (166). 
     In the studies below, we used a transient co-transfection approach to investigate the 
effects of different mutant proteins, known to affect endocytosis, on M2 mAChR 
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internalization. Although the overall transfection efficiency in our experiments ranged 
from 30 to 50%, the co-transfection efficiency in these experiments was ~95-100% (as 
judged by indirect immunofluorescence staining for both M2 mAChRs and a given 
mutant protein) (data not shown). This permitted us to quantify the effects of endocytic 
mutants on M2 mAChR internalization without background from cells that expressed M2 
mAChRs but not an endocytic mutant.  
     Previous studies have shown that agonist-induced internalization of M2 mAChRs in 
HEK 293 cells occurs via clathrin-independent endocytosis (214). M2 mAChR 
internalization is insensitive to inhibition by the K44A mutant of the 100-kDa GTPase, 
dynamin (dyn) (213), which mediates the scission of clathrin-coated pits at the PM and 
Golgi complex and also the scission of caveolae (26, 39, 85). To investigate whether M2 
mAChR internalization involved clathrin-independent mechanisms in HeLa cells, we 
transiently co-transfected HeLa cells with plasmids encoding green fluorescent protein 
(GFP)-tagged dynamin 2 K44A (dyn2-GFP K44A) and M2 mAChR or M2 mAChR 
plasmid alone and determined the effects of agonist stimulation on M2 receptor 
internalization (Fig. 26). In cells expressing M2 mAChR alone or M2 mAChR and dyn2-
GFP K44A, treatment with 1 mM carbachol for 30 min induced M2 mAChR 
internalization into numerous punctate endosomal structures (Fig. 26, A and B). In 
contrast, expression of dyn2-GFP K44A in HeLa cells completely blocked the clathrin-
dependent internalization of Alexa 594-labeled transferrin (Fig. 26C). Thus, agonist-
induced internalization of M2 mAChRs in HeLa cells appears to be mediated by clathrin-
independent mechanisms.  
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Fig. 26.   Dominant-inhibitory dynamin 2-GFP K44A does not 
block internalization of M2 mAChRs in HeLa cells. HeLa cells 
transfected with plasmids encoding M2 mAChR alone (A) or M2 
mAChR and dyn2-GFP K44A (B) were incubated in the presence 
or absence of 1 mM carbachol for 30 min and then fixed and 
processed for indirect immunofluorescence localization of M2 
mAChRs and direct epifluorescence visualization of dyn2-GFP. C, 
HeLa cells expressing dyn2-GFP K44A (arrows) were incubated 
with Alexa 594-labeled transferrin for 15 min, fixed, and processed 
for epifluorescence microscopy as described under "Experimental 
Procedures." Bar, 10 µm. 122 
 
Internalized M2 mAChRs Merge with Early Endosomes of the Clathrin-dependent 
Endocytic Pathway 
Given the findings above, we sought to determine the identity of the endosomal structures 
to which internalized M2 mAChRs localized following agonist treatment. We performed 
double labeling immunofluorescence experiments using antibodies against known 
markers of endosomal compartments along with antibodies against M2 mAChRs. We 
compared the distribution of internalized M2 with that of the early endosome marker 
EEA-1, with transferrin receptors, and with the lysosomal marker, LAMP2.  
     We observed that the M2 mAChR+ endosomal structures extensively co-localized with 
the early endosomal marker, EEA-1, and to a lesser extent with transferrin receptors (Fig. 
27). This suggested that once M2 mAChRs are internalized via a clathrin-independent 
pathway, they are transferred to early endosomes of the clathrin endocytic pathway. We 
also examined the localization of internalized M2 mAChRs in cells expressing GTPase-
defective Rab5 Q79L, which is known to stimulate homotypic early endosomal fusion 
and results in the swelling of early endosomes (24). Treatment of cells co-expressing M2 
and GFP-Rab5 Q79L with 1 mM carbachol resulted in the localization of M2 mAChRs to 
very large swollen endosomal structures that extensively co-localized with GFP-Rab5 
Q79L. This indicated that M2 mAChRs, once internalized by clathrin-independent 
mechanisms, indeed become localized to early endosomes of the clathrin-mediated 
endocytic pathway. In contrast to early endosomal markers, internalized M2 mAChRs did 
not significantly co-localize with the lysosomal marker, LAMP2 (data not shown).  
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Fig. 27.   Internalized M2 mAChRs co-localize with clathrin-dependent early 
endosomal markers. A, transiently transfected HeLa cells expressing M2 mAChRs 
were treated with 1 mM carbachol at 37 °C for 30 min, fixed, and processed for 
immunofluorescence co-localization of M2 mAChRs, using rat anti-M2 mAChR 
monoclonal antibodies and using mouse monoclonal Abs against EEA-1 or transferrin 
receptors. Primary antibodies were visualized using fluorescently labeled, non-cross-
reactive secondary antibodies. The arrows indicate endosomal profiles that co-label 
with antibodies against both M2 mAChRs and EEA-1. B, transiently transfected HeLa 
cells expressing M2 mAChRs and GFP-Rab5 Q79L were treated with 1 mM carbachol 
for 30 min prior to fixation and indirect immunofluorescence. Bar, 10 µM. 
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     To further explore this apparent transfer of M2 mAChRs between the clathrin-
independent and clathrin-dependent pathways, we compared the intracellular localization 
of M2 mAChRs and Alexa 594-labeled transferrin over time in co-internalization 
experiments (Fig. 28). Transiently transfected HeLa cells expressing M2 mAChRs were 
simultaneously incubated with 1 mM carbachol and with 50 µg/ml Alexa 594-labeled 
transferrin for various times at 37 °C, and the distributions of the two proteins were 
determined. After 5 min of internalization, M2 mAChRs localized to large endosomal 
structures, whereas Alexa 594-transferrin localized to distinct endosomal structures that 
lacked M2 mAChRs. After 15-30 min of internalization, both M2 mAChRs and Alexa 
594-transferrin extensively co-localized to large endosomal structures in the juxtanuclear 
region of cells. These results indicated that M2 mAChR and transferrin are initially 





Fig. 28.   M2 mAChRs and Alexa 594-
transferrin are initially internalized in 
distinct punctate structures but later merge 
into common endosomal compartments. 
Transiently transfected HeLa cells expressing 
M2 mAChRs were simultaneously incubated 
with both 1 mM carbachol and 50 µg/ml Alexa 
594-transferrin for various times prior to fixation 
and indirect immunofluorescence localization of 
M2 mAChRs. Bar, 10 µM. 126 
 
Arf6 Involvement in M2 mAChR Internalization  
To date, very little is known about the regulation of the endocytic pathway followed by 
the M2 mAChR. We have previously shown that the Arf6 GTPase regulates endocytic 
trafficking along a clathrin-independent pathway and delivers cargo to tubular endosomal 
structures that emanate from the centrosomal region of cells (155). Using the interleukin-
2 receptor  subunit Tac as an endocytic marker of this pathway, we observed that 
expression of the GTPase-deficient Arf6 mutant, Q67L, inhibits internalization of Tac 
into cells when assessed after 40 h of transfection. In contrast, expression of the GTP 
binding-defective Arf6 mutant T27N inhibits the recycling of internalized Tac back to the 
cell surface. Recent studies have also shown that both Arf6 Q67L and Arf6 T27N inhibit 
the clathrin-mediated internalization of 2ARs (32, 151). However, nothing is known 
about the effects of these Arf6 mutants on clathrin-independent GPCR internalization.  
     We first investigated the effects of wild type (WT) Arf6 and GTP binding-defective 
Arf6 T27N on M2 mAChR internalization in transiently transfected HeLa cells by 
measuring the agonist-induced loss of surface M2 mAChRs with the [3H]NMS binding 
assay (Fig. 29). We observed that neither co-transfection with WT Arf6 nor Arf6 T27N 
significantly affected M2 mAChR internalization after either 15 or 30 min of agonist 
treatment. After 30 min of carbachol treatment, ~60% of surface M2 receptors were 
internalized in cells expressing either M2 mAChR alone or M2 mAChR co-transfected 




Fig. 29.   Neither wild type Arf6 nor GTP binding-defective Arf6 T27N inhibit M2 
mAChR internalization. Transiently transfected HeLa cells expressing M2 mAChR 
alone or M2 mAChR plus either wild type Arf6 or Arf6 T27N were incubated in the 
presence or absence of 1 mM carbachol for 0, 15, and 30 min prior to determination of 
surface M2 mAChRs using [3H]NMS. Internalization of M2 mAChRs is expressed as 
the percentage of surface M2 mAChRs that became inaccessible to [3H]NMS 
following carbachol treatment. The data represent the means ± S.E. of four 
measurements from a representative experiment that was repeated three times. 
     We next examined the effects of persistent activation of Arf6 in cells by expressing 
the GTPase defective mutant of either Arf6 itself (Arf6 Q67L) or of an upstream activator 
of Arf6, HA-tagged G q Q209L (HA-G q Q209L), by measuring the loss of surface M2 
mAChRs with the [3H]NMS binding assay. A recent study by Boshans et al. (19) showed 
that co-expression of wild type Arf6 and a constitutively activated mutant of G q could 
mimic bombesin-induced activation of Arf6 in Chinese hamster ovary cells. We have 
previously observed that co-transfection of WT Arf6 and HA-G q Q209L together 
induces cell surface protrusions, a phenotype that is indicative of Arf6 activation (156). 
Fig. 30 shows that in cells expressing M2 mAChR alone, treatment with 1 mM carbachol 
for 30 min induced the internalization of ~78% of surface M2 mAChRs. In contrast, only 
36 and 39% of surface M2 mAChRs were internalized in cells co-expressing either Arf6 
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Q67L or G q Q209L, respectively. This suggested that persistent activation of Arf6 
inhibited M2 mAChR internalization.     In these experiments, we also observed that cells 
co-transfected with Arf6 Q67L expressed significantly fewer surface M2 mAChRs 
(116 ± 57 fmol [3H]NMS bound/mg protein or 7 ± 2%) when compared with cells 
expressing M2 mAChRs alone (1977 ± 979 fmol [3H]NMS bound/mg protein). This 
suggested that M2 receptors may be sequestered within intracellular compartments even 
in unstimulated Arf6 Q67L-transfected cells.  
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Fig. 30. GTPase-defective Arf6 Q67L and G q Q209L mutants inhibit M2 
mAChR internalization. Transiently transfected HeLa cells expressing M2 
mAChR alone or M2 mAChR plus either Arf6-HA Q67L or HA-G q Q209L were 
incubated in the presence or absence of 1 mM carbachol for 30 min prior to 
determination of surface M2 mAChRs using [3H]NMS binding. Internalization of 
M2 mAChRs is expressed as the percentage of surface M2 mAChRs that became 
inaccessible to [3H]NMS following carbachol treatment. The data represent the 
means ± S.E. of eight measurements from two independent experiments. *, 
p < 0.001 compared with M2 mAChR alone values. 
     To further investigate these effects of Arf6 Q67L and G q Q209L on M2 
internalization, we examined the effects of these mutants on the intracellular localization 
of M2 mAChR using indirect immunofluorescence microscopy (Figs. 31 and 32). In 
untreated cells, which co-expressed M2 mAChR and Arf6 Q67L, M2 mAChRs were 
localized both at the cell surface and also to large endosomal clusters where M2 mAChRs 
co-localized with Arf6 Q67L (Fig. 31B). These results indicated that there indeed was 
significant intracellular accumulation of M2 mAChRs in unstimulated Arf6 Q67L-
transfected cells, which is consistent with the reduced levels of surface M2 mAChRs 
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observed in these cells. Recent studies (23) showed that these large Arf6 Q67L+ 
endosomal clusters are enriched in phosphatidylinositol 4,5-bisphosphate and F-actin.  
     These cells also exhibited an altered morphology with many protrusive structures, 
which we have previously shown to be a phenotype of cells expressing Arf6 Q67L (23, 
156). Following carbachol treatment, the M2 receptors remained in a localization pattern 
that was indistinguishable from untreated Arf6 Q67L-transfected cells (Fig. 31B) and did 
not show the punctate vesicular structures observed in cells expressing M2 mAChR alone 
(Fig. 31A). The results of the [3H]NMS binding experiments above (Fig. 30) further 
indicate that Arf6 Q67L inhibits the internalization of the M2 mAChRs that are present at 
the cell surface in these cells. Expression of Arf6 Q67L did not affect the clathrin-
mediated endocytosis of Alexa 594-Tfn, which is consistent with our previous studies 















Fig. 31.   M2 mAChRs are sequestered in large endosomal
clusters in HeLa cells expressing constitutively active Arf6 Q67L.
HeLa cells were transiently transfected with plasmids encoding M2
mAChR alone (A) or M2 mAChR and Arf6-HA Q67L (B) and then
treated for 30 min with or without 1 mM carbachol, fixed, and
processed for indirect immunofluorescence localization of M2
mAChRs and Arf6. The arrows indicate fluorescent clusters that
label with antibodies against both M2 mAChRs and Arf6 Q67L. Bar,
10 µm. C, HeLa cells were transiently transfected with a plasmid
encoding Arf6 Q67L and incubated with Alexa 594-labeled
transferrin for 15 min prior to processing for indirect
immunofluorescence (see "Experimental Procedures"). Bar, 10 µm. 132 
 
     In cells co-expressing M2 mAChR and HA-G q Q209L, the M2 receptors were 
primarily localized at the cell surface (Fig. 32B). Following carbachol treatment, cells 
expressing HA-G q Q209L contained far fewer M2 mAChR-labeled endosomal structures 
than cells expressing M2 mAChR alone. As observed with Arf6 Q67L, expression of HA-
G q Q209L did not affect the clathrin-mediated internalization of transferrin. Taken 
together, these results indicated that persistent activation of Arf6 via expression of 
constitutively activated Arf6 Q67L or the upstream activator, G q Q209L, inhibited M2 
mAChR internalization but that co-expression of WT Arf6 and GTP binding-defective 
Arf6 T27N did not. 
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Fig. 32.   Constitutively active G q Q209L inhibits 
M2mAChR but not transferrin internalization. HeLa cells 
were transiently transfected with plasmids encoding M2 
mAChR alone (A) or M2 mAChR and HA-G q Q209L (B) 
and then treated for 30 min with or without 1 mM carbachol, 
fixed, and processed for indirect immunofluorescence 
localization of M2 mAChRs and G q. Bar, 10 µm. C, HeLa 
cells were transiently transfected with a plasmid encoding 
HA-G q Q209L and incubated with Alexa 594-labeled 
transferrin for 15 min prior to processing for indirect 
immunofluorescence (see "Experimental Procedures"). Bar, 




In this study, we investigated the intracellular trafficking of the M2 mAChR via a 
clathrin-independent endocytic pathway in HeLa cells. The M2 receptor has been shown 
to be internalized in HEK293 cells by a poorly characterized, clathrin- and arrestin-
independent mechanism (145, 165, 177, 204, 213, 214). Our present results indicate that 
persistent activation of the small GTPase Arf6 inhibits M2 mAChR internalization but 
does not affect the clathrin-mediated internalization of transferrin receptors. Interestingly, 
following internalization in structures that initially lack clathrin endocytic markers, M2 
mAChRs rapidly localize to early endosomes of the clathrin endocytic pathway where 
they co-localize with the endosomal marker EEA-1 and with internalized Alexa 594-
transferrin. This raises the intriguing possibility that although the M2 mAChR is initially 
internalized via an Arf6-associated pathway, it is quickly transferred to endosomes of the 
clathrin-dependent pathway.  
     We observed that dominant-inhibitory dynamin 2 K44A did not interfere with the 
internalization of M2 receptors in HeLa cells but completely blocked the clathrin-
dependent internalization of transferrin. This suggested that M2 internalization was 
clathrin-independent in HeLa cells and is consistent with published reports that the K44A 
mutant of dynamin does not inhibit M2 mAChR internalization in HEK293 cells (213). 
Recent reports also indicate that M2 mAChRs and angiotensin AT1A receptors exhibit a 
differential sensitivity to mutants of dynamin (219) and suggest that although M2 mAChR 
internalization is clathrin-independent, it still requires dynamin.  
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     To gain some insight into the nature of the endocytic pathway followed by M2 
mAChR, we investigated the identity of the endosomal structures to which internalized 
M2 receptors localized. To our surprise, there was extensive overlap in staining between 
internalized M2 mAChR and the early endosomal marker EEA-1. EEA-1 is a Rab5 
effector that is recruited to the cytosolic leaflet of early endosomes in a 
phosphatidylinositol 3-phosphate-dependent manner (121). It is involved in both the 
tethering of vesicles and their subsequent fusion through the assembly of oligomeric 
complexes that mediate vesicle fusion. Our observations that internalized M2 mAChRs 
also co-localize to the swollen early endosomal structures induced by expression of 
constitutively activated Rab5 Q79L lend further support to the early endosomal 
localization of internalized M2 receptors. A recent study has shown that internalized M4 
mAChRs also localize to EEA-1+ endosomes and with internalized transferrin receptors 
in PC12 cells (215). Furthermore, M4 mAChRs were shown to localize to swollen 
multivesicular endosomes formed in cells expressing constitutively activated Rab5 Q79L. 
In other studies, M4 mAChRs have been shown to internalize via arrestin- and clathrin-
dependent mechanisms (214). This suggests that different mAChRs that are internalized 
by distinct mechanisms can meet up in and transit through common endosomal 
compartments. In support of this hypothesis, we also observed that M2 mAChRs and 
fluorescently labeled transferrin are initially internalized in distinct endosomal structures 
but converge into common endosomal structures within 15 min after internalization.  
     But what is the clathrin-independent pathway by which the M2 receptor is initially 
internalized from the PM? Our results implicate a pathway that is regulated by the Arf6 
GTPase. We have previously shown that the Arf6 GTPase regulates a clathrin-
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independent endocytic pathway between the PM and tubulovesicular endosomes in HeLa 
cells (155). Arf6 itself cycles between these two cellular locations according to its GTP 
cycle (146). We and others have shown that GTP-bound Arf6 preferentially localizes to 
the PM, whereas GDP-bound Arf6 localizes to a juxtanuclear tubular endosomal 
compartment (37, 146, 155). Constitutively activated Arf6 Q67L inhibits the 
internalization of proteins that transit the Arf6-regulated pathway, such as the major 
histocompatability complex I, whereas GTP binding-defective Arf6 T27N inhibits 
recycling of such proteins from tubulovesicular endosomes back to the PM (23, 155).  
     Two observations suggest that the M2 mAChR is also internalized via an Arf6-
associated endocytic pathway. First, Arf6 Q67L strongly inhibited the agonist-induced 
internalization of M2 receptors (Fig. 30) but did not perturb the clathrin-mediated 
internalization of fluorescently labeled transferrin (Fig. 31). We also observed that M2 
mAChRs were sequestered into large endosomal clusters even in the absence of agonist 
stimulation, where they co-localized with Arf6 Q67L (Fig. 31), suggesting that M2 
mAChRs were internalized earlier in the transfection. Brown et al. (23) recently reported 
that major histocompatability complex I co-localizes with Arf6 Q67L after 20 h of 
transfection in tightly clustered endosomal structures, which accumulate in cells with 
time after transfection and are highly enriched in phosphatidylinositol 4,5-bisphosphate 
and F-actin. In contrast, after 40 h of transfection, major histocompatability complex I 
internalization was strongly inhibited by Arf6 Q67L. One explanation for the different 
temporal effects of Arf6 Q67L on M2 mAChR internalization, which we have observed, 
is that as endosomal membranes accumulate in cells, further internalization is inhibited 
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because of a depletion of either membrane and/or critical components necessary for 
vesicle formation.  
     To independently test the effects of persistent Arf6 activation on M2 mAChR 
endocytosis, we examined the effects of GTPase-defective G q Q209L on M2 
internalization. We observed that co-transfection of M2 mAChRs with constitutively 
activated G q Q209L greatly inhibited M2 mAChR internalization and to the same extent 
as Arf6 Q67L (~50% inhibition). Constitutively activated G q mutants have been shown 
to enhance Arf6 activation and to mimic, in part, the phenotypic effects of Arf6 Q67L in 
cells (19). We have observed that co-expression of wild type Arf6 and G q Q209L 
recreates the surface protrusions observed following aluminum fluoride stimulation of 
HeLa cells expressing WT Arf6 alone. A recent study showed that stimulation of the G q-
coupled bombesin receptor increased the proportion of GTP-bound Arf6 in Chinese 
hamster ovary cells. The precise mechanism by which G q Q209L enhances Arf6 
activation remains to be determined. The observation that persistent activation of G q can 
inhibit M2 mAChR internalization raises the intriguing possibility that G q-coupled 
receptors may influence the behavior of M2 receptor trafficking.  
     We also observed that neither WT Arf6 nor the GTP binding-defective Arf6 T27N 
mutant affected M2 mAChR internalization (Fig. 29). These observations contrast with 
those of Claing et al. (32), who recently showed that both Arf6 Q67L and Arf6 T27N 
inhibit the clathrin- and arrestin-mediated internalization of 2ARs. These authors also 
showed that isoproteronol stimulation of 2ARs results in the -arrestin-dependent 
stimulation of GTP exchange onto Arf6. Previous work has shown that overexpression of 
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the Arf6-specific GTPase-activating protein GIT1 also inhibits 2AR internalization but 
not M2 receptor internalization (34, 151). One major difference between 2ARs and the 
M2 mAChR is that the former requires -arrestins for internalization and the latter does 
not (145, 214). One possible explanation for the differential sensitivities of these two 
receptors to Arf6 mutants is that -arrestin stimulation of Arf6 activation is not critical for 
M2 mAChR internalization but is important for 2AR internalization. These results raise 
the exciting possibility that Arf6 can differentially affect GPCR internalization via both 
clathrin-dependent and clathrin-independent mechanisms. The significance of such a dual 
role for Arf6 in endocytic trafficking along distinct pathways is unknown.  
     Taken together, our results indicate that the clathrin-independent internalization of the 
M2 mAChR initially follows an Arf6-associated endocytic pathway but then quickly 
merges with early endosomes of the clathrin-dependent pathway. From these EEA-1+ 
endosomes, M2 mAChRs either can recycle back to the PM, can remain sequestered in 
endosomes by unknown mechanisms, or eventually could be sorted to lysosomes for 
degradation. Given the differential effects of Arf6 on the clathrin-dependent and clathrin-
independent internalization of GPCRs, determining the mechanisms by which Arf6 exerts 





Splitting Mammalian Cells 
 
1. Rinse cells with 1 mL versene. 
2. Add 2 mL trypsin and incubate for 1-2 minutes to loosen cells. 
3. Add 4 mL complete media to cells and pipet cells 10 times to get uniform suspension. 
4. Place 10 mL fresh, warm media into a new 10 cm dish. 
5. Add 0.4-0.6 mL suspended cells to new flask to get a 1:10 split. 
6. Label top of dish with date and split number, cell line, dilution, and initials. 
7. If plating cells for experiment, place a few drops of suspended cells to petri dish with 
coverslips before bleaching old flask of cells. 
 
Plating Mammalian Cells 
 
1. Place several acid washed coverslips into a 10 cm petri dish. 
2. Pour 70% EtOH over the coverslips. 
3. Flame 4-5 slips at a time very quickly and then let air dry for a few seconds.  (Make 
sure that all EtOH is evaporated or cells will not grow on the slip.) 
4. Place ~20 slips in a sterile tissue petri dish for plating. 
5. Place 10 mL of complete media into the petri dish. 
6. Add a few drops of suspended cells (from flask spilt) to the dish. 
7. Add appropriate drug/inhibitor and place in CO2 incubator overnight to do transfection 





For a transfection in a 24- well dish: 
1. Plate 70,000 HepG2 cells in complete media into each well for ~24 h. 
2. The following day, change the media to serum-free in each well. 
3. For each transfected row (6 wells total/row) dilute a total of 0.5 µg/well of DNA into 
300µl serum-free media into one labeled tube. Repeat for each row. 
4. Incubate the mixture for 15 min. 
5. Dilute lipofectamine into another labeled tube at the ratio (0.4µg DNA: 1µl 
lipofectamine) with 300 µl serum-free media. 
6. Immediately combine the tube with DNA and the tube with lipofectamine and incubate 
the mixture for 15-45 min. 




Notes for consideration: 
1. This works better in media without serum or in less than 5% serum solution.   
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2. Do not add any antibiotics to the media. 
3. Cell density must be optimized and kept consistent for reproducible results. 
For a Transfection in a 6 Well Dish: 
1. Plate cells to get recommended cell density of 40-60% confluent on day of 
transfection. 
2. For each transfection: 
a. dilute 1 µg of DNA into 100 µl SFM media into 1 labeled tube 
b. dilute 1.5 µl (per 1 µg plasmid) Lipofectin into 100 µl of SFM media into 1 
labeled tube 
3. Let stand at room temperature for 30 – 45 min (45 min is optimal). 
4. Combine the two solutions and let stand for 10 min at room temperature.   
5. Wash cells in 6 well once with 2 mL SFM and replace with 1.8 mL SFM. 
6. Add DNA/Lipofectin mix to the well and place in 37°C incubator for 4-6 h.   
7. Replace the DNA containing media with complete media and return to incubator for 
48-72 h when you can perform the experiment.   
 
ExGen 500 in vitro Transfection 
 
Considerations: 
1. High quality DNA of 1.8 OD ratio or higher is recommended. 
2. Recommended cell density is around 50% at time of transfection. 
3. Optimal detection of transfection determined by a reporter gene. 
4. Transfection efficiency is higher in the presence of serum w/o antibiotics. 
 
Day 1:  Seed 0.45x 106 HeLa cells (density depends on cell type) in a 10 cm dish 
containing complete DMEM (-antibiotics). 
Day 2: Transfect in the morning.  Prior to transfection, transfer coverslips to a 6-well 
plate containing 2 mL of complete DMEM (-antibiotics).   
Day 3: Change the media. 
Day 4: Perform the assay. 
 
Day 2:  Procedure for 6-well plate:  Use 1 µg :3.3 µl ratio of DNA to Ex-Gen. 
1. Dilute recommended amount of DNA (Total 2.0 µg/6-well) into 200 µl of 150 
mM NaCl.   
2. Vortex briefly and spin down. 
3. Add 7.0 µl of ExGen500 to DNA solution and immediately vortex for 10 sec. 
4. Incubate at room temperature for 10 min. 
5. Add the ExGen500/DNA mixture to one well of 6-well plate and place on shaker 
for 5 min.   
6. Incubate for 24 h and change media following day. 




1. Day 1:  Grow cells on 12 mm acid-washed No. 1 circle glass coverslips in a 10 cm 
dish.  Coveslips should sit in 70% ETOH.  Flame coverslips prior to use and transfer 
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to 10cm dish.  Density of cells depends on cell type. (HeLa – 0.45x106; MEFs – 
1.0x106) 
2. Day 2: Transfer individual coverslips to the wells of a 24, 12, or 6-well dish that 
contains the appropriate amount of media.  Begin transfection protocol.    
3. Day 3:  Remove media and replace with serum free or complete media.   
4. Day 4: Treat as required for experimental protocol. 
5. Transfer coverlslip to one well in a 12-well dish containing 1 mL of 2% 
formaldehyde in PBS pH 7.4. 
a. 2% formaldehyde in PBS 
i. Add 27 mL of 37% formaldehyde stock into a graduated cylinder. 
ii. Fill to 500 mL with PBS pH 7.4 
6. Incubate for 10 min at room temperature (RT). 
7. Remove fixative and add 1 mL of 10% Adult calf serum in PBS (PBS/serum/azide) 
and incubate for 5 min at room temperature.  This can be stored overnight at 4°C. 
PBS/serum 
i.   Add 50 mL of calf serum to 500 mL graduated cylinder. 
ii.  Add 0.5 mL of 20% sodium azide stock soln. 
iii. Fill to 500 mL with PBS pH 7.4 
8. Dilute primary antibodies into PBS/serum containing 0.2% saponin and spin for 5 
min at 14,000 rpm. 
PBS/serum + 0.2% saponin 
i.  Add 20 µl of 10% saponin stock (made in dH2O) to microfuge tube 
ii. Add 980 µl of PBS/serum for a total of 1 mL. 
9. Place a piece of parafilm in the bottom of a 150 mm petri dish and label with numbers 
corresponding to 12-well dish. 
10. Add 25 µl of the appropriate diluted antibody solution to each spot on the parafilm. 
11. Pick up individual coverslips with tweezers and wick excess fluid on paper towel. 
12. Invert coverslip onto antibody drop (i.e. cell side down), cover dish and incubate in a 
bench drawer for 1 h. 
13. Carefully transfer coverslip, cell-side up, back into 12-well dish. 
14. Wash coverslips with 1 ml PBS/serum (3 x for 5 min). 
15. Dilute fluorescently-labeled secondary antibodies in PBS/serum + 0.2% saponin and 
spin for 5 min at 14,000 rpm. 
16. Invert coverslips onto 25 µl drops of antibody on parafilm as described above and 
incubate for 1 h. 
17. Wash coverslips 3 x 5 min with PBS/serum. 
18. Rinse coverslips with PBS alone and mount onto glass slides with fluoromount G and 




1. Open and load image of interest 
 Deconvolute images prior to quantitation 
2. Process Menu 
 Select “2D deconvolution”  
  Click nearest neighbor and Apply (adjust if needed) 
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  Display color combine 
3. Display Menu 
 Select “Color Separate” 
  Click red, green or blue ---“new” 
4. Select rectangle box in Regions tools and place in Blank region of image 
5. Regions Menu 
 Select “Transfer Region” to place blank in all colors of image 
6. Measure Menu 
 Select “Show Region Statistics” 
 *the “Use Threshold” box should NOT be checked 
 *region around box should be blinking (active) 
 *Add the sum of average and standard deviation computed for each color  
 image.  Record measurements for each color.   
7. Measure Menu 
 Select “Threshold Image” 
 *Make sure State is Off 
 Insert the values derived from previous step into the “Low Intensity” box 
8. Region Tools 
Select line or box tool to mark the areas of image to analyze.  Double click to 
activate. 
9. Regions Menu 
 With image outline blinking, select Transfer Region 
 Transfer outline of interest to all the color images separated earlier 
10. Measure Menu 
 Select “Show Region Statistics” 
 *Check the “inclusive” box for each color of the image 
* Add the sum of the average and standard deviation computed 
11. Measure Menu 
 Select “Threshold Image” 
 *input the sum calculated above into the “Low intensity” box 
12. Applications Menu 
 Select “Measure colocalization” 
 *set image to “A” or “B” as appropriate 
 *check the “show percentage box” 
 *log into Excel spreadsheet 
 
LOSR Quantitation Assay 
 
1.    Grow cells directly on bottom of wells that contain 1 mL media. (this works best at 
150,000 cells per well). 
2.   Treat as required for experimental protocol. 
3.   Remove medium and fix cells with 1 mL of 2% formaldehyde in PBS pH 7.4. 
2% formaldehyde in PBS 
i. Add 27 mL of 37% formaldehyde stock into a graduated cylinder. 
ii. Fill to 500 mL with PBS pH 7.4 
4. Incubate for 10 min at room temperature (RT). 
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5. Remove fix and add 1 ml of 10% Adult calf serum in PBS (PBS/serum) and incubate 
for 5 min at room temperature.  This can be stored overnight at 4°C. 
PBS/serum 
i.   Add 50 mL of calf serum to 500 mL graduated cylinder. 
ii. Fill to 500 mL with PBS pH 7.4 
6. Dilute primary antibodies into PBS/serum without saponin and spin for 4 min at 
14,000 rpm. 
b. Mouse anti Flag use at 1:750. (stock = 2-5 mg/ mL)  
c. ConA Biotin use at 1:750.  (stock = 5 mg/ mL) (used at 5 µg/ mL)  (Vector 
Laboratories, B-1005) 
7. Remove the PBS serum from the wells. 
8. Add 250 µl of primary antibody to each well.   
9. Cover dish and incubate in drawer for 45 min. 
10.  Wash cells with 1 ml PBS/Serum (3 x 3 min). 
11. Dilute fluorescently-labeled secondary antibodies in PBS/serum without saponin 
 and spin for 4 min at 14,000 rpm. 
d. Goat anti Mouse HRP Conjugate use at 1:1000. (stock = 0.8 mg/mL) (used at 0.3 
µg/mL) (Promega, W4021) 
e. AP Streptavidin use at 1:1000.  (stock = 1 mg/mL) (used at 5 µg/mL) (Alkaline 
Phosphatase Streptavidin, SA-5100, Vector Laboratories) 
12. Remove the PBS Serum and add 250 µl secondary antibody to each well. 
13. Cover and incubate in bench drawer for 45 min. 
14.  Wash cells with 1 mL PBS/Serum (3 x 3 min). 
15.  Aliquot out approximate amount of 1 Step ABTS necessary and warm it up in dH2O 
bath, keeping stock bottle in fridge. (Pierce, 37615) 
16.  Rinse cells with 1 mL 1 X PBS alone for 5 min. 
17. Aliquot out approximate amount of pNPP/Sodium Bicarbonate 
pNitroPhenylPhoshate (pNPP) (vector Laboratories, SK5900) 
add 5 drops per 2 mL of 100 mM Sodium Bicarbonate 
      100 mM Sodium Bicarbonate
 75 ml dH2O 
 0.84 g Sodium Bicarbonate 
 pH to 10.0 with NaOH  
 fill to 100 mL with dH2O 
18.  Remove PBS. 
f. Add 150 µl pre-warmed ABTS to wells stained with Donkey anti Mouse HRP and 
to first column of a 96 well dish to be used as a standard. 
g. Add 150 µl pNPP solution to wells stained with AP Streptavidin and to first 
column of a second 96 well dish to be used as a standard.   
h. Incubate on benchtop for 15 min. 
19. After the 15 min, add 150 µl 1% SDS to all wells containing ABTS, including those 
of the 96 well dish. 
20.  a.   Mix thoroughly by pipetting up and down and quickly add all 300 µl of         
            ABTS/SDS wells to corresponding well of 96 well dish .   
b. Mix thoroughly by pipetting up and down and quickly add all 150 µl of pNPP 
wells to corresponding well of 96 well dish.   
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c. ABTS/SDS wells should turn green 
d. pNPP wells should turn yellow 
21.  Read absorbances on plate reader at 405 nm in SoftMax Pro Program. 
e. Assay for ABTS/SDS: Endpoint ELISA: HRP and ABTS w SDS stop  
f. Assay for pNPP: Endpoint ELISA: AP and pNPP 
 
Cloning of FLAG-LPA3 
 
Forward LPA3 primer: 5’-GCC ACC ATG AAT GAG TGT CA-3’ 
Backward LPA3 primer: 5’-CGA TTT AGG AAG TGC TTT TA-3’ 
 
HAss FLAG-LPA3 forward primer: 5’-GATC ATG AAG ACC ATC ATC GCC CTG 
AGC TAC ATC TTC TGC CTG GTG TTC GCC GAC TAC AAG GAC GAT GAT 
GAC AAG ATG AAT GAG TGT CAC -3’ 
 
Protocol adapted from Invitrogen Cloning Kit (Carlsbad, CA) 
 
1. Isolated the mRNA (GenElute Direct mRNA Miniprep kit - Sigma) from OVCAR3 
which highly express LPA3. 
2. Performed RT-PCR to obtain cDNA. The reaction used:  
10 ng RNA 
10 µM sense and anti-sense primers  
1 µl deoxynucleotides  
1 µl reaction buffer  
0.5 U of Taq DNA polymerase  
H20 for a final volume of 50 µl 
 
3. The PCR cycle was:  
 50°C          94°C               ( 94°C              55°C             72°C )           72°C             4°C 
30 min        2 min                15 s                 30 s             2 min          10 min           X h 
                                              ------------- 40 times ------------ 
 
4. After the PCR cycle, the product was run on a 1% agarose gel for 1 h: 
0.5 g agarose 
50 mL 1X TAE 
2.5 µl ethidium bromide 
5. Roughly 15 µl of product was mixed with loading dye for the unknown sample. About 
4 µl of the lambda marker was mixed with 2 µl of 6X loading dye and 6 µl H2O for the 
standard ladder. 
6. A single 1062 bp band was observed, which was purified and subcloned into 




Luciferase Assay of Transiently Transfected HepG2 Cells 
 
Day 1: 
1. Split cells as usual except get a count of the cells in the trypsin/media solution using 
a hemocytometer 
2. Plate cells in a 12-well dish, 70,000 cells/well 
3. Incubate at 37oC 
Day 2: 
1. Change media on cells from complete to serum free right before transfection 
2. Transfect cells using Lipofectamine from Invitrogen or some other lipid-based 
reagent, 0.5 µg/total plasmid/well 
3. Incubate 37oC 
Day 3: 
   1. Treat the cells with agonist such that the treatment lasts for approximately 16 h 
Day 4: 
1. Follow protocol for Dual Luciferase Assay: 
2. Lyse cells with 0.25 mL 1X Passive lysis buffer, 15-20 min. 
3. Thaw LARII at room temperature water bath and add 50 µL to each tube 
4. Mix 1X Stop and Glo reagent. 
5. Add 20 µL lysate to LARII, pipet 2-3 times, read in luminometer. 
6. Add 50 µL Stop and Glo, flick tube to mix, read in luminometer. 
7. Divide first reading by second to get normalized RLUs 
 
BCA Protein Concentration Assay 
 
1. Make BSA standard (1 mg/mL) solutions by adding the appropriate amount of BSA to 
microfuge tubes (0 µl, 5, 10, 15, 20, 25). 
2.  Add 5 µl of protein sample to a new microfuge tube. 
3.  Add 0.5 ml of BCA mixture to each microfuge tube:  
1 part Soln. B to 50 parts Soln. A  
4.  Incubate for 30 min at 37° C. 
5.  Read at 562 nm on plate reader. 
 
SDS-PAGE Gel Recipes 
 
MINIGEL: SEPARATING GEL (10ml) 
Reagent    8%  10%  13%  15%
40% Acrylamide   2ml  2.5ml  3.25ml  3.75ml 
1.5M Tris, 0.4% SDS ph 8.8  2.5ml  2.5ml  2.5ml  2.5ml 
ddH20     5.5ml  5ml  4.25ml  3.75ml 
10% APS    50µl  50µl  50µl  50µl 
TEMED    10µl  10µl  10µl  10µl 
 
MINIGEL: STACKING GEL (10ml) 
40% Acrylamide   .75ml 
0.5M Tris, 0.4% SDS pH 6.8  2.5ml 
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ddH20     6.75ml 
10% APS    100µl 
TEMED    12µl 
 
 
SDS-PAGE Set Up 
 
1. Insert comb into rig and mark a line about 1 cm below the bottom of comb. 
2. Add appropriate percentage separating gel first using a Pasteur pipet.  This can store at 
4°C overnight. Leave pipet in gel mixture and wait to harden (about 10-15 min). 
3. Add a layer of 0.1% SDS. 
4. Pour stacking gel using a Pasteur pipet taking care to get rid of bubbles. Insert comb 
into rig, making sure no bubbles form and allow this to dry like the separating gel. 
5. Load gels into running rig, short plate towards the inside. 
6. Add 1X SDS running buffer in between 2 gel rigs, check for leaks. 
7. Load bench mark standard and samples with 2X or 4X sample buffer. 
8. Fill 1X SDS running buffer on out side of gel rig till it covers the wire running across 
the inside of gel rig. 
9. Run gel at ~150V until the dye runs out into the running buffer, usually 1 h. 
 
Cell Lysis prior to Western Blotting 
 
1. Rinse culture dishes of cells twice with ice-cold 1X PBS 
2. Scrape cells into a pool at the bottom of the dish using 1X PBS with protease and 
phosphatase inhibitors added fresh each time 
3. Transfer pool of cells into an ice-cold microfuge tube and spin in a cold centrifuge at 
500-1200 rpm for about 5-15 min. 
4. Add 50 µl (A549) or 200-500 µl (HeLa, HepG2) of lysis buffer to the cell pellet after 
removing the supernatant. 
Lysis Buffer: 
1% NP-40 (IPEGAL)                                                 1mL 
1% deoxycholate salt                                                  1g 
0.15M NaCl (from 5M stock)                                     3mL 
0.1% SDS (from 20% stock)                                     0.5mL 
0.01M sodium phosphate 7.2                                     10mL 
2mM EDTA (from 0.5M stock)                                 400µl 
50mM NaF (from 1M stock-poison)                           5mL 
0.2M orthovanadate (from 0.1M stock)                      2mL 
H20 (to 100mL total volume)                                     78mL 
*Fresh protease inhibitors each time 
5. Allow the cells to lyse on ice for 30 min with vortexing every 10 min. 
6. Spin in the cold centrifuge for 15 min, remove supernatant for BCA Assay. 
 
Western Blotting (ECL Detection)
 
1. After electrophoresis, soak gel in transfer buffer (chilled) for 5-10 min. 
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2. Assemble sandwich in the order indicated on the black side of cassette: 
a. Scotch-brite pad 
b. Whatman filter paper (cut slightly larger than the gel) 
c. SDS-PAGE Gel 
d. Nitrocellulose paper (roll out bubbles with pipet) 
e. Whatman filter paper (roll out bubbles with pipet) 
f. Scotch-brite pad 
3. Seal cassette, place in apparatus, fill with transfer buffer, add a stir bar, and place the 
ice pack in the back. 
4. Place on stir plate and stir, hook up leads (- to – and + to +) 
5. Transfer at 100V for 1 h. 
6. Break down apparatus, store nitrocellulose in a dry petri dish until blotting. 
7. Block nitrocellulose filter with 5% milk/0.1% Tx-100/PBS for 1 h on shaker.  
8. Remove blocking solution. 
9. Incubate with 1° Ab diluted in milk solution for 1 h on shaker. 
10. Wash with Triton/PBS (1x 15 min, 3x 5 min). 
11. Incubate with 2° Ab for 1 h on shaker (HRP conjugated Donkey 1:5000). 
12. Wash with Triton/PBS (1x 15 min, 4x 5 min). 
13. Treat on saran wrap with ECL soln (1:1 mixture of Soln A and Soln B; make up just 
before use) 1 min, and expose the film (start with 1 min exposure). 
 
MAP Kinase Antibody Western Blot 
 
1. Block nitrocellulose with TBS/5% milk for 1 h at 37°C or overnight at 4°C. 
2. Dump off the milk wash. 
3. Cover with TBST/0.1% BSA containing anti-active MAPK antibody (1:5000) for 2 h 
at room temperature with agitation. 
4. Dump off antibody wash. 
5. Wash 3 times with 75 ml of TBS-Tween for 15 min each. 
6. Apply TBS-Tween/0.1% BSA containing Donkey anit-Rabbit HRP (1:1000) for 1 h at 
room temperature with agitation. 
7. Wash 3 times with 75 ml TBS-Tween for 15 min each. 
8. Wash 2 times with TBS only. 
9. Soak for 1 min in ECL Reagent. 
10. Expose to blot film in dark room. 
 
Immunoprecipitation and Kinase Assay 
 
1. Transfect HeLa cells in 35 mm dishes (1 well of 6 well dish) 
2. Rinse cells twice with ice-cold PBS, add 0.5 mL of lysis buffer and incubate on ice 10 
min. 
3. Scrape cells and collect lysate in microfuge tubes, vortex to break up clumps. 
4. Spin in the chilled centrifuge at 14,000 rpm (or top speed), at 4°C for 15 min. 
5. Transfer lysate to fresh tube, assay 10 µl for protein concentration with BCA mix. 
       (BSA stds: 0, 2, 4, 6, 8, 10, 15, and 20 µg) 
6. Wash 30 µl protein A-sepharose beads with PBS. 
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7. Transfer equal amount of lysate (equal protein ~ 600-800 µg) to tube with protein A-
sepharose beads and add 1 µl of mouse anti-HA antibody (BABCO clone 16B12). 
Tumble 1 h at 4°C.  
8. Pellet beads and wash 3x with IP wash buffer, and once with kinase buffer. 
9. Resuspend beads in 30 µl kinase rxn mixture (specific for each kinase) and  
incubate in a 30°C water bath for 30 min. 
10. Add 10µl of 4X reducing sample buffer, boil 3 min. 
11. Pellet beads and load 35 µl of supe onto a large 13% SDS gel (load around 5:00 
pm).  Run at 50V overnight (usually done around 7:30-8:00 am). 
12. Dry gel at 80°C for 1.5 h. 
13. Expose to phosporimager screen about 2-3 h.  
14. Expose to film about 6h- 12h at RT using an intensifying screen.  Sometimes 24 h is 
okay.   
 
Human total and [pS15] p53 ELISA (Biosource Kits)  
 
Lysing the Cells 
1. Plate A549 cells into 10 cm dishes and grow ~24 h before 16 h serum starvation 
followed by treatment with appropriate drug or lipid. 
2. Rinse the cells with cold PBS immediately before scraping. 
3. Collect the cells in PBS (with phosphatase and protease inhibitors) by scraping 
adherent cells from the culture flasks. 
4. Centrifuge (500-1200 rpm) the cells in the small, cold centrifuge. 
5. Remove and discard the supernatant carefully to collect the cell pellet (at this point the 
cell pellet can be frozen at -80°C and lysed later). 
6. Lyse the cell pellet in 50-200 µL Cell Extraction Buffer (purchase from Biosource 
because this one is compatible and low cost) for 30 min on ice with vortexing every 10 
min. 
7. Centrifuge the extract at 13,000 rpm for 10 min at 4°C. Lysate can be stored at -80°C 
until you are ready to perform the ELISA but avoid freeze/thaw cycles.  
 
ELISA Procedure 
1. Add 100 µL of the Biosource Standard Diluent Buffer to zero the wells.  
2. Add 100 µL of standards, samples or controls to the wells. (Samples prepared in Cell 
Extraction Buffer must be diluted at least 1:10 in the Standard Diluent Buffer.) 
3. Cover wells and incubate for 2 h at room temperature. (Can also do overnight at 
4°C.) 
4. Aspirate the solution from the wells and discard liquid. Wash the wells 4 times. 
5. Pipette 100 µL of the Detection Antibody solution into each well. 
6. Cover wells and incubate for 1 h at room temperature. 
7.  Aspirate the solution from the wells and discard liquid. Wash the wells 4 times. 
8. Add 100 µL of the anti-rabbit IgG-HRP working solution to each well and incubate at 
room temperature for 30 min. 
9. Aspirate the solution from the wells and discard liquid. Wash the wells 4 times. 
10. Add 100 µL of Stabilized chromogen to each well (including doing a blank well at 
this point). The wells will turn blue. Incubate for 30 min at room temperature in the dark. 
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11. Add 100 µL Stop Solution to each well. The solution will turn yellow. 
12. Read the absorbance at 450 nm having blanked using the well: chromogen +stops 
olution as the blank. 
13. Plot the standards against the standard concentration. Do not extrapolate unknowns! 
 
Making Stable Cell Lines 
 
1. Transfect cells with appropriate DNA. 
2. On day supposed to do experiment, change media and let cells grow another day. 
3. Next day trypsinize cells and split 1:25 into 5, 10 cm dishes. Cover with 10 mL 
complete media containing 0.05 mg/mL G418. 
4. On Monday, Wed, and Friday of next week, feed and treat cells with G418 (100 µl of 
the solution per dish). 
5. When colonies are large enough to see, pick them very sterilely. 
-place 1 mL of complete media into 12 well dishes with 0.05 mg/mL G418 
-add 25 µl trypsin to lid of each well. 
-mark 5 well isolated colonies on each dish   
-remove media from cells 
-pick colony with P100 tip and transfer onto drop of trypsin with ~5 µl of trypsin 
in tip 
-Let sit for 2-5 minutes 
6. Add cell/trypsin mixture to corresponding well of 12 well dish. 
7. Place into CO2 incubator. 
8. Feed cells every 3 – 4 days.   
9. When see definite colonies in 12 wells split into 10 cm dish and plate onto coverslips.  
Keep feeding/splitting 10 cm dishes while test by Immunofluorescence for stable 
transfection. 
10. When have identified stably transfected line, freeze it down and bleach the rest. 
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